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General introduction & outline of the thesis
1
General introduction
How are newborns during early development prepared for future threats? And to what 
extent are early life immune responses comparable to those in adults and vice versa? 
Around 350 BC, Plato believed that our mind is born with knowledge and ideas which 
are given by a divine being, this was called innatism. Plato’s concept of innatism was 
supported many centuries later by Descartes, who suggested that innate beliefs are 
already programmed at birth to equip newborns with an inborn structure1. Aristotle 
supported the opposite notion called empiricism and believed that humans are born 
as a blank slate (tabula rasa) and develop based on experience. The debate between 
innatism and empiricism was popularized with the phrase ‘nature versus nurture’ during 
the 20th century. Nowadays, most scientists oppose against a clear-cut separation of 
nature versus nurture as they inﬂuence each other and studies in the ﬁeld of epigenetics 
revealed that characteristics acquired during life can be passed on to the next generation. 
Nevertheless, novel insights into the nature of immune ontogeny will lead to a better 
understanding of pediatric infectious diseases in early life. 
The number one burden in pediatric infectious diseases is respiratory syncytial virus 
(RSV)2. Since the discovery of RSV in the 1950’s, there has been a cumulative increase 
in publications describing the mechanisms of innate and adaptive immunity against 
the virus, reﬂecting the importance of the host response in RSV disease (Figure 1).  
Every year during late fall, a new cycle of RSV infections begins. The majority of infants 
experience symptoms of common cold3. One third of all infected infants develop 
lower respiratory tract infections in which narrowing of the airways by inﬂammation, 
edema and the production of mucus results in airway obstruction. Around 1 percent 
of all infected infants develop severe disease and require oxygen supplementation or 
mechanical ventilation at the intensive care unit4,5. Young age is the most important 
 Plato Aristotle Descartes
 (424-348 BC) (384-322 BC) (1596-1650 AD)
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risk factor for severe RSV infections with a peak occurence in infants below 3 months 
of age6. Co-morbidities such as prematurity and cardiopulmonary disease also pre- 
dispose infants for severe infections by RSV. The exuberant inﬂammatory response 
during severe RSV infections indicates that immune mechanisms may contribute to 
disease severity7.
Before birth, the mother provides the fetus with immune defense components. 
Maternal immunoglolubin G antibodies (matAbs) are transferred via the placenta 
throughout pregnancy and remain present during the ﬁrst months of life. Although the 
role of matAbs has been elucidated for several pathogens, there are still controversies 
regarding the protective effect of matAbs during RSV infections8-16. Palivizumab, a 
humanized IgG1 monoclonal antibody (mAb) directed against the fusion (F) protein 
of RSV, offers protection through neutralization of RSV against disease progression in 
high-risk infants. This demonstrates the efﬁcacy of RSV-speciﬁc IgG to protect young 
infants against severe RSV infections17. Administration of mAbs against the fusion (F) 
or attachment (G) protein of RSV also reduces the inﬂammatory immunopathology 
during RSV infection18-20. Contrary, the induction of non-neutralizing antibodies can 
increase disease severity during RSV infections21. Maternal vaccination strategies to 
induce protective matAbs against RSV are currently being investigated in preclinical 
and clinical trials22. The contribution of antibody properties such as avidity and 
Figure 1  Number of publications per decade regarding RSV since 1945 categorized as followed: 
All publications on RSV (All), publications about immunity against RSV (Immunity), publications 
about adaptive immune responses (Adaptive immunity) and about innate immune responses 
against RSV (Innate immunity).
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 epitope-speciﬁcity to the protective effect of antibodies during RSV infection are still 
unknown and, therefore, a correlate of protection for matAbs against severe RSV 
infections in young infants is yet to be determined.
Newborns and young infants have a limited antigen encounter and an immature 
adaptive immune system. Therefore, defense mechanisms of newborns against 
infectious diseases mainly rely on innate immunity23,24. Recognition and infection of 
epithelial cells are the ﬁrst steps after infection and lead to the initiation of an antiviral 
immune response. Subsequently, recruitment of immune cells like monocytes, neutrophils, 
natural killer (NK) cells, T cells and B cells are needed to contain the infection24,25. 
Reduction of the inﬂammatory response and tissue healing are the ﬁnal steps to 
prevent immunopathology. 
Antigen-presenting cells, such as monocytes and macrophages, regulate other cells 
including lymphocytes via direct cell-cell contact or via inﬂammatory mediators26-29. 
In a murine model of RSV infection, inﬂammatory monocytes are recruited to the lung 
tissue where they exert a direct antiviral effect and prevent immunopathology30. In the 
human setting, the role of monocytes during RSV infections has so far received little 
attention. The old dogma that monocytes circulate in the peripheral blood and macro- 
phages are residential cells at the site of infection holds true in many cases. However, 
the pool of peripheral monocytes is dynamic, in particular during infections31, 32, and 
circulating monocytes may play a role in the antiviral immunity33 including the innate 
immunity against RSV. 
Early innate cytokines, like type I interferons (IFNs), are present in the inﬂammatory 
micro-environment of the lungs during RSV infection30. Type I IFNs, including IFN-т 
and IFN-у, discovered in 1957 by Isaacs and Lindenmann, are evolutionary conserved 
for millions of years as they have been found in early chordates34. The duplication of 
genes responsible for IFN activity throughout chordate evolution suggests an 
evolutionary advantage during infections. Type I IFNs have antiviral and immuno-
modulatory properties (Figure 2). Although multiple pathways after ligation of the 
 interferon-т/у-receptor (IFNAR) by IFN-т and IFN-у converge, it was shown in recent 
literature that IFN-у-speciﬁc immune mechanisms exist35. The functional consequences 
after exposure to IFN-у are dependent on cell type and may involve either activating 
or inhibitory effects on the immune response.
Although the content of this thesis is mainly focused on the importance of innate 
immune cells and innate cytokines during the immune response against RSV, we are 
well aware that the adaptive T cell response is also important. T cell immunity in 
newborns and adults is different as has previously been reported36. A major difference 
between newborn and adult T cells is the presence of a high percentage of (antigen- 
speciﬁc) memory T cells in adults. However, qualitative differences in cytokine responses 
are also present between newborn and adult T cells. Newborn T cells are usually 
considered immature and skewed toward a Th2-response. Recent publications 
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indicate that the functionality of newborn T cells is not per se impaired and can range 
from immature to fully functional as is for example the case after exposure to 
Mycobacterium bovis bacillus Calmette-Guerin (BCG)37. 
It is difﬁcult to investigate innate and adaptive immunity against RSV during the ﬁrst 
months of life because of ethical restrictions in the number and volume of blood 
samples. Therefore, we do not fully know to what extent newborns and infants already 
possess innate defense mechanisms to ﬁght RSV infections. Nor do we know the 
differences between the neonatal and adult immune response against RSV.
Figure 2  IFNAR-dependent signaling: Upon ligation by type I IFN, the IFNAR receptor induces 
a variety of pathways, including antiviral, inﬂammatory, anti-proliferative, apoptotic and pro- 
proliferative signaling. Cell type and environment determine the functional consequences 
after IFNAR ligation. (ISRE: interferon-sensitive response element; JAK1: Janus kinase 1; GAS: 
gamma interferon activation site; STAT: signal transducer and activator of transcription; TYK2: 
tyrosine kinase 2).
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We investigated in this thesis the early immune response during RSV infections by the 
use of a model that we developed in our laboratory. We acquired cord blood from the 
umbilical cord after cesarean section and we acquired peripheral blood from healthy 
adults. We used the mononuclear cell fraction which allowed for the investigation of 
multiple cell types that play a role during RSV infection (Figure 3) such as monocytes, 
B cells and T cells. Our study was performed with a particular emphasis on the 
regulatory role of monocytes and IFN-у. Elucidation of the ontogeny of the host 
response against RSV may provide a better understanding of age-speciﬁc immune 
Figure 3  Newborn immunity during RSV infection: The micro-environment contains immune 
cells, like antigen-presenting cells, neutrophils, NK cells, T cells and B cells, and (antiviral) 
soluble mediators. Newborn immunity is characterized by the presence of matAbs, Th2 bias, 
reduced IFN-т, reduced IFN-ф and an immature TLR signaling. Neutrophils and T cells 
contribute to exuberant inﬂammation and immune-pathology (Adapted from Lambert et al24) 
(DC: dendritic cell; IgG: immunoglobulin G; TLR: Toll-like receptor).
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mechanisms during RSV infections. The effects of IFN-у on the functionality of adaptive 
immune cells in newborns and adults will provide insights into age-related regulatory 
mechanisms during pediatric infectious diseases. 
In addition, clinical samples from healthy infants and RSV-infected infants with different 
degrees of disease severity were retrospectively analyzed to elucidate or unravel 
immune correlates of protection during RSV infections. RSV does not cause systemic 
infection and peripheral blood might therefore seem an irrelevant sample. However, 
the contribution of circulating immune cells to the exuberant inﬂammation during 
severe RSV infections is likely to be clinically relevant38. We used peripheral blood 
from infants with primary RSV infections to investigate monocytes and plasma 
components including matAbs. The number and phenotype of circulate monocytes 
changes during infection39 and this plasticity of monocytes may have functional 
consequences at the site of infection. In addition, determining properties of matAbs 
that are associated with mild or severe disease may direct the induction of protective 
antibodies during maternal vaccination. The analysis of clinical samples during infant 
RSV infections will lead to a better understanding of the immune response upon RSV 
infection in children with different degrees of disease severity. 
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Outline of the thesis
In Chapter 2, we discuss the role of innate immunity during RSV infections with an 
emphasis on the role of monocytes. We ﬁrst describe a model of peripheral blood 
mononuclear cells to investigate the immune response against RSV in vitro (Chapter 
2.1). We next determine the role of actin- and clathrin-dependent cellular processes 
on cell entry of RSV, the regulation of antigen-presenting molecules on monocytes 
and the induction of IFN-ф (Chapter 2.2). In Chapter 2.3, we investigate the correlation 
between disease severity after RSV infection in infants and the expression of anti-
gen-presenting molecules on monocytes such as HLA-ABC and HLA-DR.
In Chapter 3, we investigate the T cell response during RSV infection. The use of 
newborn and adult mononuclear cells (MCs) allowed us to study the production of 
IFN-ф. Newborn cells contain naïve T cells without previous encounter to RSV, 
whereas adult T cells contain both naïve and memory RSV-speciﬁc T cells. We 
determine the role of the monocyte receptor Siglec-1 on the release of IFN-ф by 
newborn and adult CD4+ T cells after RSV infection (Chapter 3.1). In Chapter 3.2, we 
investigate the inhibitory effect of RSV and IFN-у on T cells and compare 
IFNAR-mediated immune pathways between newborn and adult T cells. 
In Chapter 4, we study the humoral response during RSV infections. We ﬁrst discuss 
the role of fc gamma receptors, as ligands for antibodies, during the innate immune 
response against RSV (Chapter 4.1). In Chapter 4.2, we describe the clinical 
correlation between matAbs, including antibodies against pre-fusion and post-fusion 
F protein, and disease severity in RSV-infected infants. In Chapter 4.3, we analyze 
the effects of antibodies on chemokine production in infant and adult immune cells in 
vitro. Finally, we investigate the activation of newborn and adult B cells upon exposure 
to RSV or IFN-у and determine the neutralizing capacity of newborn IgM on RSV 
infection in vitro (Chapter 4.4).
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 18
18
Chapter 1
References
1. Gorham, G. Descartes on the innateness of all ideas. Can J Philos 32, 355-388 (2002).
2. Nair, H., et al. Global burden of respiratory infections due to seasonal inﬂuenza in young children: 
a systematic review and meta-analysis. Lancet 378, 1917-1930 (2011).
3. Nair, H., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in 
young children: a systematic review and meta-analysis. Lancet 375, 1545-1555 (2010).
4. Hall, C.B., et al. The burden of respiratory syncytial virus infection in young children. The New England 
journal of medicine 360, 588-598 (2009).
5. Hall, C.B. The burgeoning burden of respiratory syncytial virus among children. Infectious disorders drug 
targets 12, 92-97 (2012).
6. Zhang, X.B., et al. Clinical characteristics and risk factors of severe respiratory syncytial virus-associated 
acute lower respiratory tract infections in hospitalized infants. World journal of pediatrics : WJP 10, 
360-364 (2014).
7. Openshaw, P.J. & Chiu, C. Protective and dysregulated T cell immunity in RSV infection. Current opinion 
in virology 3, 468-474 (2013).
8. Bulkow, L.R., Singleton, R.J., Karron, R.A., Harrison, L.H. & Alaska, R.S.V.S.G. Risk factors for severe 
respiratory syncytial virus infection among Alaska native children. Pediatrics 109, 210-216 (2002).
9. Stensballe, L.G., et al. Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory 
syncytial virus hospitalization, and recurrent wheeze. The Journal of allergy and clinical immunology 123, 
398-403 (2009).
10. Habibi, M.S., et al. Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in 
Experimental Infection of Adults with Respiratory Syncytial Virus. American journal of respiratory and 
critical care medicine 191, 1040-1049 (2015).
11. Glezen, W.P., Paredes, A., Allison, J.E., Taber, L.H. & Frank, A.L. Risk of respiratory syncytial virus 
infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal 
antibody level. The Journal of pediatrics 98, 708-715 (1981).
12. Eick, A., et al. The role of neutralizing antibodies in protection of American Indian infants against 
respiratory syncytial virus disease. The Pediatric infectious disease journal 27, 207-212 (2008).
13. Vieira, S.E., Gilio, A.E., Durigon, E.L. & Ejzenberg, B. Lower respiratory tract infection caused by 
respiratory syncytial virus in infants: the role played by speciﬁc antibodies. Clinics 62, 709-716 (2007).
14. Jans, J., et al. Fc gamma receptors in respiratory syncytial virus infections: implications for innate 
immunity. Reviews in medical virology 24, 55-70 (2014).
15. Zinkernagel, R.M. Maternal antibodies, childhood infections, and autoimmune diseases. The New 
England journal of medicine 345, 1331-1335 (2001).
16. Piedra, P.A. & Munoz, F.M. The signiﬁcance of transplacental antibody against respiratory syncytial virus. 
The Journal of infectious diseases 210, 1526-1528 (2014).
17. Homaira, N., Rawlinson, W., Snelling, T.L. & Jaffe, A. Effectiveness of Palivizumab in Preventing RSV 
Hospitalization in High Risk Children: A Real-World Perspective. International journal of pediatrics 2014, 
571609 (2014).
18. Miao, C., et al. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab’)2 
components mediates reduced pulmonary inﬂammation in mice. The Journal of general virology 90, 
1119-1123 (2009).
19. Boyoglu-Barnum, S., et al. A respiratory syncytial virus (RSV) anti-G protein F(ab’)2 monoclonal antibody 
suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. Journal 
of virology 87, 10955-10967 (2013).
20. Han, J., et al. Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus 
infection. American journal of respiratory cell and molecular biology 51, 143-154 (2014).
21. Delgado, M.F., et al. Lack of antibody afﬁnity maturation due to poor Toll-like receptor stimulation leads 
to enhanced respiratory syncytial virus disease. Nat Med 15, 34-41 (2009).
22. Modjarrad, K., et al. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from 
a World Health Organization Meeting held on 23-24 March 2015. Vaccine (2015).
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 19
19
General introduction & outline of the thesis
1
23. Tregoning, J.S. & Schwarze, J. Respiratory viral infections in infants: causes, clinical symptoms, virology, 
and immunology. Clinical microbiology reviews 23, 74-98 (2010).
24. Lambert, L., Sagfors, A.M., Openshaw, P.J. & Culley, F.J. Immunity to RSV in Early-Life. Frontiers in 
immunology 5, 466 (2014).
25. Openshaw, P.J. & Tregoning, J.S. Immune responses and disease enhancement during respiratory 
syncytial virus infection. Clinical microbiology reviews 18, 541-555 (2005).
26. Harris, N.L. & Ronchese, F. The role of B7 costimulation in T-cell immunity. Immunology and cell biology 
77, 304-311 (1999).
27. Karwacz, K., et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation 
on CD8+ T cells. EMBO molecular medicine 3, 581-592 (2011).
28. O’Connell, R.M., et al. Type I interferon production enhances susceptibility to Listeria monocytogenes 
infection. The Journal of experimental medicine 200, 437-445 (2004).
29. Charron, L., Doctrinal, A., Ni Choileain, S. & Astier, A.L. Monocyte:T-cell interaction regulates human 
T-cell activation through a CD28/CD46 crosstalk. Immunology and cell biology 93, 796-803 (2015).
30. Goritzka, M., et al. Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV 
through recruitment of antiviral monocytes. The Journal of experimental medicine 212, 699-714 (2015).
31. Ginhoux, F. & Jung, S. Monocytes and macrophages: developmental pathways and tissue homeostasis. 
Nature reviews. Immunology 14, 392-404 (2014).
32. Sieweke, M.H. & Allen, J.E. Beyond stem cells: self-renewal of differentiated macrophages. Science 342, 
1242974 (2013).
33. van de Veerdonk, F.L. & Netea, M.G. Diversity: a hallmark of monocyte society. Immunity 33, 289-291 
(2010).
34. Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proceedings of the Royal Society of 
London. Series B, Biological sciences 147, 258-267 (1957).
35. Kaur, S. & Platanias, L.C. IFN-beta-speciﬁc signaling via a unique IFNAR1 interaction. Nature immunology 
14, 884-885 (2013).
36. Adkins, B., Leclerc, C. & Marshall-Clarke, S. Neonatal adaptive immunity comes of age. Nature reviews. 
Immunology 4, 553-564 (2004).
37. Vekemans, J., et al. Neonatal bacillus Calmette-Guerin vaccination induces adult-like IFN-gamma 
production by CD4+ T lymphocytes. European journal of immunology 31, 1531-1535 (2001).
38. Mejias, A., et al. Whole blood gene expression proﬁles to assess pathogenesis and disease severity in 
infants with respiratory syncytial virus infection. PLoS medicine 10, e1001549 (2013).
39. Shi, C. & Pamer, E.G. Monocyte recruitment during infection and inﬂammation. Nature reviews. Immunology 
11, 762-774 (2011).
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 20
© Naut Oldenburg 2017
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 21
Monocytes
2
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 22
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 23
An in vitro model to study immune  
responses of human peripheral blood 
mononuclear cells to human respiratory 
syncytial virus infections
Marloes Vissers, Marrit Habets, Inge Ahout, Jop Jans, Marien de Jonge, 
Dimitri Diavatopoulos and Gerben Ferwerda
Jourrnal of Visualized Experiments 2013 Dec; 10;(82):e50766.
2.1
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 24
24
Chapter 2
Abstract
Human respiratory syncytial virus (HRSV) infections present a broad spectrum of 
disease severity, ranging from mild infections to life-threatening bronchiolitis. An important 
part of the pathogenesis of severe disease is an enhanced immune response leading 
to immunopathology.
Here, we describe a protocol used to investigate the immune response of human 
immune cells to an HRSV infection. First, we describe methods used for culturing, 
puriﬁcation and quantiﬁcation of HRSV. Subsequently, we describe a human in vitro 
model in which peripheral blood mononuclear cells (PBMCs) are stimulated with live 
HRSV. This model system can be used to study multiple parameters that may contribute 
to disease severity, including the innate and adaptive immune response. These responses 
can be measured at the transcriptional and translational level. Moreover, viral infection 
of cells can easily be measured using ﬂow cytometry. Taken together, stimulation of 
PBMC with live HRSV provides a fast and reproducible model system to examine 
mechanisms involved in HRSV-induced disease.
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Introduction
Human Respiratory Syncytial Virus (HRSV) is the most common cause of lower 
respiratory tract infections in children. Each year, over 33 million children under the 
age of ﬁve are infected with HRSV, leading to over three million hospitalizations and 
almost 200,000 deaths1. A growing body of evidence suggests that HRSV also poses 
a signiﬁcant threat to the elderly and adults with underlying chronic illnesses2.
The majority of HRSV infections in young children presents with mild symptoms, 
comparable to the common cold, and do not require clinical intervention. However, a 
small proportion of patients requires hospitalization and mechanical ventilation due 
to severe bronchiolitis.
Part of the pathogenesis of HRSV disease is the host’s exuberant and inadequate 
immune response to infection3,4. This is illustrated by several observations. The period 
of maximal illness is often preceded by the peak of viral infection and coincides better 
with cellular inﬁltration of infected tissues and the release of inﬂammatory cytokines3. 
Another line of evidence comes from the formalin inactivated HRSV (FI-RSV) trials in 
the 1960s. Instead of inducing protection in young infants, the vaccine resulted in an 
exaggerated immune response resulting in enhanced respiratory disease and higher 
morbidity and mortality.
Several models have been developed to study the pathogenesis of HRSV infections. 
Continuous cell lines, like HEp-2 and A549, have been used extensively to study 
HRSV infection in vitro. Epithelial cells are the primary targets of HRSV infection5, 
therefore a lot of focus has been on these cell types. However, the in vivo situation is 
much more complex and not limited to one cell type. In order to examine these 
complex interactions, several animal infection models have been developed to study 
HRSV pathogenesis. Thus far, two different strategies have been employed, focusing 
either on heterologous (nonhuman) models as well as cognate host-pneumovirus 
models. Examples of heterologous models for HRSV include chimpanzees, sheep, 
cotton rats and mice. RSV infection in its natural host has been studied in cattle and 
in mice, using bovine RSV and pneumovirus, respectively.
Whilst each of these models has provided important insights into disease patho -
genesis, HRSV is highly adapted to humans. Therefore, as an addition to the cell lines 
and animal models currently used, we propose to use human primary PBMCs as a 
model for stimulation with HRSV. Human PBMCs can be obtained from a range of 
individuals to address speciﬁc research questions, including young children6, immuno-
compromised individuals as well as healthy adults7 or elderly individuals8. PBMCs 
can be used to study innate aspects of infection as well as the adaptive response to 
the virus. Activated inﬂammatory pathways important for the pathogenesis of HRSV 
disease can be studied at the mRNA and protein level. Further, viral infection of 
(subsets of) immune cells can be determined by ﬂow cytometry. We have used this 
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model previously to identify the synergistic effects of HRSV infection together with 
the bacterial ligand muramyl dipeptide (MDP) on the induction of proinﬂammatory 
cytokines7. We propose to use HRSV stimulation of human primary PBMCs as a 
robust, easy and fast in vitro model to study inﬂammatory pathways involved in the 
pathogenesis of HRSV disease.
Methods
Note: Experiments with HRSV must be performed in a biological safety cabinet in a 
biosafety level 2 laboratory. Collect all viral waste and material that has been in 
contact with the virus for proper disposal due to biological hazards. Special precaution 
must be taken when using potentially infected human blood. It is crucial to use 
endotoxin-free reagents throughout all protocols.
1. Culturing of HRSV A2
Culture HeLa or HEp-2 cells in DMEM medium + 10% fetal calf serum (FCS) + 1% 
penicillin/streptomycin (P/S) in a 175 cm2 culture ﬂask until they are approximately 
50% conﬂuent.
Wash the cells three times with room temperature phosphate buffered saline (PBS).
Thaw a vial with HRSV seeding stock virus at 37 °C in a water bath. Dilute the virus 
stock so to keep the MOI 0.1 or below. This will prevent the generation of defective 
interfering particles (DIPs). Dilute the virus stock in 4 ml/ﬂask infection medium 
(DMEM + 1% P/S) and add to the HeLa or HEp-2 cells. Keep this volume as low as 
possible without causing the cells to dry out. The lower the volume the higher the 
infection rate will be.
Incubate 2-4 hr at 37 °C, 5% CO2. Swirl the ﬂask every 15 min to redistribute the 
medium. Take off the inoculum and wash one time with PBS. Add 15 ml culture 
medium (DMEM + 10%FCS + 1% P/S) and incubate for 3-5 days at 37 °C, 5% CO2. 
Observe the cells with normal bright ﬁeld microscopy for virus-induced cytopatho-
logical changes, e.g. syncytia formation and death and ﬂoating cells. When 
cytopathology appears, harvest HRSV by scraping cells and collect the virus 
suspension in a sterile 50 ml tube. Vortex the cell suspension. Scraping and vortexing 
of the cells releases more viral particles.
Centrifuge the virus suspension for 10 min at room temperature at 1,800 x g to pellet 
the cell debris. HRSV in the supernatant does not pellet at this speed and the 
supernatant can be directly used to infect multiple 175 cm2 ﬂasks or can be stored at 
-80 °C as seeding stock in 1 ml aliquots for future use. Always snap-freeze HRSV in 
liquid nitrogen to prevent loss of infectious virus particles.
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As stated above, the seeding stock made with the above protocol is used to infect 
multiple 175 cm2 culture ﬂasks. Repeat the exact protocol to produce more virus for 
puriﬁcation. Purify up to 180 ml of virus suspension in one ultracentrifugation cycle.
When cytopathology appears, harvest HRSV by scraping cells and collect 
supernatant. Vortex the virus suspension. Centrifuge for 10 min at room temperature 
at 1,800 x g to pellet the cell debris. HRSV in the supernatant does not pellet at this 
speed and the supernatant is aliquotted in 15 ml per 50 ml tube. Snap-freeze and 
store at -80 °C until puriﬁcation.
2. Purification of HRSV
Note: Before using an ultracentrifuge, be aware that it is a potentially dangerous 
piece of equipment. Read the manuals and perform the ﬁrst ultracentrifugation spin 
under supervision of someone with experience.
Clean ultracentrifugation buckets with 70% ethanol and let them dry in a biological 
safety cabinet. Place a sterile centrifuge tube in each bucket. Prepare 30% (w/v) 
sucrose in PBS solution, ﬁlter sterilize (0.2 μm ﬁlter) and add 5 ml to the bottom of 
each centrifuge tube. For a faster protocol, the tubes with sucrose solution can be 
frozen. Be sure to keep them sterile.
If the sucrose solution was not frozen, very carefully add 30 ml of HRSV solution on 
top of this sucrose solution. Pipette slowly to avoid disturbing the sucrose solution. 
Keep a clear demarcation. If the tubes were frozen, pour the viral suspension on top 
of the frozen sucrose solution and then let it thaw.
Very carefully balance the six ultracentrifugation buckets with sterile PBS. Put the 
scale into a ﬂow cabinet to keep everything sterile. Fill the tubes until 3-5 mm below 
the edge otherwise the centrifuge tubes can collapse. Balance the buckets to within 
0.1 g and include the screw-on cap, just in case the caps are not perfectly matched.
Centrifuge in the ultracentrifuge for 1.5 hr, 4 °C at 20,000 rcf.
Carefully remove the centrifuge tube from the bucket using sterile forceps. Virus 
particles will have passed through the sucrose layer and form a pellet. Conversely, 
cell-secreted soluble factors (e.g. cytokines) will stay in solution. Tip the centrifuge 
tube to drain all the liquid. Leave it upside-down on a sterile surface, e.g. a culture 
plate, to dry but don’t let the pellet completely dry out. Carefully add 1 ml Hank’s 
Balanced Salt Solution (HBSS) to the pellet and tip the centrifuge tube to drain the 
HBSS. Again let the tube dry upside-down on a sterile surface. Don’t let the pellet 
completely dry out. Resuspend the pellet in 1 ml HBSS by pipetting up and down 
40x. Try to prevent air bubble formation as this can destroy the virus.
Aliquot the virus, snap-freeze in liquid nitrogen and store at -80 °C until further use. 
Use a new aliquot of virus for each experiment, as repeated freeze-thawing will 
reduce the infectious titer. When thawing, always thaw the virus at 37 °C as HRSV is 
less stable between -20 and 15 °C.
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3. Quantification of HRSV
Note: To ensure reproducible data, repeat the quantiﬁcation at least 3x in duplicate.
3.1. Infection of A549 cells
Culture A549 cells in a 24-well plate until conﬂuent. Wash the A549 cells two times 
with 1 ml of PBS at room temperature. Prepare 5-fold serial dilutions of HRSV in 
Reduced Serum Medium. Add 100 μl of diluted virus to both wells. Make a minimum 
of 4 dilutions (e.g. 4-, 20-, 100-, and 500-fold). Include two extra wells infected with 
the highest dose of virus (these will be used for the isotype control) and include two 
mock-infected wells.
Incubate the cells for 2 hr at 5% CO2, 37 °C. Rock the 24-well plates every 15 min to 
prevent drying out. Remove the virus suspension and wash the cells 1x with 1 ml of 
PBS at room temperature. Prepare 4% (w/v) bovine serum albumin (BSA) in Reduced 
Serum Medium. Filter-sterilize (0.2 μm ﬁlter) and add 500 μl to each well. Incubate at 
5% CO2, 37 °C for 22 hr.
3.2. Preparation for FACS
Remove medium and wash cells one time with 1 ml of room temperature PBS. Add 
200 μl of prewarmed trypsin (37 °C) to each well and incubate for 10 min at 37 °C, 5% 
CO2. Check cells for detachment under the microscope. If cells are detached, add 
800 μl DMEM + 10% FCS + 1% P/S to neutralize the trypsin. Resuspend the cells.
mTransfer the cells to a conical, nontissue culture treated 96-well plate Centrifuge 5 
min at 400 x g at room temperature. Resuspend the pellets in 200 μl cold PBS. 
Centrifuge 5 min at 400 x g at 4 °C. Decant the supernatant and resuspend in 200 μl 
cold PBS. Centrifuge 5 min at 400 x g at 4 °C. Decant the supernatant and resuspend 
in 150 μl 80% ice-cold acetone.
Fixate the cells at room temperature for 15 min. Centrifuge 5 min at 400 x g at 4 °C. 
Decant the supernatant and resuspend in 200 μl cold PBS + 0.1 % BSA. Centrifuge 
5 min at 400 x g at 4 °C. Decant the supernatant and resuspend in 50 μl anti-NP-RSV-
FITC (1:50 diluted in PBS + 1% BSA) or 50 μl IgG2 anti mouse-FITC (this is an isotype 
control; therefore use same antibody concentration). For the remainder of the 
protocol, keep tubes in dark. Incubate at least 1 hr at 4 °C but this can be extended 
to overnight.
Add 150 μl cold PBS + 0.1% BSA. Centrifuge 5 min at 400 x g at 4 °C. Decant the 
supernatant and resuspend in 200 μl cold PBS + 0.1% BSA. Centrifuge 5 min at 400 
x g at 4 °C. Decant the supernatant and resuspend in 200 μl cold PBS + 0.1% BSA. 
Keep plate on ice and in the dark until FACS measurement. Measure the infected 
cells on a ﬂow cytometer.
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3.3. FITC-50 calculation
Use a ﬂow cytometry analysis program to set the cutoff using the negative control 
(isotype control). Use the Pseudocolor graph type. Draw a quadrant gate, where the 
positive cells are in ﬁeld Q3. The percentage of false positives should be below 0.2% 
in both isotype controls.
Export the data to a spreadsheet program and prepare a table with the percentage of 
FITC+ cells for each dilution. Subtract the average value of false positives (as determined 
by the isotype control) for each experiment for each value.
Open a new ﬁle (XY scatter, Single X and multiple Y columns) in a statistics program. 
Copy data to this program: X = dilution, Y = % infected cells, n = 3, use the average 
of two measurements for each dilution. Perform a nonlinear regression, one-phase 
exponential decay statistical analysis. Check if the curve ﬁts the data points, if not, 
choose a different statistical analysis.
Copy the equation for the curve and the values for the equation to a spreadsheet 
program. Calculate the X value for Y = 50%. Accordingly determine the FITC-50 value 
by calculating the FITC-detected Infectious Particles/ml (FIP/ml) at the dilution at 
which there is 50% infection, using the following equation:
A = average number of A549 cells/well
B = μl virus per well used for infection
C = dilution at which there is 50% infection
4.  Peripheral Blood Mononuclear Cell (PBMC) Isolation from Healthy 
Volunteer Blood
Draw venous blood in 10 ml EDTA tubes from healthy volunteers upon informed 
consent. A volume of 10 ml of blood will yield approximately 107 PBMCs. From now 
on, work sterile in a ﬂow-cabinet. Dilute the blood 2x with room temperature PBS in a 
50 ml tube. Per 50 ml tube a maximal total volume of 35 ml of diluted blood can be 
used. Take a 50 ml sterile syringe and add a sterilized Luer lock needle. Take up 
density gradient media in the syringe. Place the needle on the bottom of a tube with 
diluted blood and carefully pipette 15 ml density gradient media under the diluted 
blood. Keep a clear demarcation between density gradient media and blood.
Centrifuge at 800 x g at room temperature for 20 min with acceleration at 9 (max) and 
the brake off. Set the temperature of the centrifuge to 4 °C after use. The density gradient 
centrifugation will result in multiple layers. On the bottom a pellet with erythrocytes is 
present with a silvery layer on top, which contains the neutrophils. The clear layer 
above this pellet contains the density gradient media. A thin layer between the density 
gradient media and the blood plasma layer on top contains PBMCs.
Carefully collect the PBMCs with a Pasteur pipette and transfer cells to a new 50 ml 
tube. From now on keep the PBMCs on ice and use ice-cold PBS. Add ice-cold PBS 
to a volume of 50 ml and centrifuge at 400 x g for 10 min at 4 °C (with the brake set at 9). 
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Discard the supernatant by aspiration, resuspend the pellet in 50 ml of ice-cold PBS 
and centrifuge at 400 x g 10 min at 4 °C, repeat 2x. After discarding the supernatant, 
add 1 ml of ice-cold medium (RPMI + 1% P/S) and count cells using a counting 
chamber. Adjust the cell concentration to 5 x 106 PBMCs/ml.
5. Stimulation of PBMCs with Live HRSV
Prepare a setup of the experiment; include experimental duplicates for each condition. 
Dilute all necessary stimuli in medium (RPMI + 1% P/S). Keep in mind that the ﬁnal 
volume per well will be 200 μl. A volume of 50 μl of stimuli will be added so prepare 
4x concentrated stimulation stocks. Add 100 μl of the above mentioned cell 
suspension to each well of a round bottom 96-well plate (5 x 105 PBMC/well). Add 50 
μl of the diluted stimuli to each well. It is possible to add two different stimuli, which 
gives a volume of 200 μl. If only one stimuli is needed adjust the volume to 200 μl with 
medium. Incubate the 96-well plate for the required incubation period at 37 °C in a 5% 
CO2 incubator. For most cytokines 24 hr of incubation will be sufﬁcient.
6. Readout of Stimulation
After the incubation period, centrifuge the 96-well plate for 5 min at room temperature 
at 450 x g to collect the cells at the bottom. Collect the supernatant (take a maximal 
volume of 180 μl) and store for subsequent cytokine analysis (-20 °C) or for virus 
production (-80 °C). The stimulated PBMCs that are present in the pellet can either be 
analyzed by qPCR/Western blot by adding lysis buffer or alternatively, PBMCs can be 
stained for ﬂow cytometry analysis.
Results
The HRSV A2 cultivation and puriﬁcation method described here will give a yield 
between 2 x 107 and 2 x 108 FITC-50 quantiﬁed infectious viral particles/ml. Results of 
microscopic analysis, where FITC-stained infected cells were counted (results not 
shown), were compared to results of quantiﬁcation by FACS. Both methods resulted 
in similar titers, although the FACS method had a much lower standard deviation 
between different experiments and was less laborious.
When performing a PBMC stimulation experiment we recommend using the stimuli- 
fraction method. With this method the conditions are divided in stimuli conditions and 
fraction conditions (Figure 1). The stimuli conditions are the standard conditions (e.g. 
RPMI and HRSV). The fraction conditions are the test conditions (e.g. RPMI, MDP, 
and LPS). Always include a negative control and a positive control in each experiment. 
In this experiment LPS is the positive control and RPMI is the negative control. LPS 
can often be used as a positive control when proinﬂammatory cytokines will be 
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measured such as TNFт and IL-1у. The stimuli-fraction method prevents the omission 
of important control conditions.
After 24 hr of stimulation different cell types present in the PBMC showed a dose- 
dependent infection rate (Figure 2). Different cell types show a difference in efﬁciency 
of HRSV infection. HRSV was able to infect monocytes and NK cells at a lower MOI 
value compared to CD4+ T cells and CD8+ T cells.
Figure 1  Schematic diagram of a stimulation experiment of human PBMCs in a 96-well 
plate. Always include duplicates for each condition and include positive and negative controls.
 
Figure 2  Different PBMC cell types are infected with different susceptibility and in a 
dose-dependent manner. PBMCs isolated from four healthy volunteers were stimulated with 
ﬂuorescent HRSV A2 (MOI = 0.2, 1, and 5). After 24 hr of incubation at 37 °C PBMCs were stained 
with antibodies against CD14 (monocytes), CD56 (NK cells), CD3 and CD4 (CD4+ T cells) or 
CD3 and CD8 (CD8+ T cells). Data are presented as mean percentage of infection + SEM and 
represent two individually performed experiments.
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After 24 hr of stimulation the PBMCs are lysed and analyzed by qPCR for the 
expression of TNF-т and IFN-ф (Figure 3). TNF-т is a cytokine that is mainly produced 
by monocytes and is therefore often regarded as a typical innate cytokine. IFN-ф can 
be produced by various cell types, including NK cells and T cells, and therefore 
represents both the innate as well as the adaptive response. As shown in Figure 3, 
HRSV strongly upregulated TNF-т and IFN-ф transcription. Conversely, stimulation 
with MDP and LPS only results in a weak expression increase. However, when PBMCs 
are stimulated with both HRSV and MDP together, a strong synergistic upregulation 
is observed.
Stimulated PBMCs were also analyzed for the secretion of TNF-т and IFN-ф by ELISA 
(Figure 4). For both cytokines, the negative control remains negative. Whilst LPS is a 
good positive control for TNF-т, it does not induce IFN-ф. A better control for IFN-ф 
production may be to stimulate PBMCs with Candida albicans, which is known to 
induce IFN-ф. In contrast to observations at the transcriptional level, HRSV is a poor 
inducer of IFN-ф and TNF-т protein secretion by PBMC. Stimulation with MDP results 
in the detection of low amounts of TNF-т and no IFN-ф. Similar to the transcriptional 
analysis, both TNF-т and IFN-ф show a synergistic upregulation when costimulated 
with HRSV and MDP.
As a control to see whether cytokine induction is dependent on replication of HRSV, 
we stimulated PBMCs with live and BPL inactivated HRSV9. As can be seen in Figure 5, 
inactivated HRSV is also recognized by immune cells and induces inﬂammatory 
cytokines. 
Figure 3  Costimulation with HRSV and MDP results in synergistic upregulation of TNF-͂ 
and IFN-̈́ expression. PBMCs isolated from ﬁve healthy volunteers were stimulated with 
HRSV A2 (MOI = 1), MDP (5 μg/ml) or LPS (1 ng/ml), or a combination of stimuli. TNF-т and 
IFN-ф transcription was measured by quantitative PCR and expressed as fold-increase 
compared to unstimulated cells. Cells were lysed after 24 hr of incubation at 37 °C. Data are 
presented as mean + SEM of the pooled duplicates of all ﬁve samples and represent a 
minimum of two performed experiments.
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and IFN-̈́ secretion. PBMCs isolated from ﬁve healthy volunteers were stimulated with HRSV 
A2 (MOI = 1), MDP (5 μg/ml) or LPS (1 ng/ml), or a combination of stimuli. The levels of TNF-т 
and IFN-ф in culture supernatants were measured by ELISA after 24 hr of stimulation at 37 °C. 
Data are presented as mean + SEM of the pooled duplicates of all ﬁve samples and are 
representative of minimal two experiments performed.
Figure 5  Both live HRSV as BPL inactivated HRSV induce proinﬂammatory cytokine 
responses. PBMCs from four healthy volunteers were stimulated with HRSV A2 (MOI = 1) or 
the same dose of BPL inactivated HRSV (RSV-BPL). The levels of TNF-т and IFN-ф in culture 
supernatants were measured by ELISA after 24 hr of stimulation at 37 °C. Data are presented 
as mean + SEM of the pooled duplicates of all four samples and are representative of minimal 
two experiments performed.
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Discussion
In this study, we demonstrate that infection of PBMC with HRSV is a fast and reliable 
model system in which inﬂammatory pathways can be studied. In order to stimulate 
PBMCs an HRSV stock has to be prepared and quantiﬁed.
Multiple cell lines are susceptible to HRSV infection. Cell lines most used for HRSV 
culturing are HEp-2, HeLa, and Vero cells. However, we would not recommend the 
usage of Vero cells for culturing of HRSV because it has been shown that culturing of 
HRSV in Vero cells results in a truncated G-protein of HRSV10. Also, always use low 
amounts of virus to infect the cells for culturing because of the risk of generating 
defective interfering particles11. Defective interfering particles (DIPs) are viral particles 
that miss part or all of their genome. DIPs can therefore not sustain an infection by 
themselves but rely on infectious virus. Due to their small genomes, they are more 
efﬁciently replicated than a fully functional virus, which can result in large numbers of 
noninfectious particles. These DIPs cannot be measured by quantiﬁcation techniques 
relying on replication. However, they probably will be recognized in a stimulation 
experiment of immune cells. Therefore, it is crucial to keep them as low as possible. 
Treuhaft et al. have shown that when HRSV is cultured using an MOI of 0.1, they were 
not able to detect DIPs after 8 passages11.
For reproducibility between different batches of virus, an accurate determination of the 
number of infectious particles/ml is important. Standard methods for HRSV quantiﬁcation 
are plaque formation and TCID50 determination on HEp-2 or HeLa cells. As HRSV is 
a poorly-cytopathic virus, cytopathogenic effect (CPE) detection can be hard and 
is therefore subjective. Usage of ﬂuorescent antibodies can solve the problem with 
subjectivity. However, both methods require lengthy incubation. Our described 
method of quantiﬁcation of HRSV using ﬂow cytometry has proven to be fast and 
reproducible. Similar protocols have been described for other viruses12.
In this study, we demonstrated how PBMCs can be stimulated with live HRSV. 
We showed that different cell types in PBMCs are infected by HRSV. They showed 
a dose-response to HRSV infection and different cell types showed a different 
susceptibility. We also demonstrated that whilst stimulation with HRSV alone induces 
an appreciable upregulation of inﬂammatory genes at the mRNA level, only low 
amounts of IFN-ф and TNF-т were secreted. However, costimulation with a bacterial 
ligand, i.e. MDP, induces a synergistic increase in proinﬂammatory cytokine production. 
In a previous study we showed that this model system can very easily be adapted to 
study inﬂammatory pathways induced by other viruses, e.g. inﬂuenza or rhinovirus7.
To account for interindividual variation with human primary cells, stimulation 
experiments of PBMCs should be performed with at least ﬁve donors and in two 
separate experiments. For instance, the responses of human PBMCs to e.g. LPS are 
known to be divided into high responders and low responders13. These highly 
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variable responses can be caused by differences in cell counts between individuals, 
but also by differences in the intrinsic capacity of these cells to respond to stimuli. 
Especially in the context of HRSV infections, which show such a broad spectrum of 
severities, this interindividual variation could also lead to interesting observations 
regarding individual differences in susceptibility or immune response. Due to the fact 
that donors can be divided in high and low responders, nonparametric statistical 
methods should be used in analyzing cytokine data.
Whilst many studies have used continuous cell lines, e.g. A549 cells, to study the 
response to HRSV infection, cell lines are very different from primary cells and may 
therefore not always reﬂect the biological situation in vivo. Although epithelial cells are 
generally regarded as the primary cells infected by HRSV5, the immune cells present 
below and between the epithelial cells play a very important role in disease 
pathogenesis14,15. Thus, excluding these cells from the experimental setup disregards 
an important part of the host response. Epithelial cells with a higher relevance are the 
normal human bronchial epithelial cells (NHBEs)16, which are primary bronchial cells 
that can be differentiated into ciliated mucus producing cells. These NHBEs can be 
polarized in a transwell system on an air-liquid interface and therefore resemble the 
airway epithelium much better. An example of how the complex interplay between 
epithelial cells and immune cells can be mimicked in vitro is by adding PBMCs to the 
basolateral side of polarized NHBE cells, which creates a situation that may be more 
comparable to the in vivo situation.
Inﬂammatory pathways can also be tested using whole blood. Whole blood stimulations 
are even faster and require fewer resources compared to PBMC stimulations. 
However, it is important to note that PBMCs do not contain plasma proteins. Blood 
plasma contains many proteins, including complement proteins, cytokines and 
antibodies. Because every individual above the age of two will have encountered an 
infection with HRSV, blood plasma will contain HRSV-speciﬁc neutralizing antibodies. 
Infection of cells in the presence of human serum or plasma is therefore not possible.
The biggest advantage of animal models is that it creates the opportunity to examine 
HRSV infection in vivo. Whilst this complex interplay of cells cannot be mimicked 
using PBMCs, it should be noted that no animal model to date has reproduced the 
total range of pathologies seen in HRSV infected humans. Consequently, human 
PBMCs remain relevant to study HRSV infections. A major beneﬁt of using PBMCs is 
the availability of multiple patient groups that can be compared. For instance, PBMCs 
from the elderly can be used as well as from immunocompromised adult patients. As 
HRSV is especially prone to infect very young infants, PBMCs from these age groups 
and/or patient groups are especially relevant to use. Stimulation experiments as 
described above are already feasible with an amount of 3 ml of blood. In addition, 
previous studies have shown that these experiments can also be performed on 
PBMCs from cord blood17.
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In conclusion, the procedures described in this paper offer a reproducible and easy 
to use method to examine mechanisms involved in HRSV-induced disease.
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Abstract
Background: Respiratory syncytial virus (RSV) can cause recurrent and severe 
respiratory tract infections. Cytoskeletal proteins are often involved during viral infections, 
either for cell entry or the initiation of the immune response. The importance of actin 
and clathrin dynamics for cell entry and the initiation of the cellular immune response 
against RSV in human immune cells is not known yet. The aim of this study was to 
investigate the role of actin and clathrin on cell entry of RSV and the subsequent 
effect on T cell activation and interferon gamma release in human immune cells. 
Methods: Peripheral blood mononuclear cells and puriﬁed monocytes were isolated 
from healthy adults and stimulated in vitro with RSV. Actin and clathrin dynamics were 
inhibited with respectively cytochalasin D and chlorpromazine. T cell receptor signaling 
was inhibited with cyclosporin A. Flow cytometry was used to determine the role of 
actin and clathrin on cell entry and T cell activation by RSV. Enzyme-linked immuno -
sorbent assays were used to investigate the contribution of actin and clathrin on the 
release of interferon gamma.
Results: Cell entry, virus gene transcription and interferon gamma release are actin- 
dependent. Post-endocytic processes like the increased expression of major histo-
compatibility complex II, T cell activation and the release of interferon gamma are 
clathrin-dependent. Finally, T cell receptor signaling affects T cell activation, whereas 
soluble interleukin 18 is dispensable. 
Conclusion: Analysis of cell entry and interferon gamma release after infection with 
RSV reveals the importance of actin- and clathrin-dependent signaling in human immune 
cells. Insights into the cellular biology of the human immune response against 
respiratory syncytial virus will provide a better understanding of disease pathogenesis 
and may prove useful in the development of preventive strategies. 
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Background
Respiratory syncytial virus (RSV) is a negative-sense single stranded RNA virus of the 
family Paramyxoviridae and is a major burden on the current health care system. In healthy 
adults, RSV infections are limited to the upper respiratory tract, but remarkably do not 
generate long-term immunity [1]. In children and elderly, RSV can cause severe lower 
respiratory tract infections requiring admission to an intensive care unit in a small 
percentage of cases. 
The ﬁrst line of defense against RSV infection consists of epithelial cells. Upon 
infection, epithelial cells attract antigen-presenting cells, including dendritic cells and 
monocytes. Monocytes and macrophages are able to engulf pathogens leading to 
antigen-presentation. The monocytic cell is one of the major immune cell types that 
is susceptible to RSV infection and the role of monocytes and macrophages in the 
pathogenesis of RSV infections has been appreciated for decades [2-7]. 
During RSV infection in mice, the recruitment of monocytes from the bloodstream 
limits viral replication and reduces disease severity [8]. Viral particles can interact 
with receptors at the membrane of monocytes resulting in attachment, uptake and 
initiation of the immune response [9-11]. Under many circumstances, actin or clathrin 
are essential for receptor-mediated internalization [12-16]. Internalization can be 
regulated differentially dependent on the cell type. Uptake of transferrin occurs clath-
rin-dependent in macrophages and is not dependent on clathrin in epithelial cells 
[17]. Cell-speciﬁc differences in entry mechanisms between epithelial cells and 
ﬁbroblasts have been shown for human cytomegalovirus [18]. 
Previous studies have studied the internalization of RSV in epithelial cells [19-22]. No 
data is available regarding cell entry of RSV in monocytes, which raises the question 
whether internalization of RSV occurs differentially in innate immune cells. After inter-
nalization, immune cells are involved in antigen-presentation, T cell activation and the 
production of cytokines like interferon gamma (IFN-ф). IFN-ф, a type II interferon, plays 
a critical role in the immune response against viral infections [23]. T cell activation 
may occur through cytokines like interleukin 18 (IL-18) or through stimulation of the 
T cell receptor (TCR). The relationship between cell entry, T cell activation and 
subsequent release of IFN-ф during RSV infection in primary human cells is unknown. 
Peripheral blood mononuclear cells (PBMCs) provide a useful model to investigate 
the impact of cellular pathways on antiviral immunity. PBMCs contain important cells 
that reﬂect the immune response against RSV like dendritic cells, monocytes and 
T cells  [4, 24-27]. 
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In this study, we aimed to investigate the regulation of IFN-ф by actin- and clathrin-de-
pendent mechanisms after stimulation of human immune cells with RSV. For this, we 
used pharmacological inhibitors to inhibit actin and clathrin. Hereby, the contribution 
of actin- and clathrin-dependent processes on cell entry, T cell activation and 
induction of IFN-ф in primary human immune cells during RSV infection was studied.
Methods
Pharmacological inhibitors. Actin-dependent pathways were inhibited by pre-treatment 
of cells with CytoD (1 μg/ml) or Wisko (10 μM) and clathrin-dependent pathways were 
inhibited by CPZ (5 μg/ml) (Sigma-Aldrich). CsA (Sigma-Aldrich) and IL-18bp (R&D 
Systems, United Kingdom) were used to respectively inhibit T cell receptor signaling 
and IL-18. No cytotoxic effect determined as Annexin V+/7-AAD+ cells was observed 
when using the indicated concentrations of the inhibitor (data not shown).
Cell isolation. After obtaining informed consent, peripheral blood mononuclear cells 
(PBMCs) from healthy adults were isolated using Lymphoprep and isolation of mono- 
cytes from the PBMC fraction was performed using an indirect negative selection 
magnetic labeling kit (Monocyte Isolation Kit II human; Miltenyi Biotec). Each 96-well 
plate was ﬁlled with 5 x 105 PBMC per well or 1x105 isolated monocytes per well. 
The study was approved by the committee on Research involved Human Subjects 
of the Radboudumc.
Culture of RSV. RSV A2 containing an additional transcription unit encoding GFP 
(rgRSV) was cultured as previously described [50]. GFP-labeled RSV A2 (rgRSV30) 
kindly proved by Dr. M.E. Peeples was cultured on HeLa cells (ATCC, CCL-2) in 
Dulbecco’s minimum essential medium (DMEM) with 10% fetal calf serum (FCS) and 
1% penicillin/streptomycin. Near-conﬂuent HeLa cells were infected with rgRSV A2 
and incubated for three days at 37 °C. Cells were scraped and the suspension was 
centrifuged to remove cellular debris. rgRSV was ultracentrifuged on a sucrose cushion 
for puriﬁcation and titrated on HeLa cells. Conﬂuent HeLa cells (80-90%) were 
infected with ﬁvefold viral dilutions for 20-22h. Virus titer was determined by counting 
wells with *10 and )100 infected cells/view (CKX41 microscope; Olympus, Tokyo, 
Japan). rgRSV was snapfrozen and stored at −80 °C until use.
Internalization and binding assay. PBMCs or isolated monocytes were treated with 
CytoD (1 μg/ml), Wisko (10 μM) or CPZ (5 μg/ml) for 30 min at 37°C. For quantiﬁcation 
of cell entry, monocytes were permeabilized with CytoFix/Perm (BD Biosciences) 
after incubation with RSV at MOI 1 (5 x 105 IU/well) for 1h at 37 ºC. Cells were incubated 
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for 30 min on ice with mouse anti-respiratory syncytial virus fusion protein antibody 
(Ab24011; Abcam). Goat anti-mouse IgG PE (BD Pharmingen) was used as secondary 
antibody. For the quantiﬁcation of RSV binding, co-incubations of PBMCs with RSV 
were performed for 1 hour at 4°C and cells were ﬁxed with 1% paraformaldehyde 
before staining. 
T cell activation and MHC expression. PBMCs were treated with CPZ (5 μg/ml) for 
30 min at 37°C. PBMCs were stimulated with RSV at MOI 1 or with PHA (5 μg/ml) for 
24 h. CD69 expression, a T cell activation marker, was measured with ﬂow cytometry. 
For gating, CD3 and CD4 or CD8 positive T cells were selected and the percentage 
of CD69 positive cells was determined. After pre-treatment with CPZ (5 μg/ml), 
PBMCs were incubated with RSV at MOI 1 for 24 hour and the expression of MHC-I 
and MHC-II on monocytes was determined. For gating, CD14 positive cells were 
selected and the geometric mean ﬂuorescence intensity (MFI) of MHC-I and MHC-II 
was determined.
Flow cytometry. Cell surface markers were stained with CD14 V500, CD14 AF647, 
CD3 V500, CD8 APC-H7, CD8 PE, CD4 PerCP-Cy5.5, CD69 Pe-Cy7, HLA-ABC PE 
and HLA-DR PE (BD Pharmingen). For quantiﬁcation of RSV, mouse anti-RSV F 
protein (Ab24011; Abcam) and goat anti-mouse IgG PE (BD Pharmingen) were used. 
Virus gene transcription was determined as the percentage of GFP positive cells. 
Cytoxocity was determined by calculating Annexin V+/7-AAD+ cells (PE Annexin V 
Apoptosis Detection Kit I, BD Pharmingen). Events were acquired on an LSR II ﬂow 
cytometer and analyzed using FlowJo.
In vitro cytokine production. PBMCs were treated with CytoD (1 μg/ml), CPZ (5 μg/
ml) or CsA (100 nM) for 30 min at 37°C. After pre-treatment, cells were stimulated with 
RSV at MOI 1, PHA (1 μg/ml) or heat-killed Candida albicans (1 x 106/well) for 24 h. 
IL-18bp (1 μg/ml) was added simultaneously with RSV. Concentration of interferon 
gamma were measured in the cell supernatants by enzyme-linked immunosorbent 
assays (ELISA) (Sanquin Blood Supply, the Netherlands) with a lower limit of detection 
of 20 pg/ml.
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Results
Cell entry and subsequent virus gene transcription of RSV in monocytes are 
actin-dependent. We ﬁrst examined the dynamics of cell entry of RSV into CD14+ 
monocytes by using pharmacological inhibitors. Cytochalasin D (CytoD) and Wiskostatin 
(Wisko) have been used in previous literature to inhibit actin-dependent entry and 
chlorpromazine (CPZ) for clathrin-dependent entry [28-30]. A representative ﬁgure of 
the gating strategy to determine internalization of RSV into monocytes is shown 
(Fig. 1A). Disruption of actin ﬁlaments in monocytes with CytoD or Wisko signiﬁcantly 
reduces the internalization of RSV whereas inhibition of clathrin with CPZ has no 
effect on the internalization indicating that cell entry is an actin-dependent process 
(Fig. 1B). Extracellular binding of RSV on membrane of monocytes occurred and is 
not reduced by pre-treatment of monocytes with CytoD or CPZ (Fig. 1C).  To conﬁrm 
the inhibitory effect of CytoD on cell entry, PBMCs were stimulated with RSV for 24h 
and virus gene transcription was measured in monocytes. Treatment of PBMCs with 
CytoD abrogates virus gene transcription in monocytes whereas CPZ has no effect 
(Fig. 1D). Mean percentages of internalization, binding and virus gene transcription in 
monocytes were respectively 29%, 13% and 4%.  
IFN-̈́ release after RSV infection is actin- and clathrin-dependent. Previous 
literature shows that T cells are the main producers of IFN-ф in our model of PBMCs 
and stimulation with RSV [24]. To determine whether the adaptive immune response 
against RSV is actin-dependent, the IFN-ф release was measured after stimulation of 
PBMCs with RSV. Inhibition of actin with CytoD abrogates the RSV-induced IFN-ф 
release (Fig. 2A). Although CPZ has no effect on the internalization of RSV, inhibition 
of clathrin reduces the release of IFN-ф (Fig. 2B). Both CytoD and CPZ have no effect 
on T cell activation after stimulation with the non-speciﬁc T cell activator phytohaem-
agglutinin (PHA) (Fig. 2A-B). From this, we conclude that both cell entry and 
post-endocytic processes play a role in the adaptive immune response against RSV 
whereas mere binding of RSV to the cell membrane of monocytes is not sufﬁcient to 
induce IFN-ф release.
T cell activation and upregulation of MHC-II after RSV infection are clathrin- 
dependent. To address the discrepancy between clathrin-independent internalization 
and clathrin-dependent IFN-ф release, we examined whether post-endocytic processes 
like T cell activation and upregulation of antigen-presenting molecules are clathrin- 
dependent. CD69 was used as an activation marker on T cells [31]. PHA was used as 
positive control for T cell activation. RSV induces activation of CD4 and CD8 T cells 
and pre-treatment of PBMCs with CPZ prevents T cell activation after RSV infection 
(Fig. 3A-B). To investigate whether the upregulation of antigen-presenting molecules 
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 45
45
Monocytes
2
Fi
g
ur
e 
1A
-D
  C
el
l e
nt
ry
 a
nd
 s
ub
se
q
ue
nt
 v
ir
us
 g
en
e 
tr
an
sc
ri
p
tio
n 
o
f R
S
V
 in
 m
o
no
cy
te
s 
is
 a
ct
in
-d
ep
en
d
en
t. 
(A
) G
at
in
g 
st
ra
te
g
y 
to
 d
et
er
m
in
e 
th
e 
am
ou
nt
 o
f i
nt
er
na
liz
at
io
n 
of
 R
S
V 
in
 m
on
oc
yt
es
. (
B
) M
on
oc
yt
es
 w
er
e 
pr
e-
tre
at
ed
 w
ith
 R
P
M
I, 
C
yt
oD
 (1
 μ
g
/m
l),
 W
is
ko
 (1
0 
μM
) o
r C
P
Z 
(5
 μ
g
/m
l).
 A
fte
r 
pr
e-
tre
at
m
en
t, 
m
on
oc
yt
es
 w
er
e 
in
cu
ba
te
d 
w
ith
 R
P
M
I 
or
 R
S
V 
at
 M
O
I 
1 
fo
r 
1h
 a
t 
37
ºC
 a
nd
 i
nt
er
na
liz
at
io
n 
w
as
 m
ea
su
re
d.
 (
C
) 
M
on
oc
yt
es
 w
er
e 
pr
e-
tre
at
ed
 w
ith
 R
P
M
I, 
C
yt
oD
 (1
 μ
g
/m
l),
 o
r 
C
P
Z 
(5
 μ
g
/m
l).
 A
fte
r 
pr
e-
tre
at
m
en
t, 
m
on
oc
yt
es
 w
er
e 
in
cu
ba
te
d 
w
ith
 R
P
M
I o
r 
R
S
V 
at
 M
O
I 1
 fo
r 
1h
 a
t 4
ºC
 
an
d 
bi
nd
in
g 
w
as
 m
ea
su
re
d.
 (
D
) P
B
M
C
s 
w
er
e 
pr
e-
tre
at
ed
 w
ith
 R
P
M
I, 
C
yt
oD
 (1
 μ
g
/m
l) 
or
 C
P
Z 
(5
 μ
g
/m
l).
 A
fte
r p
re
-t
re
at
m
en
t, 
P
B
M
C
s 
w
er
e 
in
cu
ba
te
d 
w
ith
 R
P
M
I 
or
 R
S
V 
at
 M
O
I 
1 
fo
r 
24
h 
an
d 
vi
ru
s 
ge
ne
 t
ra
ns
cr
ip
tio
n 
w
as
 m
ea
su
re
d 
in
 m
on
oc
yt
es
. 
O
ne
-w
ay
 a
na
ly
si
s 
of
 v
ar
ia
nc
e 
w
ith
 B
on
fe
rr
on
i’s
 
C
om
pa
ris
on
 T
es
t 
w
as
 u
se
d 
fo
r 
st
at
is
tic
al
 a
na
ly
si
s.
 D
at
a 
ar
e 
no
rm
al
iz
ed
 t
o 
un
tre
at
ed
 c
el
ls
 a
nd
 d
ep
ic
te
d 
as
 m
ea
n 
±
 S
E
M
 (
N
=
4-
6)
. 
(*
*p
<
0.
01
, 
**
*p
<
0.
00
1)
 (N
S=
no
 s
ig
ni
ﬁc
an
t d
iff
er
en
ce
 b
et
w
ee
n 
un
tre
at
ed
 a
nd
 C
yt
oD
-t
re
at
ed
 c
el
ls
 o
r b
et
w
ee
n 
un
tre
at
ed
 a
nd
 C
P
Z-
tre
at
ed
 c
el
ls
).
B
C
D
A
G
at
in
g 
st
ra
te
gy
 In
te
rn
al
iz
at
io
n
S
S
C
FS
C
R
S
V
 F
 p
ro
te
in
U
ns
tim
ul
at
ed
R
S
V
R
S
V
 +
 C
yt
oD
R
S
V
 +
 C
P
Z
M
on
oc
yt
es
0.
3%
39
.0
%
12
.4
%
40
.8
%
In
te
rn
al
iz
at
io
n
025507510
0
12
5
C
yt
oD
 (1
μg
/m
l)
W
is
ko
 (1
0
μM
)
--
-+
+-
--
C
P
Z 
(5
μg
/m
l)
-
-
-
+
N
S
**
*
**
*
F protein positive monocytes
(normalized to untreated)
B
in
di
ng
025507510
0
12
5
C
yt
oD
 (1
μg
/m
l)
C
P
Z 
(5
μg
/m
l)
--
-+
+-
N
S
N
S
F protein positive monocytes
(normalized to untreated)
V
iru
s 
ge
ne
 tr
an
sc
rip
tio
n
025507510
0
12
5
C
yt
oD
 (1
μg
/m
l)
C
P
Z 
(5
μg
/m
l)
--
-+
+-
**
N
S
GFP positive monocytes
(normalized to untreated)
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 46
46
Chapter 2
is inhibited by CPZ, the expression levels of MHC-I and MHC-II on monocytes was 
determined. RSV induces a signiﬁcant increase of MHC-I and MHC-II expression on 
monocytes (Fig. 3C-D). Upregulation of MHC-I expression is not affected by treatment 
of PBMCs with CPZ (Fig. 3C). The RSV-induced upregulation of MHC-II expression is 
not present after pre-treatment of PBMCs with CPZ indicating that upregulation of 
MHC-II is clathrin-dependent (Fig. 3D). 
IFN-̈́ release after RSV infection is dependent on T-cell receptor signaling. To 
conﬁrm the role of antigen-presenting molecules and thereby TCR signaling as its 
ligand, we evaluated whether IL-18, as a soluble T cell activator, or TCR signaling 
affects the IFN-ф release after RSV infection. Neutralization of IL-18 with IL-18bp does 
not inhibit RSV-induced IFN-ф release. As a control, we show that IL-18bp is able to 
signiﬁcantly inhibit Candida-induced IFN-ф response, which is consistent with 
previous literature (Fig. 4A) [32]. The release of IFN-ф is inhibited when TCR signaling 
is blocked with cyclosporin A (CsA)  (Fig. 4B). 
Figure 2A-B  IFN-̈́ release after RSV infection is actin- and clathrin-dependent. (A-B) 
PBMCs were pre-treated with RPMI, CytoD (1 μg/ml) or CPZ (5 μg/ml). After pre-treatment, 
PBMCs were incubated with RPMI, RSV at MOI 1 or PHA (1 μg/ml) for 24h and IFN-ф release 
was measured. Lower limit of detection: 20 pg/ml. Wilcoxon-signed rank test was used for 
statistical analysis. Data are mean ± SEM (N=4-6). (*p<0.05) (ND=non-detectable, NS=no 
signiﬁcant difference between untreated and CytoD-treated cells or between untreated and 
CPZ-treated cells).
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Figure 3A-D  T cell activation and upregulation of MHC-II after RSV infection are clathrin- 
dependent. (A-D) PBMCs were pre-treated with RPMI or CPZ (5 μg/ml). After pre-treatment, 
PBMCs were incubated with RPMI or RSV at MOI 1 for 24h. The effect of CPZ on (A) CD4 T cell 
activation, (B) CD8 T cell activation and (C) MHC-I and (D) MHC-II expression on monocytes 
cells was determined. Stimulation with PHA (5 μg/ml) was used as positive control for T cell 
activation (A-B). One-way analysis of variance with Bonferroni’s Comparison Test was used for 
statistical analysis. Data are mean ± SEM (N=4).  (*p<0.05,**p<0.01,***p<0.001). (NS=no 
signiﬁcant difference between untreated and CPZ-treated cells).
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Discussion
Internalization and subsequent virus gene transcription of RSV in human monocytes 
and the induction of IFN-ф are actin-dependent. Although clathrin is not involved in 
the internalization of RSV, upregulation of MHC-II on monocytes, T cell activation and 
the release of IFN-ф after RSV infection are clathrin-dependent processes. Finally, T 
cell receptor activation contributes to the RSV-induced IFN-ф response whereas the 
production of IL-18 is dispensable. 
Figure 4A-B  IFN-̈́ release after RSV infection is dependent on T-cell receptor signaling. 
(A) IL-18bp was added to PBMCs simultaneously with RPMI, RSV at MOI 1 or heat killed 
Candida. IFN-ф release was measured after 24h. (B) PBMCs were pre-treated with RPMI or CsA 
(100 nM). After pre-treatment, PBMCs were incubated with RPMI or RSV at MOI 1 for 24h and 
IFN-ф release was measured. Lower limit of detection: 20 pg/ml. Wilcoxon-signed rank test was 
used for statistical analysis. Data are mean ± SEM (N=4-5). (*p<0.05) (ND=non-detectable) 
(NS=no signiﬁcant difference between untreated and CPZ-treated cells).
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Actin is required for cell entry of RSV in epithelial cells [19]. We have shown for the ﬁrst 
time, that primary human monocytes also require actin to internalize RSV for 
subsequent virus gene transcription to occur. Actin plays an essential role in 
processes involving internalization, including receptor-mediated phagocytosis. For 
the Nipah virus, a paramyxovirus like RSV, infection induces the co-internalization of 
Nipah virus receptor ephrinB2 and, in general, many receptors are internalized in an 
actin-dependent manner [33-35]. Several receptors are involved in the recognition of 
RSV at the membrane, like Toll-like receptor 4 (TLR4), CD14 and nucleolin [9, 36]. 
Internalization of TLR4 and CD14 has been investigated upon bacterial ligand 
stimulation. In this process, internalization of TLR4 is dynamin-dependent and CD14 
is actin-dependent [37, 38]. Clustering of nucleolin is dependent on actin [39]. 
Whether actin-dependent clustering of nucleolin occurs after RSV infection and 
whether it is necessary for internalization is unknown. Our ﬁnding that intact actin 
ﬁlaments are required for internalization of RSV in monocytes narrows the scope of 
potential receptors that co-occur with cell entry and are required for internalization. 
Besides cell entry, intact actin is required for virus ﬁlament formation, viral transmission 
and the production of cell-associated infectious virus by epithelial cells [40-43]. We 
observed an inhibitory effect of CytoD on the release of IFN-ф during an incubation 
period of 24h. Inhibition of post-endocytic processes like virus ﬁlament formation and 
transmission could therefore explain the observed reduction of IFN-ф after treatment 
with CytoD. However, in our model of PBMCs, monocytes exhibit abortive infection 
as no replicating virus is detected in the supernatant of PBMCs stimulated with RSV 
(data not shown). This is in line with the abortive infection of RSV in alveolar 
macrophages [44]. Therefore, the role of actin on virus ﬁlament formation and viral 
transmission may be applicable to epithelial cells but most likely would not play a role 
in our model. 
After inhibition of actin with CytoD or Wisko, approximately 30% of the monocytes still 
remain positive for RSV F protein. Permeabilization of the cells in our assay will not 
exclude extracellular staining of RSV F protein and therefore the remaining 
RSV-positive monocytes after treatment could reﬂect extracellular binding of RSV. 
Because CytoD does not inﬂuence the extracellular binding of RSV, we conclude that 
actin dynamics are involved in the internalization of RSV by monocytes. Actin-inde-
pendent processes could also explain the incomplete prevention of internalization by 
CytoD. Fusion of the F protein of RSV with the cell membrane could result in entry of 
viral proteins and might act independently of actin ﬁlaments. Clathrin has previously 
been implicated for internalization of RSV in an epithelial cell line after an incubation 
period of 20h [20]. Contrary, others have shown that internalization of RSV after 1h is 
not clathrin-dependent [19]. The authors conclude that discrepancies between these 
studies may arise due to a difference in experimental design. The incubation period 
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of 1h in our study excludes inhibition of post-endocytic processes like viral replication 
and cell-to-cell transmission. In addition, differences between epithelial cells and 
monocytic cells have been described previously for internalization of nanoparticles 
and may explain our results compared to epithelial cells [17]. The role of cellular 
mechanisms on T cell activation can be studied in our model of PBMCs. Besides in-
ternalization, inhibition of actin dynamics reduces the IFN-ф response. These data 
suggest that, at least in part, the intracellular compartment is involved in the induction 
of an adaptive response and binding of RSV to the outer membrane is not sufﬁcient 
to induce IFN-ф release. These results are in line with previous data indicating that 
intact RSV particles are not able to signal via membrane-associated receptors such 
as TLR4 [45].  
In our study, inhibition of clathrin has no effect on the internalization of RSV by 
monocytes, but effectively reduces the induction of IFN-ф. CPZ at 5 μg/ml was the 
highest tolerable concentration without inducing cytoxicity (data not shown). Our 
data suggest that activation of T cells by RSV is clathrin-dependent. Calabia-Linares 
et al observed the importance of clathrin in the formation of the immunological 
synapse between T cell and antigen-presenting cells [46]. Possibly, inhibition of 
clathrin reduces the IFN-ф release due to improper formation of the immunological 
synapse and thereby inefﬁcient T cell activation. Less than 1% of the T cells in the 
peripheral blood are RSV-speciﬁc T cells [47, 48]. Therefore, the relative high percentage 
of 5-10% CD69+ T cells after stimulation with RSV in our experiments most likely indicates 
that a general activation of T cells occurs. We demonstrate that clathrin plays an 
essential role in the upregulation of RSV-induced MHC-II expression. The requirement 
of clathrin for MHC-II trafﬁcking has been observed previously [49]. The role of MHC-II 
in the induction of IFN-ф is strengthened by the observation that inhibition of TCR 
signaling, as a ligand for MHC-II, reduces the IFN-ф response, whereas inhibition of 
IL-18 has no effect. The combination of reduced T cell activation and MHC-II expression 
suggests that clathrin plays a role in the interplay between innate and adaptive 
immunity against RSV.
The simpliﬁcation of in vivo RSV infections using our model of PBMCs could be a 
limitation of the study. Although others have shown that monocytes can be become 
infected with RSV and serve as an in vitro model, alveolar macrophages or inﬂammatory 
macrophages are the most likely target of infection in vivo [4]. Therefore, there could 
be differences in the immune response in vivo compared to our model. Pre-treatment 
of isolated monocytes with the inhibitors and performing a subsequent co-culture 
with autologous T cells could be considered as an alternative instead of simultaneous 
culture of all cells present in PBMCs. However, during RSV infection in vivo, multiple 
immune cells, including monocytes, natural killer cells and T cells are recruited to the 
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lung tissue [8]. Our model can give more insights in the interplay between RSV and 
different immune cells that are present during RSV infection.
In conclusion, this study underlines the importance of actin and clathrin dynamics 
during RSV infections for cell entry and T cell activation. Currently, there is no effective 
treatment or vaccine against RSV infections. Understanding the different aspects of 
RSV disease pathogenesis and immunity, from early virus-cell interactions to ﬁnal 
induction of the adaptive immune response may contribute to the development of 
novel therapies and effective vaccines. 
Conclusions
The aim of this study was to investigate the role of actin and clathrin on cell entry of 
RSV and the subsequent effect on T cell activation and release of IFN-ф in human 
immune cells. Cell entry in human monocytes, virus gene transcription and IFN-ф 
release are actin-dependent. Post-endocytic processes like the increased expression 
of MHC-II, T cell activation and the release of IFN-ф are clathrin-dependent. Finally, T 
cell receptor signaling affects the release of IFN-ф, whereas soluble interleukin 18 is 
dispensable. Insights into the cellular biology of the human immune response against 
RSV will provide a better understanding of disease pathogenesis.
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Abstract
Background: Respiratory syncytial virus is a common cause of bronchiolitis in infants 
with a wide spectrum of disease severity. Besides environmental and genetic factors, 
it is thought that the innate immune system plays a pivotal role. The aim of this study 
was to investigate the expression of immune receptors on monocytes and the in vitro 
responsiveness of immune cells from infants with severe RSV infections. 
Methods: Peripheral blood mononuclear cells from infants with RSV infections were 
isolated. Classical, intermediate and non-classical monocytes were immunopheno-
typed for expression of CD14, CD16, HLA-ABC and HLA-DR. PBMCs were stimulated 
with LPS to determine the secretion of TNF and IL-10 with ELISA.
Results: During RSV infection, intermediate monocytes are increased in the peripheral 
blood whereas classical and non-classical monocytes are reduced. CD14 and 
HLA-ABC expression are increased on monocytes, whereas expression of HLA-DR is 
suppressed. Low HLA-DR expression is correlated with increased disease severity. 
PBMCs from infants with severe RSV infections show an impaired IL-10 response 
in vitro.
Conclusions: Phenotyping subpopulations of monocytes combined with in vitro 
responsiveness reveal signiﬁcant differences between non-severe and severe RSV 
infections. Reduced HLA-DR expression and impaired IL-10 production in vitro during 
severe RSV infections indicate that an imbalanced innate immune response may play 
an important role in disease severity. 
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Introduction
Respiratory syncytial virus (RSV) is a common cause of bronchiolitis in children under 
2 years of age(1). The clinical manifestations of RSV infection range from a common 
cold to severe lower respiratory tract infections that require oxygen treatment. 
Although known risk factors like prematurity, cardiopulmonary disease and immune 
deﬁciencies are used in clinical prediction models, these factors only successfully 
predict approximately 50% of severe RSV infections(2). Severe RSV infections that 
require oxygen treatment typically occur in infants under 3 months of age and usually 
involve primary infections. The occurrence of severe RSV infections is associated with 
subsequent wheezing episodes and diagnosis of asthma(3). Tregoning et al. describe 
several factors determining the pathogenesis of RSV disease including physical, 
environmental and genetic factors(4). In addition to these factors, it is increasingly 
thought that the innate immune system plays an important role in determining the 
clinical course of infection. 
Innate immune cells like monocytes are recruited from the blood stream to the site of 
infection, where they can either directly contribute to the host antimicrobial defense 
or supply the inﬂamed tissue with differentiated macrophages and dendritic cells to 
target the pathogen(5). Circulating monocytes are part of the innate immune system 
and appear to be heterogenic. Different subpopulations of circulating monocytes 
reﬂect developmental stages and each subset has a distinct role in inﬂammatory 
processes and infectious diseases(6). Based on the expression of CD14 and CD16, 
monocytes can be divided in three subpopulations: classical CD14++CD16-, 
intermediate CD14++CD16+ and non-classical CD14+CD16++ monocytes(7, 8). The 
regulation of the immune response and the role of monocytes and its receptors in 
disease severity has previously been shown for bacterial infections. The expression 
of HLA-DR on monocytic cells is reduced during severe bacterial infections and a 
possible mechanism for this correlation between low HLA-DR expression and 
increased disease severity is a phenomenon called immunoparalysis (9-11). HLA-DR 
molecules are membrane bound molecules that play a role in antigen presentation 
and T cell activation. Immunoparalysis refers to the combination of reduced HLA-DR 
expression and reduced in vitro responsiveness to LPS resulting in severe disease 
progression. Although extensive research is deciphering the disease enhancing 
effect of immunoparalysis in the ﬁeld of bacterial infections, the role of immuno-
paralysis is yet to be elucidated in the context of severe viral respiratory tract infections.
In the context of RSV, the role of antiviral monocytes has been appreciated for 
decades and, in vitro, interaction of RSV with monocytes leads to an upregulation 
of innate inﬂammatory mediators(12-15). These inﬂammatory cytokines shape the 
homeostatic balance for eliciting an adequate immune response. In vivo, an imbalance 
in cytokine production contributes to RSV pathogenesis and severe RSV infections(16). 
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However, it is unknown whether monocytes can play a role in the regulation of the 
immune response against RSV and thereby either prevent or contribute to disease 
severity. 
In this study, we assessed immunological markers on monocytes in infants with non- 
severe and severe RSV infections based on the need for oxygen treatment. For this 
purpose, circulating monocytes were phenotyped in a cohort of infants with RSV 
infections. The expression of CD14, HLA-ABC and HLA-DR was correlated with the 
presence of RSV infection and with disease severity. Finally, PBMC stimulation was 
performed to assess the in vitro responsiveness of PBMCs during RSV infections in 
infants.
Methods
Study design. Children below 2 years of age hospitalized with RSV bronchiolitis were 
prospectively included from November 2010 to April 2013 after informed consent from 
both parents. Bronchiolitis was deﬁned as an acute infection of the lower airways, 
characterized by increased respiratory effort and expiratory wheezing and/or crackles 
and/or apnea. Nasopharyngeal aspirates from all patients included were RSV positive. 
Clinical data were collected from questionnaires, including age, sex, gestational age, 
birth weight, breastfeeding, duration of symptoms, duration of oxygen therapy, the use 
of corticosteroids and/or antibiotics, vaccination with palivizumab and duration of 
 hospitalization. Within 24h after presentation at the hospital, 3 ml sodium heparinized 
blood were collected. Retrospectively, patients were classiﬁed into two groups; no 
oxygen treatment versus oxygen treatment by nasal cannula or mechanical ventilation 
(when oxygen saturation was <93% for >10 minutes)(17, 18). Recovery samples were 
collected 4-6 weeks after presentation. Samples from healthy infants undergoing elective 
surgery for inguinal hernia served as age- and sex-matched controls. Nasopharyngeal 
aspirates from all healthy controls were RSV negative. 
Virus detection. Multiplex real-time reverse transcription PCR for ﬁfteen viruses was 
performed on nasopharyngeal aspirates as previously described(19). 
Cell differentiation. A thin blood smear of sodium heparinized blood was made and 
Giemsa staining was used to enable cell differentiation. 
Isolation of PBMCs. Peripheral blood mononuclear cells (PBMCs) were isolated 
using Lymphoprep (Axis-Shield, Norway). Brieﬂy, blood was anticoagulated with 
sodium heparin (BD Vacutainer) and diluted with an equal volume of phosphate-buffered 
saline (PBS). The diluted blood was carefully added on top of the Lymphoprep and 
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centrifuged at 800 × g. PBMCs were harvested, washed twice in PBS, and counted 
by the use of a haemocytometer. PBMCs from infants with RSV infection were stored 
in liquid nitrogen in 10%FCS and 10%DMSO. 
Stimulation of PBMCs. Directly after collection, 5x105 PBMCs in a 100 μl volume 
were added to an equal volume of RPMI (negative control) or LPS (E. coli 1 ng/ml) 
and incubated at 37 °C and 5% CO2. After 20 hours, the supernatant was stored at -20 
°C for cytokine measurement. 
Immunophenotyping. PBMCs were thawed and leukocyte subsets were determined 
using ﬂow cytometry. 2x105 PBMC were incubated with 50 μl ﬂuorochrome-labeled 
monoclonal antibodies for 30 min in the dark on ice in 96-well microtiter plates. CD14 
V500, CD16 Alexa Fluor 700, HLA-ABC V450 and HLA-DR Qdot605 were used 
(Becton Dickinson, New York). Results were acquired on a BD LSR II ﬂow cytometer 
and data were analyzed using FlowJO (Tree Star, Inc). For gating, live cells were 
selected as 7-AAD negative cells. Next, HLA-DR positive, HLA-ABC positive and 
SSC high cells were selected to include antigen-presenting cells and exclude NK 
cells, T cells and B cells. CD14 positive cells were selected and divided in CD16 
negative and CD16 positive cells to select classical CD14++CD16-, intermediate 
CD14++CD16+ and non-classical CD14+CD16++ monocytes. CD14, HLA-ABC and 
HLA-DR expression were measured by the geometric mean of ﬂuorescence intensity 
(GMFI).
ELISA. TNF and IL-10 concentrations were measured in supernatant of the stimulation 
assay with commercial ELISA kits (Pelikine compact, Sanquin, the Netherlands) 
according to the manufactures’ instructions. The detection limits were 78 and 9.4 pg/
ml, respectively.
Statistical analysis. The distribution of categorical variables is presented as 
percentages per category. Expression levels of membrane bound receptors were 
depicted as geometric mean ﬂuorescence intensity (GMFI) and presented as 
medians with interquartile range. Kruskal-Wallis test was performed followed by 
Mann-Whitney U-test for individual comparisons. Cytokine values are presented as 
mean with standard error of the mean and Mann-Whitney U-test was performed for 
statistical analysis. Pearson tests were performed to test for correlations. A value of p 
< 0.05 was considered statistically signiﬁcant. All statistical tests were performed 
with Graphpad.
Study approval. The study protocols were approved by the Regional Committee on 
Research involving Human Subjects Arnhem-Nijmegen (serving as the IRB) and 
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were conducted in accordance with the principles of the Declaration of Helsinki. 
Written informed consent was obtained from the parents of all children.
Results
Characterization of study population. Forty-eight patients were included for ﬂow 
cytometry analysis. Fifteen healthy controls were included for comparison. There was 
no signiﬁcant difference in age and sex between groups (Table 1). The gestational 
age and birth weight from the healthy controls were lower compared to RSV-infected 
infants. There was no difference in the presence of prematurity between the groups 
(Table 1). There was no difference in gestational age between infants without oxygen 
treatment and infants with oxygen treatment (Table 1).  In a second cohort for in vitro 
responsiveness to LPS, 37 patients and 12 healthy controls were included. There was 
no signiﬁcant difference in age, sex or prematurity between groups. The gestational 
Table 1  Cohort characteristics
Healthy 
(n=15)
No oxygen 
(n=8)
Oxygen  
(n=40)
p-value
Age (days) 79.0 [68.0-94.0] 80.5 [60.0-181.5] 70.0 [37.0-181.8] NS
Male gender (%) 12 (80) 4 (50) 20 (50) NS
Gestational age (wk) 37.0 [33.0-39.0] 39.4 [38.3-40.0] 39.0 [37.0-41.0] < 0.05*
Prematurity (%) 7 (47) 1 (13) 8 (20) NS
Birth weight (kg) 2.6 [2.1-3.1] 3.2 [2.8-4.1] 3.2 [2.8-4.0] < 0.05^
Breastfeeding (%) 7 (47) 3 (37.5) 25 (62.5) NS
Symptomatic (days) 0 (0) 4.0 [3.0-5.0] 4.0 [3.0-5.0] NS
Duration O2 (days) 0 (0) 0 (0) 4.5 [2.0-8.8] < 0.001$
Duration MV (days) 0 (0) 0 (0) 0 [0 – 8.8] < 0.05#
Corticosteroids (%) 0 (0) 0 (0) 0 (0) NS
Antibiotics (%) 0 (0) 4 (50) 22 (55) NS
Palivizumab (%) 0 (0) 0 (0) 0 (0) NS
Hospitalization (days) 0 (0) 4.0 [2.0-7.5] 8.0 [5.0-11.0] < 0.001&
Infants with RSV infections and healthy controls used for ﬂow cytometry analysis are depicted and patients 
are divided by disease severity. Data are presented as median and IQR or number for continuous data and 
number with percentage for categorical data. Testing was performed with Kruskall-Wallis and if signiﬁcant 
followed by Mann Whitney U test. * Healthy versus no oxygen and oxygen  p<0.05. ^ Healthy versus oxygen 
p<0.01.  $ Oxygen versus no oxygen p<0.001. # Oxygen versus no oxygen p<0.001 & Healthy versus no 
oxygen and oxygen  p<0.001, oxygen versus no oxygen p<0.05.
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age and birth weight from healthy controls were lower compared to RSV-infected 
infants. (Supplemental Table 1).
Total monocyte count is not increased during acute infection and does not 
discriminate between disease severity. There is no signiﬁcant difference in the 
absolute number of peripheral monocytes of infants during RSV infection compared 
to the recovery phase (Figure 1). There is no difference in monocyte count between 
disease severity groups (Figure 1).
The percentage of intermediate monocytes is increased during RSV infection. 
We ﬁrst determined whether the subsets of monocytes in the peripheral blood are 
different during RSV infection compared to healthy controls or recovery samples. 
Monocytes were divided in three subpopulations based on the expression level of 
CD14 and CD16: classical CD14++CD16-, intermediate and non-classical CD14+CD16++ 
Supplemental Table 1  Cohort characteristics
Healthy  
(n=12)
No oxygen 
 (n=6)
Oxygen 
 (n=31)
p-value
Age (days) 84.5 [68.5-104.8] 161.5 [57.8 – 310.0] 53 [28.0-146.5] NS
Male gender (%) 9 (75) 3 (50) 16 (52) NS
Gestational age (wk) 37.2 [34.7-38.9] 40.6 [38.5-41.5] 38.0 [37.0-40.0] <0.05*
Prematurity (%) 4 (33) 1 (17) 7 (23) NS
Birth weight (kg) 2.5 [1.9-3.1] 4.3 [3.0-4.5] 3.1 [2.8-3.4] <0.05^
Breastfeeding (%) 7 (58) 44 (67) 18 (58) NS
Symptomatic (days) 0 (0) 5.5 [3.8-7.8] 4.0 [2.5-4.0] <0.05$
Duration O2 (days) 0 (0) 0 (0) 6.0 [3.0-7.0] <0.001#
Duration MV (days) 0 (0) 0 (0) 0.0 [0.0- 4.3] NA
Corticosteroids (%) 0 (0) 0 (0) 0 (0) NS
Antibiotics (%) 0 (0) 2 (33) 16 (52) NS
Palivizumab (%) 1 (8.3) 0 (0) 0 (0) NS
Hospitalization (days) 0 (0) 5.0 [1.8-7.0] 8.0 [5.0-13.5] <0.001&
Infants with RSV infections and healthy controls used for stimulation of PBMCs are depicted and patients are 
divided by disease severity. Data are presented as median and IQR or number for continuous data and 
number with percentage for categorical data. Testing was performed with Kruskall-Wallis and if signiﬁcant 
followed by Mann Whitney U test. * Healthy versus no oxygen p<0.05, oxygen  versus no oxygen NS.  ^ 
Healthy versus no oxygen and oxygen p<0.05, oxygen  versus no oxygen NS. $ Oxygen versus no oxygen 
p<0.05. # Oxygen versus no oxygen p<0.001. & Healthy versus no oxygen and oxygen p<0.001, oxygen 
versus no oxygen p<0.05
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monocytes. The main population of circulating monocytes consists of classical mono- 
cytes and the percentage of these classical monocytes was signiﬁcantly lower in the 
acute phase compared to the recovery phase (Figure 2a). During RSV infection, a 
signiﬁcantly higher percentage of intermediate monocytes compared to healthy controls 
and compared to the recovery phase was observed (Figure 2a). The percentage of 
non-classical monocytes is signiﬁcantly lower in the acute phase compared to healthy 
controls and the recovery phase (Figure 2a). Besides a reduced percentage of classical 
monocytes in RSV-infected infants with oxygen treatment, no differences were observed 
between disease severity groups (Figure 2b). These data suggest that the pool of 
peripheral blood monocytes is dynamic and changes in favor of intermediate mono- 
cytes during RSV infection.
Figure 1  Monocyte count in the peripheral blood determined by blood smear analysis. 
Monocyte counts during the acute phase of RSV infection and during the recovery phase. 
Values are depicted as medians ± interquartile range. Testing was performed with Krus-
kall-Wallis and if signiﬁcant followed by Mann Whitney U test.
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Figure 2  The percentage of intermediate monocytes is increased during RSV infection. 
A. Percentages of monocyte populations in the acute phase of RSV infection compared with 
healthy controls and the recovery phase. B. Percentages of monocyte populations in infants 
categorized by disease severity. Values are depicted as medians ± interquartile range. Testing 
was performed with Kruskall-Wallis and if signiﬁcant followed by Mann Whitney U test. (*p<0.05, 
**p<0.01, ***p<0.001).
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CD14 expression on monocytes is increased during RSV infection. We next 
investigated whether monocytes during RSV infection are phenotypically different. 
The expression level of the surface marker CD14 was measured and we observed an 
increased expression of CD14 on all three subpopulations of monocytes during the 
acute phase of infection (Figure 3a). This increased expression of CD14 was present 
in all RSV-infected infants and there was no difference in expression of CD14 between 
disease severity groups (Figure 3b). We observed no correlation between CD14 
expression and age (data not shown).
HLA-ABC expression on monocytes is increased during RSV infection. Antigen- 
presenting molecules on monocytes have been implicated in disease occurrence 
and progression. To determine whether monocytes contained increased amounts of 
antigen-presenting molecules during RSV infection, we ﬁrst measured the expression 
level of HLA-ABC on all subsets of monocytes. We observed an increased expression 
of HLA-ABC on all three subpopulations of monocytes during RSV infection (Figure 4a). 
There was no difference in expression of HLA-ABC between disease severity groups 
after RSV infection (Figure 4b). We observed no correlation between HLA-ABC expression 
and age (data not shown).
Low HLA-DR expression on monocytes is correlated with increased disease 
severity and prolonged hospitalization. Low HLA-DR expression on monocytes 
has been associated with increased disease severity of bacterial infections. We 
determined the level of HLA-DR expression on monocytes to correlate HLA-DR 
expression with disease severity in RSV infection. The HLA-DR expression on 
classical and intermediate monocytes was signiﬁcantly lower during RSV infection 
(Figure 5a). The expression of HLA-DR on classical and intermediate monocytes 
correlates with diseases severity. Monocytes from RSV-infected infants without 
oxygen treatment have comparable expression levels of HLA-DR compared to 
healthy controls (Figure 5b). Severe RSV-infected infants requiring oxygen therapy 
have lower expression levels of HLA-DR compared to both RSV-infected infants 
without oxygen therapy and healthy controls (Figure 5b). We observed no correlation 
between HLA-DR expression and age, suggesting that age is most likely not a 
potential confounder for the reduced HLA-DR expression in severe RSV infections 
(data not shown). As a second parameter, we determined whether HLA-DR expression 
was correlated with duration of hospitalization. Reduced HLA-DR expression on 
classical monocytes signiﬁcantly correlated with prolonged hospitalization (Figure 
5C). These data indicate that low HLA-DR expression is associated not only with the 
presence of RSV infection but also with increased disease severity, oxygen treatment 
and prolonged hospitalization.
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Figure 3  CD14 expression on circulating monocytes is increased during RSV infection. 
A. CD14 expression on monocytes during the acute phase of RSV infection compared to 
healthy controls and the recovery phase. B. CD14 expression on monocyte populations in 
infants categorized by disease severity. Values are depicted as medians ± interquartile range. 
Testing was performed with Kruskall-Wallis and if signiﬁcant followed by Mann Whitney U test 
(*p<0.05, **p<0.01, ***p<0.001).
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Figure 4  HLA-ABC expression on circulating monocytes is increased during RSV infection. 
A. HLA-ABC expression on monocytes during the acute phase of RSV infection compared to 
healthy controls and the recovery phase. B. HLA-ABC expression on monocyte populations in 
infants categorized by disease severity. Values are depicted as medians ± interquartile range. 
Testing was performed with Kruskall-Wallis and if signiﬁcant followed by Mann Whitney U test 
(*p<0.05, **p<0.01).
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Figure 5  Low HLA-DR expression is correlated with increased disease severity and 
prolonged hospitalization. A. HLA-DR expression on monocytes during the acute phase of 
RSV infection compared to healthy controls and the recovery phase. B. HLA-DR expression on 
monocyte populations in infants categorized by disease severity. Values are depicted as medians 
± interquartile range.
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Severe RSV infections are associated with impaired in vitro IL-10 production 
upon stimulation with LPS.
Besides low HLA-DR expression, impaired pro-inﬂammatory cytokine production 
has been associated with disease severity in bacterial infections. Cytokine production 
of PBMCs from healthy and RSV-infected infants upon in vitro stimulation with LPS 
was determined to investigate whether decreased LPS responsiveness was 
associated with severe RSV infections. No signiﬁcant difference in TNF production 
upon LPS stimulation was observed between the severity groups and/or the healthy 
controls (Figure 6a). PBMCs from RSV-infected infants without oxygen therapy 
produced similar amounts of IL-10 compared to healthy controls (Figure 6b). However, 
PBMCs from RSV-infected infants that require oxygen therapy produced signiﬁcantly 
lower amounts of IL-10 upon LPS stimulation compared to healthy controls (Figure 
6b). There was no correlation between age and either TNF or IL-10 production (data 
not shown). 
Figure 5  Continued. C. Correlation between duration of hospitalization and HLA-DR expression 
on classical monocytes. Testing was performed with Kruskall-Wallis and if signiﬁcant followed 
by Mann Whitney U test. Testing for correlation was performed with Pearson test. (*p<0.05, 
**p<0.01, ***p<0.001).
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Discussion
This study shows an increased percentage of circulating intermediate monocytes 
during RSV infection. Increased expression of CD14 and HLA-ABC was present 
during RSV infections. Conversely, reduced HLA-DR expression on monocytes was 
present during RSV infection and low HLA-DR expression was correlated with 
increased disease severity and prolonged hospitalization. Finally, an impaired in vitro 
IL-10 production of PBMCs from infants with severe RSV infections compared to 
healthy controls was observed. Analysis of our data indicates that the immune proﬁle 
of monocytes changes during RSV infection and that, in particular, low expression of 
HLA-DR is correlated with increased disease severity of RSV infection. 
The observed increase of intermediate monocytes is in line with studies investigating 
pediatric bacterial and viral infections(20, 21). This is the ﬁrst report implicating an 
increase of intermediate monocytes as a consequence of RSV infection. These data 
suggest that the increase of intermediate monocytes is applicable to many infectious 
diseases including viral respiratory tract infections. CD14++CD16+ monocytes are 
termed pro-inﬂammatory because of their ability to produce high amounts of 
cytokines. Secondly, they possess high levels of HLA-DR and are potent inducers of 
T cell proliferation(22, 23). Previous data suggest that these activated monocytes 
migrate to inﬂamed tissues to locally support ongoing T cell activation(24). In the 
context of RSV, the increased percentage of intermediate monocytes might be a 
Figure 6  Severe RSV infections are associated with impaired in vitro IL-10 production 
upon stimulation with LPS. Cytokine production of PBMCs from healthy controls and 
RSV-infected infants, categorized by disease severity, after 20h stimulation with LPS for (A) TNF 
and (B) IL-10. Values are represented as means with SEM. Testing was performed with Mann 
Whitney U test (*p<0.05).
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reﬂection of immune activation and are subsequently attracted to the inﬂamed lung 
tissue to exert local anti-viral immunity. 
Besides the increase of intermediate monocytes, all subsets of moncytes during RSV 
infection in our cohort expressed higher levels of CD14. Maus et al. showed that 
monocytes are recruited from the blood stream to become alveolar monocytes 
during infection. These recruited monocytes have a high expression of CD14, exert 
enhanced cytokine production and are able to replace resident alveolar 
macrophages(25, 26). Secondly, viral proteins are able to promote a Th1 response 
via CD14(27, 28). Polarization towards a Th2 dominated response is present during 
RSV infections and therefore the increased expression of CD14 on monocytes might 
be a defense mechanism against RSV(16). Whether the high CD14 expressing 
monocytes in our cohort in the peripheral blood during RSV infection are indeed 
recruited to the inﬂamed lung tissue and polarize the local immune response against 
RSV cannot be determined in this study.  
In our cohort, expression levels of HLA-ABC on monocytes are higher during infection 
whilst expression levels of HLA-DR on monocytes are suppressed. HLA-ABC and 
HLA-DR expression on monocytes function to bind peptide fragments from 
pathogens and present them for recognition by respectively CD8+ and CD4+ T cells. 
Increased expression of HLA-ABC suggests that during RSV infection circulating 
monocytes are primed for antigen-presentation. However, HLA-DR expression on 
monocytes is reduced and this is most pronounced in patients with severe RSV 
infections. Low HLA-DR expression has been associated with immunoparalysis and 
disease severity in bacterial infections(11, 29, 30). Our data suggest that RSV exerts 
a more pronounced inhibitory effect on HLA-DR expression during severe RSV 
infections. Reduction of HLA-DR expression by RSV on monocytic cells has already 
been observed in vitro (31). Connolly and co-workers describe a direct effect of RSV 
infection on hampering of HLA-DR surface translocation. However, direct blocking of 
HLA-DR surface translocation as the underlying mechanism of reduced HLA-DR 
expression in vivo is unlikely as viremia has only sporadically been detected during 
RSV infection(32). Soluble inﬂammatory mediators present in the blood could be 
responsible for the observed reduced HLA-DR expression in infants with severe RSV 
infections. For instance, high cortisol levels have been associated both with severe 
RSV infections and reduced HLA-DR expression and might explain the reduced 
HLA-DR expression in severe RSV infections(33, 34). The correlation between 
reduced HLA-DR expression and prolonged hospitalization conﬁrms our conclusion 
regarding HLA-DR and disease severity. 
The decision whether to admit RSV-infected infants or send them home is mainly 
based on the need for oxygen treatment. For many patients presenting at the 
emergency room it is difﬁcult to determine the course of disease and thereby the 
future need for oxygen treatment. Therefore, the difference in HLA-DR expression 
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between infants without oxygen treatment and infants with oxygen treatment may 
have important clinical implications and could help the clinician to decide whether to 
admit a patient with RSV bronchiolitis. Transcriptional proﬁling of blood from RSV 
infected infants showed a suppression of important T cell genes in particular in 
younger infants and CD4+ T cells are lower in severe RSV infections compared to 
non-severe RSV infections(19, 35). Our observed immune proﬁle with reduced 
HLA-DR expression on monocytes during severe RSV infections might explain the 
low CD4+ T cell responses seen in severe RSV infections(19). Further research 
dissecting the mechanism of reduced HLA-DR expression will give more insight in 
the immunomodulatory effects of RSV.
A second hallmark of immunoparalysis is a reduced TNF production upon stimulation 
with LPS, which was not observed in our cohort of infants with RSV infections. We 
conclude that although HLA-DR expression is decreased during RSV infection, there 
is no apparent immunoparalysis as seen in bacterial infections. Mella et al. observed 
a correlation between impaired LPS responsiveness and severe RSV infections by 
stimulation of whole blood(36). Although the stimulation of whole blood might include 
more cells involved in clinical disease, stimulation of PBMCs has proven to be useful 
to decipher the mechanisms between cytokine release and disease severity(37). We 
observed a signiﬁcantly impaired IL-10 production upon LPS stimulation by PBMCs 
from infants with severe RSV infections compared with healthy controls. The role of 
IL-10 is contrary as it has been associated with either the development of asthma or 
protective immunity in a murine model(38-40). IL-10 has been implicated as an 
important cytokine that inﬂuences immunopathology in RSV infection by limiting 
T-cell-mediated lung injury(41). Our observed impairment of anti-inﬂammatory 
cytokine production by PBMCs indicates a shift towards a less anti-inﬂammatory and 
a more pro-inﬂammatory proﬁle in vivo. 
In this study, we were able to include an age- and sex-matched control group with 
infants that required an inguinal hernia operation. Although age and sex were 
matched between the control group and RSV-infected infants, the gestational age in 
the control group was signiﬁcantly lower compared to the RSV-infected infants. We 
believe that this difference of two days would not signiﬁcantly impact the matching 
between healthy controls and RSV-infected infants. Low gestational age, in particular 
below 32 weeks of age, is a risk factor for severe RSV infection. When comparing 
prematurity, deﬁned as gestational age below 37 weeks of gestation, there are no 
signiﬁcant differences between the groups. Therefore, the difference in gestational 
age is unlikely to interfere with the results observed in severe RSV-infected infants.
In summary, striking differences are found in monocytes of infants with RSV infections. 
The increase of intermediate monocytes, the high CD14 expression and the high 
HLA-ABC expression suggest that activation of monocytes occurs during RSV 
infection which might result in recruitment of monocytes to the local site of infection. 
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The reduced expression of HLA-DR combined with reduced in vitro responsiveness 
during RSV infection, however, might be an important indicator of immunosuppres-
sion of monocytes during severe RSV infections.
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Abstract
Interferon gamma (IFN-ф) plays an important role in the antiviral immune response 
during respiratory syncytial virus (RSV) infections. Monocytes and T cells are recruited 
to the site of RSV infection, but it is unclear whether cell-cell interactions between 
monocytes and T cells regulate IFN-ф production. In this study, micro-array data 
identiﬁed the upregulation of sialic acid-binding immunoglobulin-type lectin 1 (Siglec-1) 
in human RSV-infected infants. In vitro, RSV increased expression of Siglec-1 on healthy 
newborn and adult monocytes. RSV-induced Siglec-1 on monocytes inhibited IFN-ф 
production by adult CD4+ T cells. In contrast, IFN-ф production by RSV in newborns 
was not affected by Siglec-1. The ligand for Siglec-1, CD43, is highly expressed on adult 
CD4+ T cells compared to newborns. Our data show that Siglec-1 reduces IFN-ф release 
by adult T cells possibly by binding to the highly expressed CD43. The Siglec-1- 
dependent inhibition of IFN-ф in adults and the low expression of CD43 on newborn 
T cells provides a better understanding of the immune response against RSV in early 
life and adulthood.
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Introduction
Respiratory syncytial virus (RSV) is a major cause of respiratory disease worldwide. 
Nearly all infants have been infected by RSV by the age of 2 years. Infants and adults 
remain susceptible every year to RSV infections with genetically related viruses or 
identical virus strains (1). The high rate of reinfections by RSV results in a signiﬁcant 
burden on health care in infants and elderly (2). Interferon gamma (IFN-ф) and T cells 
are essential to mount an adequate immune response during RSV infections in 
newborn and adult mice (3-5). This suggests an important role for IFN-ф in the 
clearance of primary infections as well as in reinfections (4, 6). Inhibition or inadequate 
activation of  T cells resulting in lower secretion of IFN-ф may explain this high rate of 
reinfections (7, 8). Monocytes and T cells are both recruited to the site of RSV infection 
and the role of monocytes in the pathogenesis of RSV infections has been appreciated 
for decades (9-15). RSV increases the expression of major histocompatibility complex 
(MHC) molecules on monocytes, activates CD4+ T cells and induces the production 
of IFN-ф by human immune cells in vitro (15). It is unknown whether monocytes exert 
a regulatory role on effector T cell function via cell-cell interaction and thus regulate 
the production of IFN-ф. In this study, we used an unbiased approach to select 
membrane-bound receptors on monocytes that are induced during RSV infection in 
infants and could play a role in cell-cell interactions with T cells. We selected 
acid-binding immunoglobulin-type lectin 1 (Siglec-1) and monitored the induction of 
Siglec-1 on monocytes after exposure of newborn and adult immune cells to RSV in 
vitro. In addition, we determined the role of Siglec-1 during RSV-induced release of 
IFN-ф by T cells in newborns and adults and investigated the expression of CD43, as 
the natural ligand for Siglec-1, on newborn and adult T cells.
Materials and methods
Transcriptome analysis of whole blood from RSV-infected infants and RSV- 
stimulated PBMCs. Our group has published whole blood gene expression of 
RSV-infected infants and healthy control infants. The methods are described by Jong 
et al. (34) and the microarray data was deposited in the ArrayExpress database under 
the access number E-MTAB-5195. Ìn addition, we previously published a microarray-
database regarding PBMCs from healthy adults that are untreated or stimulated with 
RSV. The methods have been described by our group previously (35) and this 
microarray data has been deposited in the NCBI Gene Expression Omnibus (GEO) 
database under GEO Series accession number (GSE59391) (35). We combined 
these two microarray databases for the current study. To ﬁrst select clinically relevant 
genes, we used a cut-off value of 4-fold difference between RSV-infected infants and 
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healthy controls in the whole blood transcriptome analyses. A similar cut-off value of 
4-fold difference was used for the microarray data published by Vissers et al. (35) to 
identify genes that are upregulated in vitro upon exposure of adult PBMCs to RSV. 
We then determined which genes were upregulated in both microarray analyses, being 
upregulated genes derived from whole blood from RSV-infected infants and upregulated 
genes derived from in vitro RSV-stimulated adult PBMCs, to identify clinically relevant 
genes that could be investigated in our model of PBMCs. 
Virus culture. Green ﬂuorescent protein (GFP)-labeled RSV A2 (rgRSV30), kindly 
provided by Dr. M.E. Peeples, was cultured as previously described (35). 
Cell isolation and stimulation. Human newborn cord blood was collected from the 
umbilical cord after Cesarean section. Premature births and births to HIV-positive 
mothers were excluded. Peripheral blood was collected from healthy adult volunteers. 
Experimental guidelines of the Regional Committee on Research involving Human 
Subjects Arnhem-Nijmegen were observed. Newborn or adult blood was layered 
onto Ficoll-Hypaque (GE Healthcare) to collect cord blood mononuclear cells 
(CBMCs) and peripheral blood mononuclear cells (PBMCs), respectively. When 
indicated, monocytes were puriﬁed via negative selection (Monocyte Isolation Kit II 
human; Miltenyi Biotec). CD4+ T cells, memory CD4+ T cells, CD8+ T cells or CD56+ 
natural killer (NK) cells were depleted from the mononuclear (MC) fraction using 
speciﬁc microbeads (Miltenyi Biotec), according to the manufacturer’s instructions. 
MCs or monocytes were incubated at 5x105 or 1x105 cells/well respectively and 
incubated with RSV at an MOI 1 at 37ºC and 5% C02 for 48h or 5 days. When indicated, 
MCs were pre-treated with anti-Siglec-1 monoclonal antibodies (HSn 7D2, ab18619; 
Abcam) for 1h at 37ºC. Blocking experiments were performed with matching isotype 
controls (mouse IgG1 Isotype, eBioscience).
Flow cytometry. To analyse expression of surface markers, MCs were incubated 
with ﬂuorochrome-labeled monoclonal antibodies for 30 min in the dark on ice and 
ﬂuorescence intensity was measured using a LSR II ﬂow cytometer (BD Biosciences). 
CD3 V500, CD3 Alexa Fluor 647, CD4 PerCP-Cy5.5, CD8 APC-H7, CD14 V500, CD14 
Pe-Cy7, CD27 BV510, CD43 FITC, CD45RA PeCy-7, CD56 BV510 (BD Biosciences) 
and Siglec-1 Alexa Fluor 647 (Sanbio) were used. Relative mean intensity ﬂuorescence 
(MFI) of CD43 was calculated as follows: MFI stained/MFI unstained. GFP ﬂuorescence 
was used to determine replication of (GFP)-labeled RSV. 
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Cytokine release. IFN-ф concentrations were measured in culture supernatants by 
enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s 
instructions (Sanquin, Amsterdam, The Netherlands). The detection limit was 19 pg/
ml. All conditions were measured in duplicate.
Statistical analysis. Statistical analyses employed the Wilcoxon matched-pairs 
signed rank test for paired analysis between two conditions and repeated measures 
ANOVA with Bonferroni’s Multiple Comparison Test for paired analysis between more 
than two conditions. Comparison between newborns and adults employed Mann- 
Whitney U test. Comparison between more than two groups employed the Kruskal- 
Wallis test followed by Dunn’s Multiple Comparison Test. Tests were considered 
signiﬁcant if P<0.05. All statistical analyses were done with GraphPad Prism.
Results
Induction of Siglec-1 expression during RSV infection. We ﬁrst compared whole 
blood gene expression levels from RSV-infected infants with healthy infants to select 
genes that are upregulated during RSV infection in vivo. Fifteen genes were 
upregulated during in vivo RSV infection using a cut-off value of 4-fold difference 
(Table 1). We next compared in vitro gene expression levels of unstimulated adult 
PBMCs versus RSV-stimulated adult PBMCs. More than four hundred genes were 
upregulated in adult PBMCs during in vitro RSV infection using a cut-off value of 
4-fold difference (Figure 1A). Seven genes were upregulated in both the analysis 
derived from RSV-infected infants and the analysis derived from RSV-stimulated 
PBMCs: C19ORF59, IFI27, IFI44L, IFI1, IFI6, OASL, RSAD2 and SIGLEC1 (Table 1; 
Figure 1B). Via this approach, we combined transcriptome analyses from RSV-infected 
infants with in vitro RSV-stimulated adult PBMCs and identiﬁed potential genes that 
could be involved in the cell-cell interaction between monocytes and T cells. SIGLEC1 
was the only gene that has been implicated in direct cell-cell contact with T cells (16) 
and was therefore selected as our gene of interest for further investigation. We 
observed a correlation between the RSV titer in the nasopharyngeal aspirate of 
RSV-infected infants and expression of Siglec-1 (Figure 1C). The expression of 
Siglec-1 was higher in infants during the acute phase of infection compared to infants 
in the recovery phase, which suggests a temporal induction of Siglec-1 during RSV 
infection (Figure 1D). Eight children provided a blood sample during the acute phase 
and the recovery phase. From these eight individuals, paired analysis showed a 
reduction of Siglec-1 expression in all cases (data not shown).
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RSV induces Siglec-1 on monocytes. We employed newborn CBMCs and adult 
PBMCs to investigate the induction of Siglec-1 by RSV in vitro. We observed an 
increase of Siglec-1+ cells only in the CD14+ fraction that consists of monocytes 
(Figure 2A, representative ﬁgure). The RSV-induced increase of Siglec-1+ monocytes 
was observed in newborn and adult (Figure 2B). Only a small percentage of newborn 
and adult CD14- cells expressed Siglec-1 which did not increase after exposure to 
RSV (Figure 2A, representative ﬁgure). The increase in frequency of Siglec-1 positive 
monocytes when stimulating puriﬁed adult monocytes with RSV suggests a direct 
effect of RSV on monocytes (Figure 2C). In addition, we showed that RSV increased 
the quantitative expression of Siglec-1 on newborn and adult CD14+ monocytes 
determined by mean ﬂuorescence intensity (Figure 2D).
RSV-induced IFN-̈́ is delayed in newborns and dependent on CD4+ T cells. 
During RSV infection, IFN-ф is an important cytokine that can be produced by T cells. 
Newborn CBMCs are naïve and devoid of RSV-speciﬁc memory T cells whereas 
adults contain RSV-speciﬁc memory T cells (17). Signiﬁcant amounts of IFN-ф were 
measured in the supernatant of adult MCs two days after exposure to RSV, whereas 
Table 1  
Gene Median 
expression level 
RSV-infected 
infants ( N=40)
Median 
expression level 
healthy controls
( N=14)
Difference 
expression level 
(RSV vs healthy)
Log2 transformed 
difference in 
expression level
IFI27 12.03 6.71 5.3 39.4
CD177 10.90 7.39 3.5 11.3
LTF 10.75 7.98 2.8 7.0
OLFM4 8.87 6.03 2.8 7.0
MMP8 8.81 6.22 2.6 6.1
RSAD2 11.69 9.23 2.5 5.7
SIGLEC1 9.68 7.28 2.4 5.3
IFI44L 11.56 9.20 2.4 5.3
ARG1 9.64 7.38 2.3 4.9
CEACAM8 9.01 6.70 2.3 4.9
C19ORF59 11.51 9.32 2.2 4.6
RSAD2 10.93 8.73 2.2 4.6
DEFA4 9.55 7.48 2.1 4.3
IFI6 11.86 9.82 2.0 4.0
IFIT1 11.94 9.91 2.0 4.0
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Figure 1A-D  Induction of Siglec-1 expression during RSV infection. A: Transcriptome analysis 
of unstimulated adult PBMCs (N=5) (x-axis) compared to RSV-stimulated adult PBMCs (N=5) 
stimulated with RSV for 24h (y-axis). Plots in the upper left corner represent genes that are 
upregulated during in vitro RSV infection of adult PBMCs. A difference of ± 4-fold difference 
between expression levels of unstimulated compared to expression levels of RSV-stimulated 
PBMCs was used to determine up- and downregulation of genes. B: Transcriptome analysis of 
unstimulated adult PBMCs (x-axis) compared to RSV-stimulated adult PBMCs (y-axis) 
combined with upregulated genes in whole blood from RSV-infected infants in Table 1 (white 
dots). C: Correlation of Siglec-1 gene expression (y-axis) and RSV titers in the nasopharyngeal 
aspirate (x-axis) during infant RSV infection. D: Comparison of Siglec-1 gene expression level 
in healthy infants (Healthy; N=14), RSV-infected infants (Acute; N=40) and infants 4-6 weeks 
after RSV infection (Recovery; N=30). Data are represented as median ± interquartile range. 
Statistical analysis employed Kruskal-Wallis test and if signiﬁcant followed by Mann-Whitney U 
test. Spearman correlation test was used for correlation tests. Dashed lines indicate a 4-fold 
difference of expression level between x-axis and y-axis. **: P<0.01. ***: P<0.001.
A
C
B
D
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 88
88
Chapter 3
Fi
g
ur
e 
2A
-D
  R
S
V
 in
d
uc
es
 S
ig
le
c-
1 
o
n 
m
o
no
cy
te
s.
 A
: R
ep
re
se
nt
at
iv
e 
ga
tin
g 
st
ra
te
g
y 
to
 d
et
er
m
in
e 
S
ig
le
c-
1 
ex
pr
es
si
on
 o
n 
m
on
oc
yt
es
 (
C
D
14
+
 
ce
lls
) a
fte
r s
tim
ul
at
io
n 
of
 M
C
s 
w
ith
 R
S
V.
A
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 89
89
T cells
3
Fi
g
ur
e 
2A
-D
  C
o
nt
in
ue
d
. B
-C
: P
er
ce
nt
ag
e 
of
 S
ig
le
c-
1+
 m
on
oc
yt
es
 a
fte
r s
tim
ul
at
io
n 
of
 (B
) M
C
s 
or
 (C
) a
du
lt 
m
on
oc
yt
es
 w
ith
 R
S
V.
 N
=
5-
7.
 D
: M
ea
n 
ﬂu
or
es
ce
nc
e 
in
te
ns
ity
 o
f 
S
ig
le
c-
1 
on
 C
D
14
-  a
nd
 C
D
14
+
 c
el
ls
 a
fte
r 
st
im
ul
at
io
n 
of
 M
C
s 
w
ith
 R
S
V 
(N
=
5)
. 
D
at
a 
re
pr
es
en
t 
m
ea
ns
 ±
 S
E
M
. 
S
ta
tis
tic
al
 
an
al
ys
es
 e
m
pl
oy
ed
 th
e 
W
ilc
ox
on
 m
at
ch
ed
-p
ai
rs
 s
ig
ne
d 
ra
nk
 te
st
. *
: P
<
0.
05
. *
*:
 P
<
0.
01
.
B D
C
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 90
90
Chapter 3
A
C
B
D
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 91
91
T cells
3
IFN-ф was not detectable in supernatants from newborn MCs (Figure 3A). However, 
RSV induced IFN-ф release by newborn MCs after an incubation period of 5 days was 
comparable to the induction of IFN-ф in adults after 5 days (Figure 3B). Mononuclear 
cells were depleted from CD4+, CD8+ and CD56+ cells to discern which cells within 
the MC fraction produced IFN-ф in response to RSV (Figure 3C). Depletion of CD4+ 
cells reduced the RSV-mediated production of IFN-ф in cultures of both newborn and 
adult MCs (Figure 3D). No reduction of RSV-induced IFN-ф release was observed 
after depletion of CD8+ cells and CD56+ cells (Figure 3D).
RSV-induced Siglec-1 inhibits IFN-̈́ release by adult T cells but not by T cells 
from newborns. Siglec-1 is the only siglec without a signaling motifs which suggests 
a mode of action via cell-cell interaction (18). To investigate cell-cell interactions 
between monocytes and T cells, we used monoclonal blocking antibodies against 
Siglec-1 to determine the effect of Siglec-1 on the release of IFN-ф by CD4+ T cells. 
Exposure of MCs to the blocking antibodies alone did not induce IFN-ф in newborns 
or adults (data not shown). Blocking Siglec-1 did not affect the percentage of 
RSV-infected adult monocytes or the amount of replication in adult monocytes as 
depicted by mean ﬂuorescence intensity (Figure 4A-B). Blocking of Siglec-1 did not 
affect RSV-induced IFN-ф release by T cells from newborn MCs (Figure 4C), but, in 
contrast to newborns, blocking Siglec-1 signiﬁcantly increases the RSV-induced 
IFN-ф release by adult MCs (Figure 4D). To determine whether the inhibitory effect of 
Siglec-1 in adult PBMCs was due to the presence of memory CD4+ T cells, adult 
PBMCs were depleted from memory CD4+ T cells. Depletion of memory CD4+ T 
cells reduced the production of RSV-induced IFN-ф by adults (Figure 4E), Blocking 
Siglec-1 no longer affected RSV-induced IFN-ф release by adult T cells when PBMCs 
are depleted of memory CD4+ T cells (Figure 4F). 
Figure 3A-D  RSV-induced IFN-̈́ is delayed in newborns and dependent on CD4+ T 
cells. A-B: Production of IFN-ф by CBMCs and PBMCs after stimulation with RSV for (A) 48h or 
(B) 5 days. N=5. C: Representative results of MCs after depletion of CD4+, CD8+ or CD56+ 
cells. D-E: RSV-induced IFN-ф release by (D) CBMCs, CD4-depleted CBMCs, CD8-depleted 
CBMCs or CD56-depleted CBMCs after 5 days and (E) RSV-induced IFN-ф release by PBMCs, 
CD4-depleted PBMCs, CD8-depleted PBMCs or CD56-depleted PBMCs after 48h. N=5. Data 
represent means ± SEM. Statistical analysis employed Wilcoxon matched-pairs signed rank 
test for two conditions and repeated measures ANOVA with Bonferroni’s Multiple Comparison 
Test for more than two conditions. Comparative testing between newborns and adults was 
performed with Mann-Whitney U test. *: P<0.05.
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3Low CD43 expression on newborn and adult naïve CD4+ T cells. Our data 
showed that despite comparable induction of Siglec-1 expression in newborn and 
adult monocytes, Siglec-1 inhibited IFN-ф by adult T cells in the presence of memory 
CD4+ T cells. Siglec-1 is a sialic-acid binding receptor and CD43 is a highly sialylated 
receptor on T cells that acts as a natural ligand for Siglec-1. We hypothesized that 
CD43 may be differentially expressed on newborn,, adult naïve and adult memory T 
cells that would explain the inhibitory effect of Siglec-1 only when adult memory 
CD4+ T cells are present. The expression of CD43 was higher on adult CD4+ T cells 
compared to newborns (Figure 5A-B). Additionally, we investigated the expression of 
CD43 on the major subsets of CD4+ T cells, being naïve, central memory, effector 
memory and terminally differentiated CD4+ T cells (Figure 5A). Adult CD4+ T cells 
consisted of all the measured subsets of CD4+ T cells, whereas, as expected, 
newborn effector memory (average of 0.019%) and terminally differentiated CD4+ T 
cells (average of 0.006%) were barely detected (Figure 5A). CD43 expression on 
newborn naïve and newborn central memory CD4+ T cells was signiﬁcantly lower 
compared to adults (Figure 5C). Adult effector memory and terminally differentiated 
CD4+ T cells contained a higher expression of CD43 compared to adult naïve CD4+ 
T cells (Figure 5D).
Figure 4A-D  RSV-induced Siglec-1 inhibits IFN-̈́ release by adult T cells but not by T 
cells from newborns. A-B: (A) Percentage of RSV+ monocytes and (B) GFP ﬂuorescence 
(MFI) of monocytes after stimulation of adult MCs with RSV in the absence (No blocking) or 
presence of monoclonal antibodies against Siglec-1 (Anti-Siglec-1) or in the presence of 
matching isotype controls (Isotype). N=5. C-D: RSV-induced IFN-ф release by (C) newborn 
CBMCs after 5 days or (D) adult PBMCs after 48h in the absence (No blocking) or presence of 
monoclonal antibodies against Siglec-1 (anti-Siglec-1) or in the presence of matching isotype 
controls (Isotype). N=4-6. E: RSV-induced IFN-ф by PBMCs or PBMCs depleted from memory 
CD4+ T cells. RSV-induced IFN-ф by PBMCS was set to 100. N=5. F: RSV-induced IFN-ф 
release by adult PBMCs depleted from memory CD4+ T cells after 48h in the absence (No 
blocking) or presence of monoclonal antibodies against Siglec-1 (anti-Siglec-1) or in the 
presence of matching isotype controls (Isotype). N=5. Data represent means ± SEM. Statistical 
analyses employed the Wilcoxon matched-pairs signed rank test for paired analysis between 
two conditions and repeated measures ANOVA with Bonferroni’s Multiple Comparison Test for 
paired analysis between more than two conditions. *: P<0.05. ***: P<0.001.
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Discussion
We demonstrate for the ﬁrst time that (a) Siglec-1 is upregulated after RSV infections 
in vivo and in vitro on newborn and adult monocytes, (b) the RSV-induced production 
of IFN-ф is dependent on CD4+ T cells in both adults and newborns but delayed in 
newborns, and (c) Siglec-1 inhibits the RSV-induced IFN-ф release by adult T cells 
whereas the production of IFN-ф by newborn T cells is not affected by Siglec-1. Finally, 
we show that (d) the expression of CD43, the natural ligand for Siglec-1, is lower on 
newborn CD4+ T cells compared to adult CD4+ T cells. 
In this study, a micro-array data base was used to identify Siglec-1 as a clinically 
relevant monocytes receptor. Our microarray data also showed that a considerable 
number of genes are downregulated in adult PBMCs following RSV exposure. 
However, none of these genes were signiﬁcantly downregulated in vivo in whole 
blood from RSV-infected infants (data not shown). Upregulation of Siglec-1 on 
monocytes has been observed in patients with atherosclerosis, systemic sclerosis, 
rheumatoid arthritis, systemic lupus erythematous and human immunodeﬁciency 
virus infections (19-23). The common denominator in these studies appears to be 
type I interferons (IFNs). Our study showed an upregulation of multiple interferon 
regulated genes in whole blood from infants with RSV infection indicating that the 
induction of Siglec-1 during RSV infection could be dependent on type I IFNs. Human 
experimental RSV infection models in adults have been performed (24) and could be 
used to conﬁrm our results derived from RSV-infected infants. Whole blood gene 
expression may not accurately reﬂect the inﬂammatory response at the site of 
infection but rather reﬂect inﬂammation in general. Therefore, we determined the in 
vitro expression of Siglec-1 on monocytes after exposure of PBMCs to RSV directly. 
In addition, we measured the expression of Siglec-1 after exposure of PBMCs to lipo-
polysaccharide (LPS), a bacterial ligand, and we observed no increase of  Siglec-1 
expression after exposure to LPS (data not shown). These data are in line with 
previous literature (19) and suggest that the induction of Siglec-1 on monocytes may 
be interferon- or viral-speciﬁc rather than an induction due to inﬂammation in general. 
We decided to use adult PBMCs to evaluate the upregulation of Siglec-1 in adults, 
because this model would allow us to compare mononuclear cells form newborns 
and adults in vitro and investigate Siglec-1-dependent immune signaling. The 
comparable RSV-induced expression of Siglec-1 on newborn and adult monocytes 
suggests a viral-induced pathway that is already functional at birth. RSV-induced 
expression of Siglec-1 may be present on recruited monocytes and/or resident 
macrophages to regulate T cell functionality at the site of infection (9). 
The functionality of Siglec-1 during viral infection differs between viruses. Siglec-1 
has been implicated in cell entry of human immunodeﬁciency virus (HIV). Sialoglycans 
are present on the gp120 envelope of HIV and mediate cell entry via Siglec-1. Little is 
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known about cellular receptors for RSV and nucleolin has been proposed as an 
important receptor for RSV fusion protein to allow cell entry of epithelial cells (25). Our 
data indicate that Siglec-1 is not required for RSV infection of monocytes. 
In general, newborn CD4+ T cells produce low amounts of IFN-ф compared to adults 
(26). We show that newborn CD4+ T cells are capable of producing comparable 
levels of IFN-ф compared to adults but in a delayed fashion compared to adults. The 
formation of IFN-ф-producing cells upon RSV infection in newborn mice is also 
delayed and may underlie the susceptibility of young infants to severe RSV infections 
in vivo (3). We propose that RSV-speciﬁc IFN-ф-producing memory T cells in adults 
rapidly produce IFN-ф in vitro, whereas IFN-ф production by newborn naïve T cells 
newborns is delayed. In our assay, depletion of CD4+  T cells reduced the production 
of IFN-ф by CBMC and PBMC upon exposure to RSV, whereas depletion of CD8+ T 
cells did not. Because our model does not include epithelial cells and lung-residen-
tial immune cells, CD8+ T cells may still contribute to the production of IFN-ф during 
RSV infections in vivo. In addition, depletion of memory CD4+ T cells reduced the 
production of IFN-ф in adults. The remaining induction of IFN-ф may be due to 
incomplete depletion of memory CD4+ T cell as ﬂow cytometry showed approximately 
70-80% reduction in memory CD4+ T cells (data not shown). Alternatively, naïve T 
cells could also be responsible for the induction of IFN-ф.
This study shows a distinct inhibitory effect of Siglec-1 on the release of IFN-ф by adult 
CD4+ T cells in contrast to newborns. The expression of Siglec-1 is comparable 
between newborn and adult monocytes. The expression of Siglec-1 can, therefore, 
not explain the differences in Siglec-1-dependent signaling between newborns and 
adult T cells. Siglec-1 is the only siglec without a signaling motifs which suggests a 
mode of action via cell-cell interaction (18). A major difference between newborn and 
adult T cells is the high percentage of memory CD4+ T cells in adult PBMCs. Our data 
indicate that the presence of memory CD4+ T cells is required for Siglec-1 to have an 
inhibitory effect on RSV-induced IFN-ф release. CD43 is a highly sialylated receptor 
on T cells and has been identiﬁed as the major receptor for Siglec-1 (27). T cells from 
mice lacking CD43 are able to bind Siglec-1, which suggests that in mice another 
receptor may also be involved  (28). However, in humans only human CD43 has been 
proposed as the main receptor for Siglec-1 (27). We show that the expression of 
CD43 is lower on newborn naïve CD4+ T cells compared to adult naïve CD4+ T cells. 
In addition,  we show a high expression of CD43 on adult differentiated T cells such 
as effector memory T cells and terminally differentiated T cells compared to adult 
naïve CD4+ T cells. Cross-linking of CD43 is important for proper cytokine production 
(29) and Siglec-1 may prevent this process. We hypothesize that newborn and adult 
naïve T cells produce IFN-ф in response to RSV but their low expression of CD43 may 
prevent the inhibitory binding of Siglec-1. Contrary, adult memory T cells have a high 
expression of CD43 that allows Siglec-1 to exert an inhibitory effect on the release of 
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IFN-ф. The use of primary human cells and the absence of a commercially available 
CD43 blocking antibody warrants the use of other models, such as mouse models, 
for future research to demonstrate that Siglec-1 directly inhibits the production of 
IFN-ф during RSV infection through CD43. Clinically, these data suggest that the 
inhibitory effect of Siglec-1 on T cells mainly affects memory T cells during reinfections. 
Mejias et al also observed an inhibitory effect of RSV on T cells during RSV infections 
in infants (30). Future research should determine at what time after birth this inhibitory 
effect takes place, because our data indicate that in certain circumstances Siglec- 
1-dependent inhibition of T cells is not present directly after birth.  
CD43 can bind other receptors than Siglec-1 such as MHC-I (31). The low expression 
of CD43 on newborn CD4+ T cells and the inhibitory role of Siglec-1 in adults could 
therefore have multiple implications on T cells during infectious diseases. The inhibitory 
effect of monocytes on T cells via Siglec-1 may apply to other antigen-presenting cells 
such as dendritic cells (DCs) and macrophages. During in vitro human rhino virus 
infections, DCs inhibit T cells via Siglec-1 (16, 21, 32). Future research to investigate 
the cell-cell interaction between monocytes, DCs, macrophages and T cells would 
enhance our understanding of the regulatory role of antigen-presenting cells during 
RSV infection. In vivo, Siglec-1-deﬁcient mice have an enhanced T cell response to 
exosomal antigens indicating an inhibitory Siglec-1-dependent pathway in mice (33). 
Infection of Siglec-1-deﬁcient mice with RSV may give more insight into the role of 
Siglec-1 during RSV infection in vivo.
In conclusion, this study identiﬁed a regulatory pathway during RSV infection that 
involves Siglec-1, monocytes and T cells. Our data show a delayed kinetic of RSV- 
induced IFN-ф by newborn CD4+ T cells compared to adult CD4+ T cells and an 
inhibitory role of Siglec-1 on the production of IFN-ф in adults. Insights into the distinct 
Siglec-1-dependent inhibition of IFN-ф by RSV in adults compared to newborns and 
the low expression of CD43 in newborns will provide a better understanding of the 
antiviral immune response against RSV directly after birth compared to adults.
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Abstract
Type I IFNs are key regulators of the adaptive immune response during infectious 
diseases1. Type I IFNs, such as interferon alpha (IFN-т) and interferon beta (IFN-у), 
are induced rapidly upon infection and lead to divergent intracellular pathways. The 
activating and inhibitory consequences of type I IFNs depend on cell type and their 
environment2. Newborns are characterized by an immature immune system, in 
particular aspects of CD4+ T-cell-mediated immunity3. It is unknown whether the 
immune modulation of human newborn CD4+ T cells by type I IFNs is different 
compared to adults. Here, we show that IFN-у inhibits the proliferative capacity of 
newborn and adult CD4+ T cells and reduces the phosphorylation of retinoblastoma. 
The IFN-у-mediated inhibition of CD4+ T cells is reduced in newborns compared to 
adults. In addition, IFN-у induces gene expression in newborn CD4+ T cells with high 
levels of the oncogene c-MYC and low levels of the cyclic-dependent kinase inhibitor 
p21 compared to adults. The distinct IFN-у-signaling in newborns will give novel 
insights into the ontogeny of T cell functionality during early life immune responses.
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Introduction
Newborns encounter a large variety of infectious microorganisms during the ﬁrst 
months of life. Maternal antibodies can offer protection against certain pathogens, 
whereas the T cell-mediated immunity from the newborn itself is important to protect 
against intracellular pathogens like respiratory syncytial virus (RSV)4, human cyto-
megalovirus or herpes simplex virus5. A delicate balance between proper T cell 
activation and prevention of T-cell-mediated immunopathology is essential to mount 
a protective immune response. The low production of cytokines such as interferon 
gamma (IFN-ф) in newborns indicates reduced effector function of CD4+ T cells6. 
On the other hand, neonatal sepsis7, 8 and severe viral infections, including RSV 
infections9, in early life are characterized by a strong inﬂammatory response. These 
data suggest that regulatory mechanisms of inﬂammation may also be different in 
newborns. Type I IFNs, such as interferon alpha (IFN-т) and interferon beta (IFN-у), 
are key regulators of the innate and adaptive immune response1. Type I IFNs bind the 
interferon т/у receptor (IFNAR) to activate a variety of intracellular immune pathways 
resulting in activation or suppression of the immune response1, 10-12. It is largely 
unknown whether the immune modulation of CD4+ T cells by type I IFNs is different 
in newborns compared to adults. In this study, we employed newborn and adult 
mononuclear cells (MCs) to characterize IFN-у-dependent and RSV-induced 
modulation of T cells. We used isolated CD4+ T cells to gain insights into intrinsic 
T cell-based mechanisms in newborns and adults that depend on type I IFNs. 
Dissecting the effects of type I IFNs and IFNAR signaling in newborn and adult CD4+ 
T cells will give novel insights into the ontogeny of T cell functionality during early life 
immune responses. 
Methods
Virus culture. Green ﬂuorescent protein (GFP)-labeled RSV A2 (rgRSV30), kindly 
proved by Dr. M.E. Peeples, was cultured on HeLa cells (ATCC, CCL-2) as previously 
described (Vissers et al 2015). The virus stock was snap-frozen and stored at -80 °C.
Cell isolation. After cesarean section delivery of the placenta, human newborn cord 
blood was collected. Premature births and birth to HIV-positive mothers were excluded. 
Peripheral blood was collected form healthy adult volunteers. Human experimental 
guidelines of the Regional Committee on Research involving Human Subjects 
Arnhem- Nijmegen, were observed, following protocols approved by the local 
institutional review boards. Newborn or adult blood was layered onto Lymphoprep 
(Stemcell Technologies) to collect CBMCs and PBMCs, respectively. CD4+ and 
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 106
106
Chapter 3
CD8+ T cells were isolated from MC fractions by positive selection with magnetic 
CD4 and CD8 microbeads, respectively, according to the manufacturer’s instructions 
(Miltenyi Biotec, Auburn, CA). Purity of T cell preparations was consistently > 93%. 
When indicated, CD25+ cells were depleted from isolated T cells. For this, untouched 
CD4+ T cells were isolated from whole blood (RosetteSep CD4 Enrichment Kit; 
Stemcell Technologies) and subsequently CD25high T cells were depleted using 
magnetic CD25 microbeads (Miltenyi Biotec, Auburn, CA). More than 80% of CD25+ 
T cells were depleted as conﬁrmed by ﬂow cytometry (Supplemental Figure 2C). 
RPMI 1640 medium (Invitrogen) + 10% fetal calf serum (FCS) + 2 mM L-Glutamine 
was used as culture medium.
Cell stimulation. Each 96-well plate was ﬁlled with 5 x 105 CMBCs or PBMCs per well 
or with 1 x 105 isolated newborn or adult T cells per well. In separate experiments, the 
supernatants from RSV-stimulated MCs (sup RSV-MC) were harvested, centrifuged 
and used for subsequent stimulation of cells from different donors. No viral particles, 
determined by ﬂuorescent staining of RSV fusion protein, were detected after 
exposure of HeLa cells to supernatant from RSV-stimulated cells (data not shown). 
For the proliferation assay, MCs or isolated T cells were labeled with CFSE, respectively 
5 μg/ml or 1 μg/ml. Cells were incubated with RSV (MOI 0.04, 0.2 or 1), recombinant 
human IFN-т (PBL Interferon Source, NJ) or recombinant human IFN-у (PBL 
Interferon Source, NJ). Subsequently, MCs or isolated T cells were activated with 
respectively PHA (1 μg/ml; Sigma) or CD3/CD28 beads (Dynabeads ThermoFisher 
Scientiﬁc). When indicated, the human interferon alpha/beta receptor (IFNAR2) was 
blocked with monoclonal antibodies against IFNAR2 (5 μg/ml, IgG2a, clone 
MMHAR-2, PBL Interferon Source, NJ) or isotype controls for 1h before stimulation. 
Flow cytometry. Proliferation was determined by CFSE ﬂuorescence (Figure 1A). 
The following ﬂuorochrome-labeled monoclonal antibodies were used for immuno-
phenotyping: CD3 Alexa Fluor 647, CD4 PerCp-Cy5.5, CD8 APC-H7, CD45RA 
Pe-Cy7, CD27 V500, CD25 Alexa Fluor 700, CD127 V450 (BD Biosciences). Mean 
ﬂuorescence intensity of IFNAR1 PE and IFNAR2 PE (PBL Interferon Source, NJ) 
were determined for the expression of IFNAR1 and IFNAR2. 7-Aminoactinomycin D 
(7-AAD) was used to measure cell death. Cells were analyzed with LSR II ﬂow 
cytometer.
Phosﬂow. Isolated CD4+ T cells were incubated with medium for 2h at 37ºC  to 
reduce background phosphorylation after which IFN-у was added. CytoFix (BD 
Biosciences) was added to the cells for 10 min at 37ºC. Cells were washed with 
PBS/1%BSA and permeabilized with Perm Buffer III (BD Biosciences) for 30 min 
on ice. Cells were washed and labeled with the following monoclonal antibodies: 
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STAT1(pY701)-PE and Rb(pS780)-Alexa Fluor 647; BD Biosciences) for 30 min at RT. 
Cells were analyzed with LSR II ﬂow cytometer.
Quantitative real-time polymerase chain reaction (qRT-PCR). After stimulation, 
cells were stored in lysis buffer containing 1% у-mercaptoethanol at -80 ºC. RNA was 
extracted according to the manufacturer’s protocol (Macherey-Nagel). cDNA was 
synthesized by iScript (BioRad) and stored at -20ºC. qRT-PCR was conducted on a 
CFX96 (BioRad) using Taqman gene expression assays (GAPDH: Hs02758991_g1, 
CDKN1A/p21: Hs00355782_m1, CDKN1B/p27: Hs01597599_m1, IRF9 (Hs00196051_
m1), STAT1: Hs01013996_m1, STAT2: Hs01013123_m1). The PCR program consisted 
of 5 min at 96ºC, followed by 50 cycles of 15 s at 96ºC and 45 s at 60ºC. CFX 
Manager 3.0 (BioRad) was used for analysis. Data were normalized and ЮCt was 
calculated by subtracting the Ct value of the housekeeping gene GAPDH from the Ct 
value of the target gene. Relative expression was calculated as followed: 2 -^(ЮCt). 
Fold induction (ЮЮCt) was calculated as followed: 2 -^(ЮCt (stimulated cells) - ЮCt 
(unstimulated cells)). All conditions were measured in duplicate.
Enzyme-linked immunosorbent assay (ELISA). Tumor necrosis factor (TNF; R&D 
Systems) and interleuking 10 (IL-10; Sanquin PeliKine) concentrations were measured 
in the cell supernatants by ELISA according to the manufacturer’s instructions with a 
lower imit of detection of 39 pg/ml.
Data analysis. For all experiments, the following statistical analyses were performed. 
Statistical analyses employed the Wilcoxon matched-pairs signed rank test for paired 
analysis between two conditions Statistical analysis employed Repeated measures 
ANOVA with Bonferroni’s Multiple Comparison Test for paired analysis between more 
than two conditions. Comparative testing between newborns and adults was 
performed with Mann-Whitney U test. *: P: <0.05. **: P<0.01; ***: P<0.001.
Results
IFN-̓-mediated inhibition of T cell proliferation is reduced in newborns. To assess 
whether human newborns are differently modulated by type I IFNs compared to 
adults, we employed cord blood mononuclear cells (CBMCs) and adult peripheral 
blood mononuclear cells (PBMCs). We determined the effect of type I IFNs on T cells 
by exposing newborn and adult MCs to IFN-т and IFN-у prior to the induction of 
proliferation by phytohaemagglutinin (PHA) (Figure 1A). PHA-induced proliferation of 
T cells was higher in newborns (Figure 1B). IFN-т had no effect on newborn and adult 
CD4+ T cell proliferation (Figure 1C). IFN-у inhibited PHA-induced proliferation of 
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Figure 1  Continued. (B) PHA-induced proliferation of newborn and adult CD4+ T cells (N=14-17). 
(C-E): Newborn and adult MCs were exposed to (C) IFN-т, (D) IFN-у or (E) RSV and the effect 
on PHA-induced proliferation of newborn and adult CD4+ T cells was determined. PHA-induced 
proliferation without prior exposure to IFN-т, IFN-у or RSV was set to 100. (N=5-7). (F-G) Newborn 
and adult MCs were exposed to medium-exposed (sup medium-MC) or RSV-stimulated (sup 
RSV-MC) MCs and the effect of PHA-induced proliferation of newborn and adult CD4+ T cells 
was determined. (N=5-9). (*p<0.05, **p<0.01, ***p<0.001).
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CD4+ T cells and this inhibitory effect of IFN-у was reduced in newborns compared 
to adults (Figure 1D). Comparable results were obtained for newborn and adult CD8+ 
T cells (Supplemental Figure 1A-C). 
RSV-induced inhibition of T cells is IFNAR-dependent in adults and reduced in 
newborns. To conﬁrm the inhibitory role of type I IFNs during a clinically relevant viral 
infection in early life, we investigated the effect of RSV on T cell proliferation. We 
observed a dose-dependent inhibition of CD4+ T cell proliferation in adults by RSV 
(Figure 1E). Again, inhibition of CD4+ T cells by RSV was reduced in newborns (Figure 
1E). Comparable differences between newborns and adults were obtained for 
RSV-induced inhibition of CD8+ T cells (Supplemental Figure 1D). Our group 
previously showed the induction of type I IFNs, including IFN-т and IFN-у, by 
newborn and adult MCs after exposure to RSV13. We determined whether RSV could 
inhibit T cell proliferation via soluble mediators and IFNAR signaling. We stimulated 
MCs with medium or RSV for 24h and stored the supernatant (respectively sup 
medium-MC and sup RSV-MC). Subsequently, we incubated MCs from different 
donors with sup RSV-MC to investigate the effect of soluble mediators on T cell 
proliferation. We observed an inhibitory effect of sup RSV-MC that was reduced in 
newborn T cells compared to adult T cells (Figure 1F & G). In newborns, blocking of 
IFNAR did not affect the inhibitory effect of RSV on T cell proliferation (Figure 1H). In 
adults, IFNAR signaling contributed to the inhibitory effect of RSV on T cell proliferation 
Figure 1  Continued. (H) Newborn and (I) adult MCs were exposed to RSV in the absence or 
presence of anti-IFNAR blocking antibodies or isotype controls and the effect on PHA -induced 
proliferation of newborn and adult CD4+ T cells was determined. (N=6). Data represent means 
± SEM. (**p<0.01, ***p<0.001). 
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(Figure 1I). Comparable results were obtained for CD8+ T cells (Supplemental Figure 
1E & F). These data indicated that RSV-induced IFNAR-dependent inhibition of 
T cells is only effective in adult T cells.
IFN-̓-mediated inhibition of retinoblastoma phosphorylation and proliferation 
is reduced in newborn CD4+ T cells. To investigate the direct effect of IFN-у on 
CD4+ T cells, we exposed isolated CD4+ T cells to IFN-у prior to activation with CD3/
CD28 beads. Purity of CD4+ T cells was consistently >93% (data not shown). 
Bead-induced proliferation of CD4+ T cells was similar between newborns and adults 
(Figure 2A). IFN-у-mediated inhibition of CD4+ T cell proliferation was reduced in 
newborns compared to adults (Figure 2B), which is in line with our previous results 
regarding IFN-у-mediated inhibition in a model of MCs. No increase of cell death was 
observed after exposure of CD4+ T cells to IFN-у (Figure 2C). To further dissect the 
IFN-у-mediated T cell inhibition, we measured phosphorylation of retinoblastoma 
(Rb), an important requisite for T cell proliferation14 (Figure 2D). Bead-induced phos-
phorylation of Rb was similar between newborn and adult CD4+ T cells (Figure 2E). 
IFN-у inhibited bead-induced phosphorylation of Rb in CD4+ T cells and this inhibition 
by IFN-у was reduced in newborn T cells compared to adults (Figure 2F). 
IFN-̓-mediated inhibition of cytokine release is absent in newborn CD4+ T 
cells. To determine the effect of IFN-у on effector functions other than proliferation 
and Rb phosphorylation, we measured the capacity of CD4+ T cells to produce pro- 
and anti-inﬂammatory cytokines, respectively TNF and IL-10, after exposure to IFN-у. 
Bead-induced production of TNF and IL-10 by newborn CD4+ T cells was reduced 
compared to adults (Supplemental Figure 2A & B). IFN-у inhibited the bead-induced 
production of TNF and IL-10 by adult CD4+ T cells, whereas no inhibitory effect of 
IFN-у on cytokine production was observed in newborns (Figure 2G & H). The 
production of IL-10 by regulatory CD4+ T cells (Tregs) has been implicated in the 
inhibition of conventional CD4+ T cells15. The inhibitory effect of IFN-у on IL-10 
production in our assay by adult T cells already suggests that IFN-у-mediated 
inhibition of T cells in our assay most likely does not depend on an increased 
production of IL-10. To conﬁrm these results, we depleted CD4+ T cells of Tregs 
(Supplemental Figure 2C) and showed that depletion of Tregs did not affect 
IFN-у-mediated inhibition of adult T cell proliferation (Supplemental Figure 2C & D). 
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Figure 2  (A) Proliferation of newborn and adult CD4+ T cells after exposure to CD3/CD28 
beads for 72h. Bead to cell ratio are depicted on the x-axis. (N=6-8) (B) Newborn and adult 
isolated CD4+ T cells were exposed to IFN-у for 24h and the effect on bead-induced proliferation 
was determined. Bead-induced proliferation without prior exposure to IFN-у was set to 100. 
(N=6-8). (C) Newborn and adult isolated CD4+ T cells were exposed to IFN-у for 24h and the 
effect on cell death was determined. (N=4). (D) Gating strategy to select for T cells that contain 
phosphorylated Rb. (E) Phosphorylation of Rb in newborn and adult CD4+ T cells after 
exposure to CD3/CD28 beads for 72h. (N=5-6). (F) Newborn and adult isolated CD4+ T cells 
were exposed to IFN-у for 24h and the effect on bead-induced phosphorylation of Rb was 
determined. (N=5-6). (*p<0.05, **p<0.01).
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3IFN-̓ induces comparable levels of phosphorylated STAT1 and transcription 
factors in newborn and adult CD4+ T cells. Our observation of a reduced inhibitory 
effect on isolated newborn CD4+ T cells by IFN-у led to the hypothesis that IFN-у 
may differentially induce IFN-у-dependent signaling in newborn CD4+ T cells compared 
to adults. Therefore, we analyzed newborn and adult IFNAR-dependent pathways 
from receptor to the induction of interferon-stimulated genes (ISG). The expression 
level of IFNAR1 and IFNAR2 was higher in newborn naïve CD4+ T cells and newborn 
central memory CD4+ T cells compared to adults (Figure 3A-C). IFNAR expression 
could not be determined on newborn effector memory and terminally differentiated 
T cells as these populations are barely present or undetectable in newborns (<0.01%) 
(Supplemental Figure 3A & B). In adults, IFNAR1 and IFNAR2 expression was higher 
on naïve T cells compared to effector memory and terminally differentiated T cells 
(Supplemental Figure 3C & D). Phosphorylation of signal transducer and activator of 
transcription 1 (STAT1) occurs after ligation of IFNAR by type I IFNs and leads to the 
transcription of ISGs2. STAT1 phosphorylation in CD4+ T cells was detected after 
5 minutes exposure to IFN-у and IFN-у-induced phosphorylation of STAT1 was 
comparable between newborn and adult CD4+ T cells (Figure 3D-E). STAT1 induces 
transcription factors such as STAT1, STAT2 and interferon regulatory factor 9 (IRF9) 
that bind to IFN-stimulated response element (ISRE). Baseline expression of STAT1, 
STAT2 and IRF9 and the induction of these transcription factors by IFN-у were 
comparable between newborn and adult CD4+ T cells (Figure 3F-H). 
Figure 2  Continued. (G-H): Newborn and adult isolated CD4+ T cells were exposed to IFN-у 
for 24h and the effect on bead-induced production of (G) TNF and (H) IL-10 was determined. 
(N=6-7). Data represent means ± SEM. (*p<0.05, **p<0.01, ***p<0.001).
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Figure 3  Continued. (B-C) Expression of IFNAR1 and IFNAR2 on newborn and adult (B) naïve 
CD4+ T cells and (C) central memory CD4+ T cells. Expression is depicted as MFI. (N=4-5). 
(D) Representative gating strategy to determine STAT1 phosphorylation in CD4+ T cells. (E) Phos- 
phorylation of STAT1 in newborn and adult CD4+ T cells after exposure to IFN-у for 5, 15 or 
45 minutes. (N=5-6).
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IFN-̓ induced high expression of c-MYC and low expression of p21 in newborn 
CD4+ T cells and mediates c-MYC-dependent inhibition of Rb phophorylation. 
We next investigated ISGs that are known to affect cell cycle progression and proliferation. 
Cyclic-dependent kinase inhibitor (CDKI) p21 is essential for anti-proliferative signals 
and tightly regulated via activating and inhibitory factors16. P53 activates p2117, 
whereas the oncogene c-MYC inhibits p21 via binding to the p21 promotor region16. 
We determined whether p53, c-MYC and p21 were differentially induced by IFN-у in 
newborn CD4+ T cells compared to adults. We observed no induction of p53 mRNA 
upon exposure of newborn and adults CD4+ T cells to IFN-у (Figure 4A).
IFN-у-mediated induction of c-MYC was higher in newborns compared to adults after 
2h (Figure 4B). The induction of c-MYC was still observed in newborns after 24h, 
whereas c-MYC expression in adult CD4+ T cells was no longer induced by IFN-у at 
that time point (Figure 4C). In contrast, induction of p21 by IFN-у was signiﬁcantly 
lower in newborn T cells compared to adults (Figure 4D). These data indicate IFN-у 
favors pro-proliferative genes in newborn CD4+ T cells and anti-proliferative genes in 
adult CD4+ T cells.
Figure 3  Continued. (F-H) mRNA expression levels of (F) STAT1, (G) STAT2 and (H) IRF9 in 
newborn and adult CD4+ T cells after exposure to IFN-у for 2h. (N=5-6). Data represent means 
± SEM. (*p<0.05).
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Discussion
In newborn CD4+ T cells, we demonstrate for the ﬁrst time a reduced inhibitory effect 
of IFN-у on (a) proliferation, (b) phosphorylation of Rb and (c) cytokine production 
upon TCR stimulation. Newborn CD4+ T cells have a distinct pathway of IFN-у-sig-
naling in which: (d) newborn CD4+ T cells express high levels of IFNAR1 and IFNAR2 
compared to adults. IFN-у-mediated (e) STAT1 phosphorylation and (f) induction of 
transcription factors STAT1, STAT2 and IRF9 are comparable between newborn and 
adult CD4+ T cells. In addition, IFN-у induces (f) high c-MYC levels and low p21 
levels in newborn CD4+ T cells compared to adult CD4+ T cells (Figure 5). 
In this study, we show that the IFN-у-mediated inhibition of T cells in newborns is 
reduced compared to adults. The differences in IFN-у-signaling between CD4+ T 
cells derived from newborns and adults indicate that CD4+ T cells change from birth 
Figure 4  (A-D) mRNA expression levels of (A) p53, (B-C) cMYC or (D) p21 were determined after 
exposure of newborn and adult CD4+ T cells to IFN-у. (N=5-8). Data represent means ± SEM. 
(*p<0.05, **p<0.01). 
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to adulthood. Previous literature has identiﬁed intrinsic differences and similarities 
between newborn and adults CD4+ T cells18. However, during infections in vivo, a 
micro-environment that contains immunomodulatory cytokines such as IFN-у will be 
present and the effect of IFN-у on newborn and adult CD4+ T cells is currently 
unknown. Our data indicate that a difference in IFN-у-signaling between newborn 
and adult CD4+ T cells occurs at the transcriptional level and affects the functionality 
of CD4+ T cells with respect to proliferation and cytokine production upon TCR 
stimulation. 
Figure 5  Graphical abstract summarizing the data presented in this manuscript.
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We show that newborn CD4+ T cells have a higher expression of IFNAR1 and INFAR2. 
Nevertheless, phosphorylation of STAT1 and the induction of several transcription 
factors are comparable between newborn and adult CD4+ T cells after exposure to 
IFN-у. These data indicate that IFNAR-dependent induction of transcription in 
newborns may be intrinsically impaired but compensated by an increased expression 
of IFNAR receptors in order to respond to IFN-у to a similar extent as adults.  In this 
study, pathways leading up to the induction of c-MYC by IFN-у such as STAT1 phos-
phorylation and the induction of several transcription factors were comparable 
between newborn and adult T cells. Signals that follow c-MYC induction such as 
phosphorylation of Rb, induction of p21 and suppression of T cell proliferation and 
suppression of cytokine production were different between newborns and adults. 
Therefore, we pinpointed IFN-у-inducible gene induction as a step that is differentially 
regulated in newborns compared to adults. Regulation of gene expression, including 
IFN-у-dependent regulation, can occur via different mechanisms. Ivashkiv et al 
extensively reviewed the regulation of gene expression by IFN-у2 in which IFN-у can 
modulate the epigenetic signature and chromatin states to inﬂuence the induction of 
gene expression2. The main focus of previous literature has been on the epigenetic 
signature of Th1 versus Th2 in newborns to explain the relative Th2 responses in early 
life19. The development of Th2 cells is more pronounced in newborns due to 
epigenetic conformation in newborn CD4+ T cells20. In addition, newborn T cells 
produce Th2 cytokines, such as IL-4 and IL-13, after activation due to hypomethylation 
of those regions compared to adults6. These data indicate that newborns are 
intrinsically prone to develop a Th2 response due to their epigenetic signature. 
However, no data is available regarding the effect of IFN-у on this epigenetic 
signature, methylation and subsequent gene induction in newborns. Future research 
could elucidate whether IFN-у has a differential effect on the epigenetic signature of 
newborn versus adult CD4+ T cells that explains our observation of high expresison 
of c-MYC and low expression of p21 in newborns. We show that c-MYC is induced by 
IFN-у in both newborn and adult CD4+ T cells. In newborns, the induction is higher 
and prolonged whereas the induction of c-MYC is transient and is no longer present 
after 24h in adults. Negative feedback loops could be responsible for the transient 
induction of c-MYC in adults. MicroRNAs (miRNAs), in particular miR-145, miR-34, 
miR148 and miR494, are responsible for negative feedback signaling upon IFNAR 
engagement and could be involved in the transient induction of c-MYC in adults2, 21. 
Although miRNA levels at baseline and after activation have been compared in 
newborn and adult T cells22, kinetics of miRNA levels after exposure to IFN-у are 
unknown, but could explain the prolonged and transient gene induction of c-MYC in 
respective newborn and adult CD4+ T cells.
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We used a model to investigate newborn and adult CD4+ T cells and their responsiveness 
after exposure to IFN-у. It is important to note that in these assays different populations 
of CD4+ T cells are compared, speciﬁcally naïve and memory CD4+ T cells in 
respectively newborn and adult blood. Therefore, the results may be explained by 
functional  differences between naïve and memory T cells. We chose to compare all 
subsets of newborn and adult T cells. We believe that our results may resemble in 
vivo T cell responsiveness to a greater extent than results obtained by comparison of 
isolated subsets of CD4+ T cells. In addition, future research could elucidate whether 
our results are due to differences in subsets of CD4+ T cells or whether a direct 
comparison between newborn and adult naïve CD4+ T cell will lead to the same 
conclusions. 
The exposure of human newborn primary CD4+ cells to IFN-у is novel but also has 
limitations regarding clinical applicability. Our study cannot predict whether the differential 
effects of IFN-у on newborn CD4+ T cells would be protective or detrimental for 
disease progression during infection in vivo. Proliferation and expansion of T cells are 
pivotal for growth and the development of an adaptive immune response after birth. 
The observed reduced inhibitory effect of IFN-у could be beneﬁcial for newborns to 
allow proper growth. In addition, adult-like IFN-у-mediated inhibition in newborns 
could even further limit the already impaired T cell response to pathogens such as 
RSV4. On the other hand, neonatal infections can be characterized by exuberant 
inﬂammation and newborn T cells can secrete higher levels of pro-inﬂammatory 
cytokine such as interleukin 8 compared to adults23. Low inhibition of newborn T cells 
by IFN-у could result in a defective control of T-cell-dependent inﬂammation and 
inﬂammation- mediated disease progression in vivo. Future research using a murine 
model would give more insights into the clinical effects of IFN-у-induced T cell 
inhibition during early life. Nevertheless, our results will lead to a better understanding 
of IFN-у-mediated molecular mechanisms of T cell biology directly after birth.
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Supplemental Figure 1 (A) PHA-induced proliferation of newborn and adult CD8+ T cells 
(N=14-17). (C-E): Newborn and adult MCs were exposure to (C) IFN-т, (D) IFN-у or (E) RSV 
and the effect on PHA-induced proliferation of newborn and adult CD8+ T cells was determined. 
PHA-induced proliferation without prior exposure to IFN-т, IFN-у or RSV was set to 100. 
(N=5-7). (E) Newborn and (F) adult MCs were exposure to RSV in the absence or presence of 
anti-IFNAR blocking antibodies or isotype controls and the effect on PHA-induced proliferation 
of newborn and adult CD8+ T cells was determined. (N=6). Data represent means ± SEM.
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Supplemental Figure 2 (A) Different bead to cell ratios were used to determine bead-induced 
production of (A) TNF and (B) IL-10 by newborn and adult CD4+ T cells. (N=6-7). (C) Representative 
results of gating strategy to show depletion of regulatory T cells as depicted by CD127+CD25low 
CD4+ T cells. (D) CD4+ T cells or CD25-depleted CD4+ T cells were exposed to IFN-у for 24h 
and bead-induced proliferation was determined. (N=3). Data represent means ± SEM.
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Supplemental Figure 3 (A) Representative gating strategy to select different subsets of 
CD4+ T cells based on the expression of CD3, CD4, CD45RA and CD27: naïve, central memory, 
effector memory and terminally differentiated T cells. (B) Percentage of naïve, central memory, 
effector memory and terminally differentiated CD4+ (upper graph) and CD8+ (lower graph) T cells. 
(N=4).
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Supplemental Figure 3 Continued.  (C-D) Expression of IFNAR1 andI IFNAR2 to on (C) 
adult naïve, central memory, effector memory and terminally differentiated CD4+ T cells and (D) 
adult naïve, central memory, effector memory and terminally differentiated CD8+ T cells. (N=5). 
Data represent means ± SEM.
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Summary
Respiratory syncytial virus (RSV) infections are a major burden in infants less than 3 
months of age. Newborns and infants express a distinct immune system that is 
largely dependent on innate immunity and passive immunization with maternal 
antibodies. Antibodies can regulate immune responses against viruses through 
interaction with Fc gamma receptors leading to enhancement or neutralization of viral 
infections. The mechanisms underlying the immunomodulatory effect of Fc gamma 
receptors on viral infections have yet to be elucidated in infants. Herein, we will 
discuss current knowledge of the effects of antibodies and Fc gamma receptors on 
infant innate immunity to RSV. A better understanding of the pathogenesis of severe 
RSV infections may provide insight into novel therapeutic strategies like vaccination.
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Introduction
Respiratory syncytial virus (RSV) can cause bronchiolitis that is a major burden in 
infants as almost all children will have had an RSV infection by the age of two years 
[1, 2]. RSV infection ranges from mild upper respiratory symptoms to severe lower 
respiratory tract infection resulting in mechanical ventilation and admission to an 
intensive care unit. Strikingly, severe infections occur predominantly in infants below 
6 months of age and usually involve primary infections. Risk factors such as prematurity, 
lung disease and congenital heart disease only account for ~50% of the severe 
cases [1]. It is currently unknown which other factors may account for the remaining 
50% patients with severe RSV infections. 
Infants below 6 months of age are largely dependent on innate immunity and the 
presence of maternal antibodies (matAbs) during infectious diseases. As severe 
RSV cases involve primary infections, innate immunity and maternal Abs are likely to 
have an important role. This raises the question why severe RSV infections are highly 
prevalent in a population having matAbs. This lack of protection might be due to the 
matAb properties and/or inefﬁcient interaction between these matAbs and the innate 
immune system.
Innate immunity comprises particular cells and mechanisms that are the ﬁrst line of 
defense against infections after the physical barrier has been breached. It is 
comprised of innate immune cells and soluble components such as the complement 
system, antimicrobial proteins and peptides. Cells such as monocytes, macrophages, 
dendritic cells, natural killer cells (NK cells) and granulocytes contain speciﬁc patho-
gen-recognition molecules, e.g. Toll-like receptors (TLRs), which induce the 
production of cytokines and activate the adaptive immune response. The innate 
immune response is supported by a soluble biochemical host defense cascade 
known as the complement system. Upon activation, this system complements the 
ability of Abs and phagocytic cells to clear pathogens. Due to an immature adaptive 
immune system and limited antigen (Ag) encounter in utero, neonates and infants 
below 6 months of age rely particularly on their still maturing innate immune system 
to defend themselves against infectious diseases [3]. The importance of innate 
immune receptors at this age is illustrated by the fact that deﬁciencies in TLR signaling 
increase susceptibility to infections with Streptococcus spp., Listeria monocytogenes, 
respiratory syncytial virus and Toxoplasma gondii in the ﬁrst years of life [4].
Besides the role of innate immunity, the presence of matAbs is an important distinctive 
aspect of neonatal and infant immunity. MatAbs are produced by the mother after 
infection or vaccination. The induction of Ag-speciﬁc Abs is called afﬁnity maturation 
and leads to high avidity, neutralizing Abs. During pregnancy, matAbs are transferred 
across the placenta to the fetus and remain in the serum of infants during the ﬁrst 
months of life. Immunoglobulin G (IgG), and mainly IgG1, IgG3 and IgG4, cross the 
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placenta easily and are therefore the most important maternal antibodies [5]. IgM is 
a molecule too large to be transported placentary and IgA is transferred to the 
neonate in small amounts through breast milk [6]. The importance of matAbs is 
illustrated in patients with a genetic inability to produce Abs such as agammaglobu-
linemia. These patients are usually protected against invasive bacterial infections up 
to 6 months when matAbs are still present [7]. 
Fc gamma receptors (Fc̈́Rs) are essential for the recognition of IgG and internal-
ization of immune complexes to induce an immune response. FcфRs can be divided 
in either activating or inhibitory receptors and all innate immune cells contain their 
own speciﬁc set of FcфR. B cells only express the inhibitory FcфRIIB (Table 1). The 
balance between activating and inhibitory FcфRs together with the avidity of this 
binding determines the threshold to immune activation [8].  Interaction between 
FcфRs and pathogen-recognition receptors and the complement system as 
components of the innate immune system has been described and the role of IgG in 
this cross-talk is currently being elucidated [9-11] (Figure 1.) 
In this review, we will discuss the presence and the properties of RSV-speciﬁc Abs in 
infants and elaborate on the interaction between Abs and the innate immune system, 
both in general and in RSV infections. An emphasis will be made on FcфRs as being 
the main IgG binding receptors. We will conclude with future directions regarding the 
role of matAbs in eliciting a non-protective immune response against RSV infections 
in infants below 6 months that could potentially lead to enhanced disease. 
RSV specific antibodies in infants
RSV-speciﬁc matAbs are present during the ﬁrst 6 months of life and have an 
estimated half-life of 1.5 months [12-15]. IgG1 (66%) and IgG3 (5.3%) are the 
predominant subtypes present in infants [16-20]. These titers are highest among 
infants < 6 months and infants > 24 months, possibly indicating matAbs and ‘’self 
made antibodies’’ respectively. Furthermore, RSV-speciﬁc IgG2 and IgG4 are not 
detected in the sera [20].
The clinical relevance of RSV-speciﬁc IgG is unknown at this moment and conﬂicting 
evidence is present regarding the effect of matAbs. Several studies observed that 
matAbs do not have a clinically beneﬁcial effect and high anti-RSV Ab levels are 
associated with an increased risk of recurrent wheezing [21-23]. Other studies 
indicate that high titers of maternal IgG are associated with protection against RSV 
infection [23-27]. These studies calculated the amount of IgG by investigating the 
neutralizing effect of the sera via plaque reduction or the reduction of the RSV-induced 
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cytopathic effect in in vitro cell culture systems.  The amount and effect of non-neutralizing 
Abs are not measured by these methods. An ELISA assay without pre-selecting 
neutralizing Abs might more accurately represent the total amount of RSV-speciﬁc 
IgG. By using an ELISA assay, a marginal increased risk of hospitalization has been 
associated with moderate levels of matAbs compared to low levels [28]. RSV infected 
infants have comparable amounts but signiﬁcantly lower avidity of RSV-speciﬁc IgG1 
compared to non-RSV infected infants. These data indicate that Ab properties, like 
avidity, might play a role in RSV infections [20]. 
Figure 1  Interplay between FcфRs and other receptors on innate immune cells and B cells. 
FcфRs can be divided in activating (blue) and inhibitory (red) receptors. Activating receptors are 
able to initiate cell activation and induce phagocytosis, ADCC and the oxidative burst. FcфR 
activation creates a positive feedback loop by activating C5a. Complement activation leads to 
binding of C5aR, which lowers the threshold to FcфR activation by decreasing the expression of 
the inhibitory FcфRIIB. FcфRIIB induces cell inhibition. Cross-talk withTLR-4 has been suggested 
for a proper immune response. In B cells, engagement of FcфRIIB to BCR leads to inhibition of 
cellular proliferation and induces apoptosis. (BCR: B cell receptors; C5aR: complement 5a 
receptor; ERK: extracellular-signal-regulated kinases; FcфR: Fc gamma receptors; IgG-IC; 
immune complex; ITAM: immunoreceptor tyrosine-based activation motif; ITIM: immunoreceptor 
tyrosine-based inhibition motif; LYN: member of src-related family of protein-tyrosine kinases; 
MyD88: myeloid differentiation primary response gene 88; RAS: member of small GTPase 
proteins; SHIP: SH2 domain containing inositol-5 phosphatase; Syk: spleen tyrosine kinase)
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Besides Ab properties, another important aspect to consider are the different 
epitopes that Abs can be directed to. RSV has several epitopes recognized by the 
immune system; the F protein, a surface glycoprotein, causes immune cell 
membranes to merge and mediates cell entry. The G protein is either membrane 
bound (mG) or secreted in a soluble form (sG) and has been implicated in immune 
evasion. The role of other viral proteins like the small hydrophobic (SH) protein and 
the non-structural (NS) protein are less well deﬁned and currently being investigated. 
The protective role of RSV-speciﬁc Abs is demonstrated by the introduction of 
palivizumab. Palivizumab is a monoclonal Ab (mAb) against the F protein of RSV 
and reduces hospitalization and decreases the total number of wheezing days in 
high-risk groups and preterm infants [29, 30]. In mice, mAbs against the RSV G 
protein offer protection against respiratory disease. Both neutralizing and non-neu-
tralizing anti-RSV G protein mAbs induce protection by inhibition of replication or 
reduction of pulmonary inﬂammation [31, 32]. Given a half-life of 20 days, mAbs offer 
short-term protection and should be administered monthly. Therefore, the induction 
of a persistent protective immune response against RSV through vaccination has 
been a topic of interest for decades. The failure of a vaccine trial with formalin-inacti-
vated RSV shows the complexity of inducing a proper immune response against RSV. 
Proper afﬁnity maturation and the induction of neutralizing Abs are important for an 
adequate immune response against RSV [33, 34]. Formalin-inactivated RSV induces 
non-neutralizing Abs and thereby causes an enhanced respiratory disease after 
concurrent RSV infection [34]. This process is mediated through insufﬁcient TLR 
stimulation in B cells and is dependent on the formation of immune complexes. 
Inactivation of RSV with formalin induces reactive carbonyl groups that may alter 
immunogenicity and favor a Th2 response possibly resulting in deleterious immune 
responses [35].  
Maternal Abs might inhibit the B cell response and the production of Abs upon RSV 
infection [36, 37]. A more pronounced Ab response after RSV infection in individuals 
with low titers of matAbs has been observed [37]. In mice, passive transfer of 
RSV-speciﬁc Abs attenuates the titer and the neutralizing activity of Abs against F 
and G-proteins expressed by vaccinia virus recombinants [38-40]. These data 
suggest that matAbs alter the humoral response against RSV resulting in a 
non-protective immune response. 
Overall, the clinical and immunological effects of matAbs on RSV infection are still 
unclear and highly dependent on Ab properties (Table 2).
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The effect of fc gamma receptors on  
the innate immunity
Fc gamma receptorson monocytes, macropahges and dendritic cells 
FcфRI, FcфRIIA and FcфRIIIA are involved in Ab-mediated phagocytosis of pathogens 
by monocytic cells like monocytes, macrophages and dendritic cells. Phagocytosis 
is important for the activation of Syk kinase and the induction of the immune response 
by release of inﬂammatory cytokines [41]. The down-side of Ab-mediated phagocytosis 
is shown in the context of several viral infections and is called Ab-dependent 
enhancement (ADE). ADE has been observed in secondary dengue infections of 
both monocytes and dendritic cells in which Abs increase infectivity via FcфRI and 
FcфRIIA [42]. Furthermore, the ligation of dengue virus particles with Abs reduces the 
expression of TLR and shifts the formation of cytokines towards anti-inﬂammatory 
cytokines [43, 44]. The same principle has been observed in the context of HIV- 
infections and is dependent on FcфRs [45, 46]. These data suggest a mechanism by 
which ADE in the context of viral infections increases infectivity and impairs the innate 
immune response [42, 47]. A comprehensive review has been published concerning 
the different mechanisms of ADE in viral infections after secondary infections or 
vaccination [48]. 
Beside initiating phagocytosis, FcфRIII has been implicated in cross talk with TLRs. 
The presence of immune complexes results in the association between TLR4 and 
FcфRIII. Furthermore, the activation of FcфR requires the presence and integrity of 
TLR4 as both FcфRIII-deﬁcient mice and TLR4-deﬁcient mice were unable to elicit an 
immune response upon stimulation of macrophages with IgG [11].
The remaining FcфR, FcфRIIB, is known as an inhibitory receptor resulting in immuno-
suppression and decreased phagocytosis by monocytic cells [49].  Pre-treatment of 
macrophages with IgG1 inhibits the LPS-induced TLR4 response, a process 
dependent on the activation of FcфRIIB. [50]. In dendritic cells, anti-FcфRIIB Abs in the 
presence of IgG ligands lead to dendritic cell maturation, up-regulation of the type I 
interferon genes and increased amounts of CCL-5 (chemokine C-C motif ligand 5) 
conﬁrming the inhibitory effect of FcфRIIB [51, 52].
The role of monocytes, dendritic cells and macrophages in RSV infections. In animal 
studies, macrophages are essential in the restriction of RSV replication in the lungs. 
ADE after vaccination has been observed in RSV infections in vitro with both human 
and a mouse monocyte-like cell lines and macrophages. Monoclonal Abs can have 
a neutralizing effect, a disease enhancing effect or both [53]. The concentration of 
IgG and the simultaneous presence of different mAbs determines whether the Abs 
are neutralizing or disease enhancing [53, 54]. The enhancing activity of RSV-speciﬁc 
Ab levels is conﬁned to sera from infants aged 0 to 6 months and acts via FcфR [55]. 
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This suggests that matAbs may contribute to ADE of RSV infections of young infants 
resulting in increased severity of RSV disease in this population. 
RSV has evolved different mechanisms to alter or counteract the antiviral effect of 
monocytic cells. RSV evades Ab neutralization by the production of sG. [56, 57]. 
Other structural and non-structural proteins alter the antiviral immune response 
through direct interaction with recognition receptors [58-62]. All experiments in the 
context of human cells were performed in a serum-free environment. Therefore, the 
role of antibodies in the immune evasion mechanisms of RSV is unknown. 
Fc gamma receptors on NK cells 
NK cells are activated by virus-infected cells directly through activation receptors or 
through immune complexes.  FcфRIIIA is the most important FcфR present on NK 
cells [63]. In the context of Abs, CD56dim NK cells are of interest considering their 
abundant presence in peripheral blood and their expression of FcфRIIIA. IgG is able 
to enhance the production of cytokines by CD56dim NK cells upon encountering 
target cells [64]. Binding of immune complexes to FcфRIIIA induces antibody-depen-
dent cellular cytoxicity (ADCC) through CD56dim NK cells by degranulation and per-
forin-dependent targeted cell lysis [65, 66]. In the absence of a pathogen, IgG is able 
to inhibit NK cell activity [67]. ADCC has extensively been studies in the context of HIV 
infections in which the interaction of anti-HIV Abs with NK cells offers protection and 
even predicts viral load and clinical outcome [68, 69]. ADCC against herpes simplex 
virus and HIV is decreased in neonates compared to adults possibly reﬂecting, in 
part, deﬁcient interaction of matAbs and NK cells in the neonatal period [70-72]. 
FcфRIII is aided in its cytotoxic effect by FcфRIIC. Not all individuals express FcфRIIC 
on their NK cells. The FcфRIIC gene originates from the unequal crossover between 
IIA and IIB genes, which results in an FcфR that is homologous to FcфRIIB extra-
cellularly and to FcфRIIA intracellularly [73]. When FcфRIIC is expressed on NK cells, 
it mediates IFN-ф production and aids FcфRIII in its cytotoxic effect [65, 74]. Although 
current data is not conclusive, the inhibitory FcфRIIB was detected in only a few 
individuals and was able to suppress NK cell function [73, 75].
The role of NK cells in RSV infections. In RSV infected mice, NK cells accumulate in 
the lung upon RSV infection and cause acute lung injury through the production of 
IFN-ф [76, 77]. RSV infection induces ADCC via NK cells as shown by the cytotoxic 
effect of NK cells on a RSV-infected human cell line. This process is already present 
in young infants, implying a role of matAbs [78, 79]. Recent studies are unraveling the 
speciﬁc subsets of NK cells responsible for the RSV-induced ADCC. Lung tissues 
from fatal RSV infections showed a near absence of NK cells [80]. These low amounts 
of NK cells, however might represent the end-stage values of NK cells considering 
the use of lung tissue samples after the patients died. In the acute phase of RSV 
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infection, increased amounts of NK cells are found. CD56+/FcфRIIIA+ NK cells and 
IFN-ф production are increased in the acute phase of hospitalized RSV-infections 
compared to control patients without RSV-infection [81]. An increase of activated NK 
cells in RSV infections of both mice and human subjects results in acute lung injury 
due to the production of IFN-ф [77, 82]. The  increased presence of FcфRIIIA+ NK 
cells, IFN-ф and lung damage in severe RSV infections, raises the possibility that IgG, 
as a ligand for FcфRIIIA, negatively inﬂuences the immune response in RSV infections.
Fc gamma receptors on granulocytes
Neutrophils
Activation of FcфR on neutrophils mainly results in phagocytosis and ADCC [83]. 
Upon stimulation with IFN-ф, FcфRI and FcфRIIA, present in neutrophils, are upregulated. 
FcфRIIA binds IgG-coated particles displayed by the formation of rosettes and is 
dependent on speciﬁc activating factors [83, 84]. Neutrophil activating compounds, 
like fMLP and PMA, can either induce or suppress FcфRII [85]. The exact mechanism 
by which these activating factors are able to exert opposite effects has not been 
elucidated. 
The activation of FcфRIIIB leads to phagocytosis, the induction of chemokines and 
thereby the recruitment of neutrophils to inﬂammatory sites [86-88]. As stated before 
in the context of macrophages, stimulation of neutrophils with IgG results in the 
association between TLR4 and FcфRIII and FcфRIII-deﬁcient mice and TLR4-deﬁcient 
mice are unable to elicit an immune response upon stimulation of macrophages with 
IgG [11].
The precise role of the inhibitory FcфRIIB in human neutrophils is as of yet unknown. 
Resting human neutrophils express FCGR2B2 mRNA, but express low levels of 
FcфRIIB on the cell surface. FcфRIIB might inhibit phagocytosis, superoxide production 
and neutrophil adhesion [89].
The role of neutrophils in RSV infections. Neutrophils play an important role in the 
development of lung pathology in severe primary RSV infections in infants below 6 
months [90]. Neither RSV alone nor speciﬁc RSV-Abs alone are able to activate 
neutrophils. The presence of RSV and RSV-speciﬁc Abs results in the formation of 
RSV immune complexes [91]. After phagocytosis of the immune complexes, profound 
activation of neutrophils and increased amounts of interleukin 8, oxygen radicals and 
thromboxane B2 are observed. These products cause immune complex-mediated 
lung pathology and bronchoconstriction in RSV infections [91-93]. 
Mast cells
IgG Abs have been known to activate mast cells, long before the currently established 
correlation between IgE, mast cells and allergic reactions [94]. Upon stimulation with 
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IFN-ф, FcфRI expression on mast cells is upregulated and IgG has an activating effect. 
The increased expression of FcфRI allows IgG, and particularly IgG1, to cause 
degranulation and prolonged survival of mast cells [95-97]. 
FcфRIIIA expression is present on mast cells and induces IgG-mediated degranulation 
[98, 99]. Inhibition of Kit-induced mast cell proliferation upon activation of FcфRIIB 
has been observed and bone marrow-derived mast cells do not respond to IgG 
unless they are FcфRIIB-deﬁcient [100]. These data suggest that IgG does bind to 
bone marrow-derived mast cells, but has an inhibitory effect through FcфRIIB that 
was conﬁrmed by the increased sensitivity of mast cells from FcфRII-deﬁcient mice 
upon stimulation with IgG [94, 101].
Currently, there is compelling evidence of a role for mast cells in the immune response 
against viral infections [102]. Studies observed that viral infection of mast cells leads 
to the recruitment of monocytes, NK cells and T lymphocytes [103]. The addition of 
dengue-speciﬁc Abs to dengue infected mast cells leads to increased expression of 
RIG-1 and MDA-5 and induces a profound and possibly harmful release of cytokines 
and chemokines. It has been concluded that FcфRIIA plays a role in the ADE of 
dengue infections in mast cells [104-106]. 
The role of mast cells in RSV infections. Mast cells express TLR4 suggesting direct 
recognition of pathogens including RSV. RSV infection of rodents and cows has been 
associated with mast cell activation. In humans, RSV bronchiolitis is associated with 
an increased number of mast cells [107].  Pre-treatment of mast cells with puriﬁed 
human total IgG results in increased amounts of chemokines compared to stimulation 
with RSV alone [108]. 
Eosinophils
Although eosinophils are mostly involved in allergic reactions, they also possess 
antimicrobial properties [109-111]. FcфRII is responsible for Ab-mediating killing of 
tumor cells and antibodies are able to enhance the killing ability and activate Fcф-
RII-dependent degranulation of eosinophils against a variety of pathogens like 
Toxoplasma gondii and Candida albicans [109, 112, 113]. Abs, particularly IgG1 and 
IgG3 but not IgE, activate eosinophils resulting in their degranulation and causing 
bronchial hyperreactivity as seen in asthma patients, a process dependent on FcфRII 
[114]. Interestingly, immobilized IgG induces death of eosinophils and soluble IgG is 
able to prolong survival of eosinophils [115].
After activation with chemoattractants or IFN-ф, FcфRI and FcфRII become mem-
brane-expressed on eosinophils. Resting eosinophils express FcфRIII mainly 
intracellular. Upon activation however, FcфRIII becomes membrane-expressed 
transiently before secretion of the receptor takes place [116, 117]. The exact role of 
FcфRIII in eosinophils is yet to be determined. 
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The role of eosinophils in RSV infections. Increased amounts of eosinophils are 
observed in nasal pharyngeal aspirates of RSV infected infants compared to 
non-infected infants [118].  RSV replication in eosinophils results in the release of 
infectious virions and the pro-inﬂammatory mediator interleukin 6 [119]. Eosinophils 
inactivate RSV by the release of a speciﬁc protein called eosinophil cationic protein 
(ECP) [120, 121]. Infants with elevated levels of ECP during a primary RSV infection 
are ten times more likely to develop wheezing later in childhood [122]. Pulmonary 
eosinophilia attracted in response to primary RSV infection is particularly evident in 
the youngest human infants and in neonatal mouse models [123, 124]. Currently no 
data is available concerning the effect of Abs or immune complexes on RSV-infected 
eosinophils. In the context of RSV vaccination, Polack et al. showed that IgG mediated 
increased activation of eosinophils and enhanced respiratory disease after challenge 
with formalin inactivated RSV [33]. Therefore, abundant eosinophilic acitivation or 
ECP release might induce an ineffective immune response in RSV infections.
Basophils
Basophils are a sparse subset in the population of leukocytes and they are involved 
in allergic reactions. Only recently, the role of FcфR on basophils is being elucidated. 
IgG is not able to activate basophils probably due to the high expression of the 
inhibitory FcфRIIB in this cell type.  A low degree of basophil activation is achieved by 
selectively activating FcфRIIA and thereby bypassing FcфRIIB [125-128]. 
The role of basophils in RSV infections. RSV induces basophil accumulation in a 
mouse model. Furthermore, basophils were the only cells responsible for the release 
of interleukin 4,  a cytokine which might contribute to the pulmonary pathogenesis of 
RSV infections [129]. No published data is available on the role of Abs and basophils 
in the context of RSV. 
Fc gamma receptors on B cells 
The B cell compartment is predominantly known for its adaptive aspects in the 
immune defense. However, the expression of TLRs and the internalization of viruses 
upon binding with the B cell receptor (BCR) suggest that B cells are involved in 
directly sensing microbes [130]. A speciﬁc B cell population, called B1 cells, is already 
present during the fetal period. A progressive loss of B1 cells was shown with a 
fourfold difference between cord blood and adults above 20 years of age that 
indicates a speciﬁc role of B1 cells in childhood [131]. Natural Abs are spontaneously 
produced by B1 cells without prior infection or immunization and are a major 
recognition molecule of innate immunity [132-134].  In mice, natural Abs activate the 
complement system, facilitate antigen uptake and protect against S. pneumoniae, 
Listeria monocytogenes and inﬂuenza virus [132, 135-138]. 
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B cells only express the inhibitory FcфRIIB and the expression of FcфRIIB varies 
among the different subtypes of B cells. Engagement of FcфRIIB to BCR leads to 
inhibition of cellular proliferation and induces apoptosis. B cells that express 
high-afﬁnity BCR will receive signals from both BCR and FcфRIIB, whereas B cells 
that have low-afﬁnity BCR will predominantly receive signals via FcфRIIB resulting in 
apoptosis. Plasma cells express high levels of FcфRIIB and are therefore susceptible 
to the induction of apoptosis by Abs [139]. Thus, overall, FcфRIIB acts as a regulator 
of humoral immunity. 
The role of B cells in RSV infections. B cell responses may contribute to the 
protective and/or pathological effect of primary RSV infections and are increased in 
the acute and reconvalescent phase of RSV infection [140, 141]. The characteristics 
of RSV-speciﬁc B cells from RSV infected individuals have been determined. B cells 
from RSV infected infants below 3 months express less somatic mutations after both 
a primary and a secondary infection compared to individuals above 3 months. 
Somatic mutation is an important property of B cells in order to produce neutralizing 
Abs upon encountering a pathogen [142]. These data suggest that inefﬁcient somatic 
mutation underlies the poor Ab response in neonates against RSV infections. As 
mentioned before, high levels of matAbs reduce the Ab response of infants against 
RSV [37]. Although B cells are the main source of Abs, no study so far has investigated 
the effect of antibodies on the humoral response in natural RSV infections. The 
insufﬁcient TLR stimulation on B cells resulting in the lack of a protective Ab response 
upon formalin-inactived RSV vaccine highlights the importance of adequate activation 
of B cells [34]. 
Fc gamma receptors and the complement system
The complement system is a cascade that aids Abs in the clearance of pathogens. 
IgG1, IgG2 and IgG3 are capable of activating the classical pathway of complement. 
In this cascade, the formation of complement factors C3a and C5a allows induction 
of phagocytosis and pro-inﬂammatory cytokines through complement receptors 
(C3aR and C5aR) [143]. The interplay between complement and FcфR is essential 
in this process (Figure 1). Pre-treatment with IgG1 is able to shift this balance 
by selectively activating FcфRIIB and thereby limiting the inﬂammatory response [144, 
145]
The role of complement in RSV infections. The complement system is important in 
the pathogenesis of RSV infections.  RSV activates the complement system and 
induces the production of C3a and C5a [146]. C3aR-deﬁcient mice show decreased 
viral replication suggesting a non-protective role of C3aR. The disease enhancing 
effect of C3aR has been conﬁrmed in the context of the formalin-inactivated RSV 
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vaccine. Vaccinated C5-deﬁcient mice express an upregulation of C3aR and enhanced 
respiratory disease upon infection with RSV [147]. Moreover, C3 is increased in enhanced 
respiratory disease caused by vaccination with formalin-inactivated RSV [33]. Both 
studies conclude that C3aR might contribute to the pathogenesis of RSV infection 
[148]. Indeed, increased complement activation has been observed in patients that 
died from RSV bronchiolitis [33]. The effects of pre-existent RSV-speciﬁc Abs has 
been studied by injecting naïve mice with RSV-speciﬁc Abs to mimic infants having 
matAbs. The following Ab-mediated viral restriction is dependent on the complement 
system [57]. IgG1 is the predominant RSV-speciﬁc Ab present in infants with RSV- 
infections and suppresses complement-mediated inﬂammation. This predominant 
interaction of IgG1 with FcфRIIB as stated by Karsten et al. is yet to be investigated 
in the context of RSV infections [145]. Studies on the effect of Abs on the adaptive 
immune response against RSV show that FcфR and complement contribute to the 
Ab-mediated induction of CD4+ T cells resulting in a high ratio of CD4+/CD8+ T cells 
[149]. The balance between CD4+ and CD8+ T cells might be important considering 
patients with severe RSV infections have relative low amounts of CD4+ T cells compared 
to CD8+ T cells [69, 150]. A role of complement and the induction of neutralizing versus 
non-neutralizing Abs in shaping the CD4+/CD8+ ratio and disease severity has been 
suggested [149]. 
Conclusions
This review has presented the extensive evidence for the immunomodulatory effect 
of Abs and FcфRs on innate immunity. Most of these mechanisms are present in the 
context of RSV (Figure 2). Therefore, it is likely that these pathways play a signiﬁcant 
role in the development of severe RSV infections. Currently, clinical evidence is 
lacking and future research is necessary to investigate how the balance between 
activating and inhibitory FcфRs determines the resulting immune response during 
severe RSV infections. In vitro experiments using primary cells represent an important 
approach to studying these pathways. Characterizing the effect of Abs and activated 
FcфRs on neutralization of RSV in vitro, cytokine production and the adaptive immune 
response could advance our knowledge on this subject. Crosstalk between Abs and 
innate immune receptors, such as TLRs will be of particular interest in the context of 
an infection that frequently strikes young infants.  Studies of FcфR-deﬁcient mice can 
be used to study the effect of FcфRs in vivo. Although immune evasion mechanisms 
of RSV are currently being unraveled, the presence of Abs has not been investigated 
when contemplating clinical relevance.  These mechanisms will give more insight into 
the effects of matAbs on the immune response and disease severity during RSV 
infections in infants. Secondly, it will provide essential knowledge relevant to the 
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induction of protective Abs during maternal or neonatal immunization. Therefore, 
characterizing the role of FcфRs will provide new insights in the pathogenesis of 
severe RSV infections and the development of novel preventive strategies.
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Abstract
Respiratory syncytial virus (RSV) is the leading cause for respiratory illness that 
requires hospitalization in infancy. High levels of maternal antibodies can protect 
against RSV infection. However, RSV-infected infants can suffer from severe disease 
symptoms even in the presence of high levels of RSV-speciﬁc antibodies. This study 
analyzes several serological characteristics to explore potential deﬁciencies or 
surpluses of antibodies that could relate to severe disease symptoms. We compare 
serum antibodies from hospitalized patients who suffered severe symptoms as well 
as uninfected infants. Disease severity markers were oxygen therapy, tachypnea, 
oxygen saturation, admission to the intensive care unit and duration of hospitaliza-
tion. Antibodies against RSV G protein and a prefusion F epitope correlated with in 
vitro neutralization. Avidity of RSV-speciﬁc IgG antibodies was lower in RSV-infected 
infants compared to uninfected controls. Severe disease symptoms were unrelated to 
RSV-speciﬁc IgG antibody titers, avidity of RSV-IgG, virus neutralization capacity or 
titers against pre- and postfusion F or G protein ectodomains and the prefusion F 
antigenic site Ø. In conclusion, the detailed serological characterization did not 
indicate dysfunctional or epitope-skewed composition of serum antibodies in 
hospitalized RSV-infected infants suffering from severe disease symptoms. It remains 
unclear, whether speciﬁc antibody fractions could diminish disease symptoms.
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Introduction
Human respiratory syncytial virus (RSV) infections are a major burden for infants [1]. 
The symptoms of RSV infection range from a common cold to severe bronchiolitis 
and pneumonia. Children below 3 months of age are at risk for developing severe 
symptoms that require admission to the hospital, whereas the vast majority shows 
only mild disease [2].
Early in life, the infant’s immune system relies mostly on innate immunity and the 
presence of maternal, transplacentally transferred immunoglobulin G (matAbs). 
Consistently, high levels of RSV-speciﬁc matAbs in the cord blood are reported to 
delay the time point of primary RSV infection [3, 4]. Intriguingly, primary infections 
occur even though high levels of matAbs are present. This raises the question to what 
extent serum antibodies play a role in infants suffering from severe symptoms during 
RSV infection and whether antibodies are any different from those of infants with a 
mild course of disease or uninfected controls. To answer these questions, we 
investigated whether properties of matAbs such as the level of prefusion F protein- 
speciﬁcity or levels of non-neutralizing antibodies, could relate to severity of disease.
Here, we studied the properties of anti-RSV IgG in plasma of infants that were 
hospitalized with an acute RSV-infection before 3 months of age. Antibodies observed 
in a peer group of uninfected individuals represent a base line for: (1) RSV-IgG 
antibody titers, RSV-IgG avidity, and neutralization capacity, (2) antibody titers against 
G protein, prefusion F protein, postfusion F protein and (3) antibody titers against 
prefusion antigenic site Ø and postfusion antigenic site I. The composition of 
antibodies and/or their combination with properties might represent a signature that 
is typical for severe RSV disease. We analyzed the antibodies for a correlation with 
multiple severity parameters, including oxygen therapy, age, respiratory rate, 
transcutaneous oxygen saturation, admission to an intensive care unit and duration 
of hospitalization. A better understanding of how antibody properties relate to disease 
progression is essential to develop safe and effective immunization strategies.
Methods
Study design.  Hospitalized children below 3 months of age with PCR-conﬁrmed 
RSV infections were included during 2011–2013. Within 24 h after admission, a blood 
sample was taken. Patients with congenital heart or lung disease, immunodeﬁciency 
or glucocorticoid use and infants born at a gestational age below 35 weeks were 
excluded. For primary analyses, patients were classiﬁed into two severity groups 
based on the necessity for oxygen therapy. For secondary analyses, additional disease 
severity parameters were used to categorize patients: the presence of tachypnea, 
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transcutaneous oxygen saturation (*93% or <93%), admission to an intensive care 
unit and duration of hospitalization. The correlation with age was investigated for all 
analyses to determine whether age would be a potential confounding factor. Infants 
below 3 months of age requiring surgery for an inguinal hernia repair were included 
as healthy, uninfected controls. Nasopharyngeal aspirates from all uninfected 
individuals were RSV negative. The study protocols were approved by the Regional 
Committee on Research involving Human Subjects Arnhem-Nijmegen (serving as 
the IRB) and were conducted in accordance with the principles of the Declaration of 
Helsinki. Written informed consent was obtained from the parents of all children.
Plasma collection. Coagulation of blood samples was prevented by sodium heparin 
(BD Vacutainer). After centrifugation at 800 x g, the plasma fraction was diluted with 
an equal volume of phosphate-buffered saline (PBS) and stored at -80°C.
Culture of virus and neutralization assay. Recombinant RSV-A2 expressing green 
ﬂuorescent protein (rgRSV) was kindly provided by Dr. Peeples and cultured on HeLa 
cells as described previously [5]. RSV was puriﬁed by ultracentrifugation over a 30% 
sucrose layer for 1.5h at 20.000 x g. RSV was quantiﬁed by end point titration assays 
on HeLa cells. Recombinant RSV-X expressing green ﬂuorescent protein (RSV-X) has 
been described earlier as E1-rRSV_X [6]. RSV-X is a more recent clinical isolate of 
genotype GA2 with 98.5% amino acid sequence identity with RSV-A2 F protein and 
86.2% amino acid sequence identity with RSV-A2 G protein. A derivative of recombinant 
RSV-X that is lacking the G protein was generated by replacing the G protein reading 
frame by a gene encoding green ﬂuorescent protein (RSV-X-dG) [7]. RSV-X and 
RSV-X-dG (Dutch genetically modiﬁed organism license IG-99-210) were propagated 
in Vero cells (CCL-81, American Type Culture Collection) using Dulbecco’s Modiﬁed 
Eagle Medium (DMEM, Life Technologies) supplemented with 5% FCS and Pen Strep 
Glutamine (Life Technologies). The cell culture supernatants were concentrated by 
polyethylene glycol-6000 precipitation and stored with 10% sucrose. Virus titration by 
end point dilution and plaque reduction neutralization assays were performed as 
described earlier [6]. The 50% plaque reduction neutralization titers (PRNT) were 
normalized using a correction factor derived from the intra-assay variation of the 
WHO513 standard (BEI Resources) and half maximal inhibitory concentrations 
calculated by ﬁtting a non-linear curve (GraphPad Prism).
RSV-speciﬁc IgG titer and avidity ELISA. RSV-speciﬁc IgG concentrations in 
plasma samples were determined by ELISA. ELISA plates were coated with rgRSV at 
a concentration of 2 x 105 U/ml in PBS or PBS as negative control. Plates were washed 
with PBS containing 0.05% Tween-20 and blocked with PBS containing 1% BSA 
(Sigma-Aldrich). Plasma samples were incubated for 2 h at room temperature (RT). 
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After washing, plates were incubated with alkaline phosphatase (AP)-conjugated 
anti-human IgG in PBS containing 1% BSA for 2 h (1:10,000; Southern Biotech). 
Detection of AP activity was performed with 10 mM diethanolamine with 0.5 mM 
MgCl2 using an ELISA plate reader. Optical density at 450 nm wavelength (OD) from 
PBS-coated wells was subtracted from parallel samples coated with RSV. OD values 
from serial dilutions of healthy adult pooled plasma ranging 1:10 to 1:10,240 were 
used as standard to calculate arbitrary units (AU). To determine the IgG avidity of 
RSV-speciﬁc antibodies, wells were treated with sodium thiocyanate (NaSCN, 2 mM) 
for 10 min to weaken antibody binding and compared to untreated wells [8]. The IgG 
avidity index was calculated as follows: (RSV-IgG titer without NaSCN (AU) / RSV-IgG 
titer with NaSCN (AU) *100).
Recombinant RSV F and G ELISA. Expression constructs, production, and 
puriﬁcation of the postfusion F ectodomain (Fwt, called postfusion F protein 
hereafter), the trimeric, furin cleavage site-mutated, heptad repeat B domain-deleted, 
prefusion F ectodomain (Flys. HRB-GCN, called prefusion F protein hereafter), and a 
tetrameric subtype A RSV G ectodomain (residues 64 to 298) have been described 
previously [9–11]. The antibody response to RSV F or GA was determined using 
ELISA. NUNC multisorp plates were coated with 25 ng of recombinant protein at 4°C 
overnight. After washing with PBS containing 0.05% Tween-20, wells were blocked 
with 3% BSA in PBS containing 0.1% Tween-20 at RT. Two-fold serial dilutions of 
human patient plasma in blocking buffer were incubated for 1h at RT. After washing, 
antibodies were labeled with HRP-conjugated goat anti-human IgG (ITK Southern 
Biotech) for 1h at RT. HRP activity was detected by tetramethylbenzidine substrate 
(BioFX). The IgG titer for RSV F or G were determined by calculating the corresponding 
dilution at OD = 1. Antibody response against antigenic site Ø and I was assessed 
by competition ELISA as previously described [11]. Two-fold serial dilutions of plasma 
samples or non-labeled monoclonal antibodies (D25 directed at the speciﬁc prefusion 
F antigenic site Ø, and 131-2a directed at a speciﬁc postfusion F antigenic site I) in 
blocking buffer were added and incubated for 1h at RT. After washing, wells were 
incubated with 0.6 μg/ml biotin-D25 or 0.2 μg/ml biotin-131-2a to enable binding to 
prefusion F after preincubation with the diluted plasma samples. After 1h at RT, the 
biotinylated antibodies were labeled with 1 μg/ml HRP-conjugated Streptavidin 
(Thermo Scientiﬁc) and detected by adding tetramethylbenzidine substrate (BioFX) 
using an ELISA plate reader (EL-808, Biotek). Wells incubated with biotinylated 
antibodies alone represent uncompeted, positive controls and wells blocking buffer 
alone served as negative control. Percentage inhibition was calculated for every 
dilution using the following equation: (OD biotinylated MAb—OD plasma samples) / 
OD biotinylated MAb X 100. Using a nonlinear 4-parameter ﬁt curve analysis 
(GraphPad) the inhibition titer for each plasma samples were determined as the 
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plasma dilution that resulted in 25% inhibition of D25 or 15% inhibition of 131-2a 
binding.
Statistical analysis. Normality tests were performed on all parameters using the 
Shapiro-Wilk normality test and showed non-parametric distribution. Comparison 
between two groups was analyzed by two-tailed Mann-Whitney U test and comparison 
between more than two groups was analyzed by the Kruskall-Wallis test and if 
signiﬁcant followed by two-tailed Mann-Whitney U test. Spearman correlation test 
was used for correlation tests. Tests were considered signiﬁcant if P < 0.05. All 
statistical analyses were done with GraphPad Prism.
Results
Study population. Plasma IgG from thirty-three hospitalized RSV patients was compared 
to eleven uninfected infants. In our primary analysis, the distinction between severe 
or moderate RSV disease is determined by whether or not patients received oxygen 
therapy. Medical doctors make the decision to hospitalize patients based on most 
severe symptoms that indicate oxygen therapy or on moderate symptoms in combination 
with other indicators, for example frailty or age, but not requiring oxygen. Consistent 
with more severe disease, the group that received oxygen was hospitalized for a 
longer period, as compared to RSV-infected infants without oxygen (Table 1). Gender, 
gestational age, presence of breastfeeding and presence of parental smoking were 
comparable between all groups (Table 1). Only children below three month of age 
were considered for this study. The group of uninfected infants was slightly older and 
had a lower birth weight compared to the RSV-infected groups (Table 1). There was 
no signiﬁcant difference in age and duration of symptoms before hospitalization 
between RSV-infected infants with or without oxygen therapy.
Level and avidity of RSV-speciﬁc IgG in infant sera. Age is correlated with a decay 
of matAbs and young age is a risk factor for severe RSV disease [12]. In this study, we 
observed no correlation between age at RSV infection and the levels of RSV-speciﬁc 
IgG (Fig 1A). Moreover, there was no signiﬁcant difference in RSV-IgG levels between 
RSV patients and healthy children (Fig 1B). Next, we asked how antibody levels relate 
to severity of disease. We observed similar levels of RSV-speciﬁc IgG in RSV-infected 
children with or without oxygen therapy (Fig 1C). In addition, similar serum RSV-IgG 
levels were found when comparing other measures of severity (Table 2). The presence 
of low-avidity RSV-speciﬁc IgG enhances disease symptoms in animal models [13]. 
RSV-speciﬁc IgG in plasma from RSV-infected infants had a lower RSV-IgG avidity 
compared to healthy controls, respectively 45 [41–51] versus 55 [48–68] (Fig 1D). 
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 161
161
B cells
4
However, no difference in RSV-IgG avidity was observed when categorizing RSV 
patients based on oxygen therapy or other disease severity measures (Fig 1E and 
Table 2).
RSV neutralization capacity of infant sera. Next, we investigated whether the RSV 
neutralization capacity in vitro relates to RSV infection or severity of disease. We 
determined the capacity of patient plasma to neutralize infection by RSV-X and the G 
protein-deﬁcient RSV-X-dG. Plasma from healthy controls and RSV-infected infants 
neutralized RSV-X and RSV-X-dG to a similar extent (Fig 2A and 2C). Also, the median 
PRNT against both viruses was similar between RSV-infected infants with or without 
oxygen therapy (Fig 2B and 2D). In addition, no difference in neutralization of RSV-X 
and RSV-X-dG was observed when categorizing RSV-infected infants based on other 
disease severity parameters (Table 2). Furthermore, we analyzed whether the 
contribution of anti-G antibodies to neutralization was different between infant groups. 
To that end, ratios were calculated from the PRNT using RSV-X and RSV-X-dG. 
Average PRNT ratios of 0.9 indicated that 10% of the neutralizing activity could be 
contributed by anti-G antibodies (Fig 2E). These average PRNT ratios were 
signiﬁcantly different from 1, which would occur if RSV-X and RSV-X-dG were 
neutralized equally well. A similar PRNT ratio of 0.9 was observed when comparing 
RSV-infected infants based on oxygen therapy and healthy infants (Fig 2E). The 
functionality of this assay was veriﬁed by measuring the ratio of RSV-X and RSV-X-dG 
Table 1  
Healthy  
(n=11)
No oxygen  
(n=11)
Oxygen 
(n=22)
P value
Age (days ± IQR) 68 [61 – 80] 58 [36-66] 39.5 [23-70] <0.05*
Male gender (%) 9 (82) 6 (55) 11 (50) NS
Gestational age 
(wk ± IQR)
37.3 [34.5-39.0] 39.4 [37.3-40.4] 38.6 [36.9-39.9] NS
Birth weight (kg ± IQR) 2.6  [2.13-3.01] 3.16 [2.79-3.62] 3.27 [2.96-3.97] <0.05#
Breastfeeding (%) 6 (55) 8 (73) 13 (59) NS
Parental smoking (%) 0 (0) 0 (0) 2 (9) NS
Symptomatic 
(days ± IQR)
NA 3.0 [3.0-4.0] 3.5 [2.0-5.0] NS
Duration hospitalization 
(days ± IQR)
NA 3.0 [2.0-6.0] 10.0 [8.0-11.3] <0.001+
* Healthy versus no oxygen p<0.05, healthy versus oxygen  p<0.01, oxygen versus no oxygen NS.
# Healthy versus no oxygen p<0.05, healthy versus oxygen p<0.05, oxygen versus no oxygen NS.
+ oxygen versus no oxygen <0.001.
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neutralization by palivizumab, a monoclonal antibody that neutralizes RSV by binding 
only to the F protein. Thus, neutralization by palivizumab is independent of the absence 
or presence of the G protein. Correspondingly, the ratio of PRNT for RSV-X and 
RSV-X-dG for palivizumab was 1.01
Figure 1  RSV-speciﬁc IgG titer and RSV-IgG avidity do not correlate with disease severity. 
RSV-speciﬁc IgG levels in plasma of infants was determined by ELISA using virus particles. 
RSV-IgG avidity was assessed by supplementing NaSCN during ELISA. (A) RSV-speciﬁc IgG 
levels were displayed versus age. (B-C) Median RSV-speciﬁc IgG levels (± IQR) were compared 
between healthy and RSV-infected infants as well as between RSV patients with and without 
oxygen therapy. (D-E) Median (± IQR) avidity of RSV-IgG in healthy infants was compared to 
RSV-infected infants or between RSV patients with or without oxygen therapy. Associations 
were assessed by Spearman correlation test. Statistical analyses employed Mann Whitney U 
test. (**P<0.01).
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RSV-speciﬁc IgG against viral surface antigens. An excess of anti-G antibodies 
have been linked with the failure of the formalin-inactivated RSV vaccine in the 1960s 
and enhanced disease in mice [14, 15]. Also, antibodies speciﬁc for the postfusion F 
protein seem not to contribute to RSV neutralization [16]. We tested whether antibodies 
against individual antigens would correlate with disease severity. The levels of anti-
gen-speciﬁc IgG present in plasma were determined using soluble, recombinant G 
protein, pre- and postfusion F protein ectodomains in ELISA. Median antibody levels 
against G protein were comparable in plasma derived from healthy infants and RSV 
infections (Fig 3A). Similarly, we did not ﬁnd a difference of antibody levels against 
pre- or postfusion F proteins between healthy infants and RSV-infected infants (Fig 
3C and 3E). The same was true for median antibody levels when categorizing RSV 
infections based on oxygen therapy or other disease severity parameters (Fig 3B, 3D, 
3F and Table 2). To investigate whether the balance between different antibodies is 
associated with disease severity, we analyzed the difference between prefusion F 
and G-speciﬁc antibodies as well as pre- and postfusion F–speciﬁc antibodies by 
subtracting antibody levels against G protein or postfusion F protein from those 
against prefusion F protein. The relative abundance of RSV-antigens was comparable 
in all groups (Fig 3G and 3H), thus no symptom-related antibody composition was 
identiﬁed.
RSV-speciﬁc IgG against a prefusion F epitope. Antibodies against prefusion F 
protein have received much attention recently, because they correlate best with RSV 
neutralization in vitro. We reﬁned our analysis to detect antibodies against epitopes 
that discriminate between pre- and postfusion F [16, 17]. Sera from healthy and 
RSV-infected infants were titrated to compete with the monoclonal antibody D25 for 
prefusion-speciﬁc antigenic site Ø or with the monoclonal antibody 131-2a for the 
postfusion-speciﬁc epitope I [9, 11, 16, 18]. The median competition titers were similar 
between healthy infants and RSV-infected infants for D25 (Fig 4A) and for 131-2a (Fig 
4C). We observed no difference in D25 competition or 131-2A competition when 
categorizing RSV infections based on oxygen therapy (Fig 4B, 4D and Table 2). A 
previous study showed that prefusion F protein-speciﬁc antibodies determine the 
neutralization activity of seroconverted individuals older than 6 years of age [16]. To 
assess whether this is represented in our measurements of RSV-speciﬁc matAbs, we 
considered the relationship between antigen- and epitope-speciﬁc antibody titers 
and neutralizing capacity (PRNT). Antibodies against postfusion F and 131-2a 
competition titers represent a negative control and were not associated with 
neutralization (Fig 5A and 5B). Prefusion F-speciﬁc antibodies and D25 competition 
titers correlated with PRNT (Fig 5C and 5D). Furthermore, antibody titers against G 
protein also correlated positively with PRNT (Fig 5E).
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Figure 2  RSV neutralization does not correlate with severity of disease. 50% plaque 
reduction neutralization titers (PRNT) were determined against RSV-X and RSV-X-dG, the latter 
is lacking the G protein. (A-B) Median (± IQR) PRNT against RSV-X were compared between 
healthy and RSV-infected infants as well as between RSV patients with and without oxygen 
therapy. (C-D) Median (± IQR) PRNT against RSV-X-dG were compared between healthy and 
RSV-infected infants as well as between RSV patients with or without oxygen therapy. (E) The 
PRNT against RSV-X was divided the PRTN against RSV-X-dG, so that values below 1.0 indicate 
a contribution of anti-G antibodies to the neutralization. The median (± IQR) ratio was compared 
between plasma from healthy infants and RSV patients with or without oxygen therapy and all 
were signiﬁcantly different from 1.0. Statistical analyses employed Mann Whitney U test for 
comparison between two groups and Kruskall-Wallis for comparison between more than two 
groups. (*P<0.05, **P<0.01).
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Figure 3  RSV-speciﬁc IgG against individual RSV glycoproteins do not correlate with 
disease severity. RSV glycoprotein-speciﬁc antibody levels were determined by ELISA against 
recombinant, soluble ectodomains. Median IgG levels (± IQR) were compared between 
healthy and RSV-infected infants as well as between RSV patients with and without oxygen 
therapy. Glycoproteins used for ELISA coating were (A-B) RSV G protein, (C-D) prefusion F 
protein, and (E-F) postfusion F protein.
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Figure 3  Continued. (G-H) The relative abundance of antibodies against prefusion F 
compared to G protein as well as pre- compared to postfusion F protein were categorized 
assessed by subtracting their levels. The median (± IQR) difference was compared between 
plasma from healthy infants and RSV patients with or without oxygen therapy. No signiﬁcant 
differences were observed by Mann Whitney U test for comparison between two groups and 
Kruskall-Wallis for comparison between more than two groups.
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Figure 4  RSV-speciﬁc IgG against F protein antigenic sites Ø and I not correlate with 
disease severity. The abundance of antibodies in human infant plasma that bind to the 
prefusion F protein antigenic site Ø or the postfusion F protein antigenic site I was determined 
by competition with site-speciﬁc monoclonal antibodies in ELISA. (A-B) Median (± IQR) IgG 
titer that blocks 25% binding of D25 (site Ø) were compared between healthy and RSVinfected 
infants as well as between RSV patients with and without oxygen therapy. (C-D) Median (± IQR) 
IgG titer that blocks 15% binding of 131-2A (site I) were compared between healthy and 
RSV-infected infants as well as between RSV patients with and without oxygen therapy. No 
signiﬁcant differences were observed by Mann Whitney U test.
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Figure 5  RSV-speciﬁc IgG against prefusion F epitope and G protein correlate with 
neutralization. Neutralization titers against RSV-X (PRNT) were compared to IgG levels against 
(A) postfusion F protein, (B) site I (131-2A competition titer), (C) prefusion F protein, (D) site Ø 
(D25 competition titer) and (E) G protein. Testing for correlation was performed with Spearman 
correlation test.
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Discussion
Infants encounter primary RSV infections even though matAbs are present in their 
blood. We investigated whether individual serologic properties of antibodies or any 
signature combinations thereof would be related to the observed disease symptoms. 
Our results indicate that (i) disease severity is not associated with differences in 
RSV-speciﬁc IgG titers, RSV-IgG avidity, or virus neutralization and (ii) plasma titers of 
RSV-speciﬁc IgG against the G protein and the prefusion F protein correlate with neutralizing 
capacity. In addition, (iii) IgG titers directed against the G protein, prefusion F protein, 
postfusion F protein, F-antigenic site Ø and site I, or any combination of thereof could 
not be associated with severity of symptoms.
Plasma from infants below 3 months of age was selected because of the high incidence 
of severe RSV infection even though high levels of matAbs are present in this group. 
Indeed, we found a median RSV neutralization titers of about 1:512 for all infants (Fig 2), 
which is similar to what is reported for cord blood in some studies [19, 20]. We omitted 
age as a confounder for different severity of symptoms, as the age of RSV-infected 
infants without oxygen therapy was comparable to that of oxygen-treated children. 
A potential limitation of our study is the difﬁculty to separate the presence of matAbs 
from endogenous RSV-induced antibodies of the infant during infection. With a 
median onset of disease of three days and the short time between symptoms and 
hospitalization, production of endogenous RSV-IgG is improbable. Moreover, as 
Dutch newborns in general suffer their ﬁrst respiratory infection after 3–7 months of 
age and only 11% of respiratory infections within the ﬁrst year of life are caused by 
RSV, infants in our study most likely experienced a primary RSV infection [21]. 
Therefore, it is plausible that we detect matAbs [22]. Our plasma selection facilitates 
the comparison of antibodies from hospitalized patients with symptoms ranging from 
moderate to severe. As this is not a prospective study, the ideal control group of 
RSV-infected children with mild symptoms was not available, because blood of these 
children is not routinely sampled. A common practice in RSV research is to use 
age-matched infants as control. One assumes that this group is not protected and if 
healthy infants become RSV infected, a vast majority of 98–99% would develop only 
mild symptoms [23]. We too, substituted the group with mild disease by the analysis 
of antibodies from uninfected infants. This has no signiﬁcant impact on our ﬁndings 
and conclusions. The sample size of our control group is relatively small and deﬁnitive 
conclusions in the context of correlation with infection warrant future studies. 
Nevertheless, the median levels of antibody properties are in close proximity with the 
median levels of RSV-infected infants. Therefore, it seems unlikely that an addition of 
more control samples would signiﬁcantly affect our interpretation. Future studies may 
include mild infections or prospectively follow healthy infants until RSV infections 
occurs to investigate the protective effect of RSV-speciﬁc antibodies.
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High titers of IgG matAbs against RSV have been inversely associated with prevention 
of hospitalization for RSV disease [24], whereas mucosal IgA reduces the propensity 
to become infected with RSV [25]. We did not study IgA-mediated prevention of 
infection, because RSV-IgA is not transplacentally transferred during gestation. We 
speciﬁcally investigated IgG antibodies during an acute infection and observed no 
correlation between RSV-IgG titer or RSV neutralization and severity of symptoms. 
Differences in the design of studies investigating prevention of RSV infection versus 
prevention of severe disease symptoms in hospitalized infants may explain the 
different conclusion. However, our data is in line with some studies that describe that 
hospitalization during RSV disease is not correlated to matAb levels [22, 26]. 
Furthermore, we found RSV-IgG avidity from uninfected infants was signiﬁcantly 
higher than from RSV patients, but was not associated with disease severity. Previous 
studies in mice suggest that non-neutralizing and low afﬁnity antibodies could 
contribute to the enhanced pathology [13, 14, 27]. The biological relevance of the 
small but signiﬁcant differences in RSV-IgG avidity between uninfected infants and 
infants with RSV infection should be carefully interpreted, because the threshold for 
antibody avidity to be efﬁcacious during RSV infections is currently unknown. These 
results should be validated with a prospective study to determine the association of 
avidity and the protection against severe RSV infections in infants.
As global antibody properties such as titers and neutralization capacity did not correlate 
with severity of disease, we analyzed whether this was also the case for antibodies 
against speciﬁc RSV antigens. Anti-G protein antibodies have been suggested to 
facilitate immunopathology in children [14, 27]. In contrast, RSV neutralizing antibodies 
are usually directed against prefusion F and can be administered as prophylaxis [16, 
28]. By comparing the PRNT of patient plasma against full length RSV-X and 
RSV-X-dG, which lacks the G gene, we observed that anti-G protein antibodies 
contribute to neutralization in vitro. This is supported by a positive relationship 
between anti-G protein antibody titers and PRNT. However, the median anti-G 
antibody titers were similar across all infant sera, regardless of disease and severity. 
Our serology using RSV A-derived materials does not account for potential impact of 
the RSV genotype on disease. We believe this is not affecting the interpretation of our 
results, because only a single serotype for RSV exists. Plasma antibodies from human 
infants prior to RSV infection, i.e. maternal antibodies, generally show very similar 
activity against major RSV subtypes regarding the conserved F protein but also the 
more variable G protein [29]. Moreover, different RSV genotypes have not been 
convincingly or continuously linked to the epidemiology of RSV outbreaks. We next 
asked whether the ratios between antibodies against G, pre- and postfusion F would 
represent a speciﬁc signature in severely sick infants compared to mildly sick children 
and controls. We found that the balance between prefusion F and other antibodies 
was similar in all infants and independent of their disease severity.
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 172
172
Chapter 4
Recent data suggests that especially antibodies targeting the prefusion F protein 
epitope Ø efﬁciently neutralize RSV [30, 31]. To determine whether infants suffering 
from severe disease symptoms have different epitope Ø binding antibodies compared 
to controls, we analyzed patient plasma from all groups in a competition assay with 
D25 and 131-2A. As we did not ﬁnd any difference, we argue that sera from mildly 
sick RSV patients have average epitope Ø-speciﬁc antibody titers just like children 
with severe symptoms. We did observe an association between recognition of the 
D25 epitope and the PRNT of matAbs, like previously shown in seroconverted 
individuals above 6 years of age [16]. We tested for this prefusion F speciﬁc antibody 
because it is the focus of current therapeutic developments. We note that there are 
more prefusion epitopes that could theoretically correlate with disease.
Apart from interacting with viral antigens on virions, antibodies also have Fc region- 
mediated immunological functions during natural infection. For example, antibodies 
form immune complexes that can reshape the cytokine and chemokine response of 
human immune cells [32, 33] or facilitate complement deposition. We did not study 
antibody effector functions that could relate to severity of disease.
In conclusion, this study investigated the properties of naturally occurring RSV-speciﬁc 
matAbs hoping to provide clues about a speciﬁc signature of antibodies that is 
needed to prevent severe RSV infections. Our detailed characterization did not ﬁnd 
any difference in matAbs between infants with severe RSV disease symptoms, 
controls with mild RSV disease and uninfected infants. This means that the matAb 
properties we studied do not indicate whether a child would be protected from severe 
symptoms. It will be very important to ﬁnd such properties or signatures in order to 
design effective vaccination strategies in the future.
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Abstract 
Respiratory syncytial virus (RSV) bronchiolitis is a major burden in infants below three 
months of age, when the primary immune response is mainly dependent on innate 
immunity and maternal antibodies. We investigated the inﬂuence of antibodies on 
innate immunity during RSV infection. 
PBMCs from infants and adults were stimulated with live RSV and inactivated RSV in 
combination with antibody-containing and antibody-depleted serum. The immune 
response was determined by transcriptome analysis and chemokine levels were 
measured using ELISA and ﬂow cytometry. 
Microarray data showed that CXCL10 gene transcription was RSV dependent, 
whereas CXCL11 and IFNт were upregulated in an antibody-dependent manner. 
Although the presence of antibodies reduces RSV infection rate, it enhances the 
innate immune response. In adult immune cells, antibodies enhance CXCL10, 
CXCL11, IFNт and IFNф production in response to RSV infection. Contrary, in infant 
immune cells only CXCL10 was enhanced in an antibody-dependent manner. 
Monocytes are the main source of CXCL10 and they produce CXCL10 in both an 
antibody- and virus-dependent manner. 
This study shows that antibodies enhance CXCL10 production in infant immune cells. 
CXCL10 has been implicated in exuberating the inﬂammatory response during viral 
infections and antibodies could therefore play a role in the pathogenesis of RSV 
infections.  
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Introduction 
Respiratory syncytial virus (RSV) infections are a major cause of respiratory illness in 
young infants. Infants below three months of age are more likely to develop severe 
bronchiolitis due to an RSV infection. Multiple factors can be responsible for severe 
RSV infections, like co-infections, infectious dose, infection route or physiology of the 
very young host. However, the most classical factors inﬂuencing severity are the 
pathogen and the immune response of the host. During each RSV outbreak, a limited 
number of RSV strains circulate1, while the level of disease severity shows a very wide 
spectrum. This suggests that severe infections are largely the result of variations in 
the host immune response, resulting in an overactive or aberrant inﬂammatory response. 
Very young infants have not developed speciﬁc and mature adaptive responses yet 
and are largely dependent on their innate immunity to protect them during their ﬁrst 
encounter with bacteria and viruses. This is illustrated by the fact that deﬁciencies in 
Toll-like receptors (TLR) signaling increase susceptibility to infections with RSV in the 
ﬁrst years of life2. 
Infants below three months of age still have considerable amounts of maternal RSV- 
speciﬁc antibodies3. The current consensus about the role of antibodies during RSV 
pathogenesis is that antibodies are protective, as most studies report that high levels 
of neutralizing maternal antibody titers are associated with protection against RSV 
infections4-9. However, there is also some evidence that points toward a less evident role 
of antibodies. Some studies observe that maternal antibodies do not have a protective 
effect9-12 and in one study high anti-RSV antibody levels were even associated with an 
increased risk of recurrent wheeze4. In line with these last observations, the vaccination 
trials with formalin inactivated RSV in the sixties resulted in poorly neutralizing anti- 
bodies which formed immune complexes with RSV and resulted in enhanced 
disease13,14. These latter results suggest that antibodies may skew the immune 
response and cause pathogenesis during RSV infections. Palivizumab, a humanized 
monoclonal mouse antibody (IgG1), reduces disease severity in high-risk infants 
showing that antibodies can contribute to protection15,16. The above data together 
indicate that the current insight in the role of antibodies during RSV infections and more 
speciﬁcally, the interaction between antibodies and the innate immune response, 
justiﬁes additional study. Therefore, we studied the inﬂuence of antibodies on the 
innate immune response during RSV infection of infant and adult immune cells.  
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Methods
Medical ethical approval. Written informed consent was obtained from all donors or 
from all parents of patients. The study was approved by the Central Committee on 
Research involving Human Subjects of the Radboudumc. 
Virus culture. GFP labeled RSV A2 (rgRSV30) was kindly provided by Dr. M.E. 
Peeples17 and was cultured on HeLa cells as described previously18. RSV was 
puriﬁed by ultracentrifugation over a 30% sucrose layer for 1.5 h at 20 000*g. The 
virus was quantiﬁed by titration on HeLa cells. Brieﬂy, HeLa cells (80–90% conﬂuent) 
were infected with ﬁve-fold viral dilutions for 20-22 h. Virus titer was determined by 
counting wells with >10 and <100 infected cells/view (Olympus CKX41 microscope) 
where each data point was the average of an experimental duplicate. rgRSV30 was 
inactivated using у-propiolactone (BPL)19. 0.025% BPL was added to the virus stock 
and incubated for 16h at 4°C under continuous slow shaking. Next, the stock was 
incubated for 4h at 37°C to hydrolyze the BPL and stored at -80°C until further use.
PBMC isolation and stimulation. Blood, from healthy volunteers and healthy infants 
younger than three months of age, was drawn into EDTA tubes (Monoject). The PBMC 
fraction was obtained by density gradient centrifugation using Lymphoprep 
(Axis-Shield) following the protocol as described previously20. In short, blood was 
diluted with an equal volume of PBS. The diluted blood was added on top of the 
Lymphoprep and centrifuged at 800*g to separate the PBMC fraction. PBMCs were 
harvested, washed three times in PBS, and resuspended in culture medium (RPMI 
1640 GlutaMAX-I medium (Invitrogen) with 1% Penicillin/Streptomycin (Invitrogen). 
Cells were counted using a haemocytometer. Cell number was adjusted to 5x106 
cells/ml for total PBMCs. A total volume of 100 μl was added to round-bottom 96-wells 
plates (Nunc) and incubated with an equal volume of culture medium (negative 
control) or the various stimuli: RSV or inactivated RSV in combination with human 
serum (HS, Sigma), total antibody depleted HS (Ig- HS, Sunnylab) or palivizumab 
(MedImmune). One batch of human serum was used during all experiments, to 
exclude batch-effects. Combinations of ligands were added simultaneous. After 24h 
or 48h, the supernatants were collected and stored at -20°C for ELISA measurement. 
To determine the level of infection after 24h of stimulation, PBMCs were ﬁxed and 
analyzed on an LSRII (BD Biosciences) with FACSDiva software (BD Biosciences). 
Data was analyzed with FLOWJO, version 8.8.7. (TreeStar, Inc.). RSV infection was 
determined as the percentage of cells that were GFP positive. 
Microarray. Adult PBMCs from four donors were stimulated with inactivated RSV in 
combination with HS and Ig- HS for 24h. After 24h, the PBMCs were resuspended in 
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180 μl RLT buffer (Qiagen) with 1% у-mercaptoethanol and stored at -80°C. RNA was 
isolated using an RNeasy Minikit (Qiagen) according to manufacturer’s instructions. 
RNA was treated with Turbo DNase (DNA-free kit, Ambion). DNA-free RNA was used 
to generate Cy3-labeled cDNA according to standard Nimblegen gene expression 
protocol. Labeled cDNA was hybridized to a Nimblegen 12-plex 135 K human gene 
expression array and scanned. Expression data were analyzed using Arraystar 
(DNASTAR) with quantile RMA normalization. Different conditions were compared 
and genes that were highest differentially upregulated were shown. The top 100 of 
differentially expressed genes were mapped to Gene Ontology (GO) terms to enrich 
for gene class using the Genemania online tool21. All microarray data have been 
deposited in NCBI Gene Expression Omnibus (GEO) database under GEO Series 
accession number (GSE59391). 
Chemokine and cytokine ELISA. CXCL10, CXCL11 (both R&D systems), IFNт 
(E-Bioscience) and IFNф (Sanquin) concentrations were measured in the cell 
supernatants by commercial ELISA kits according to the manufacturer’s instructions. 
CXCL10, CXCL11, IFNт and IFNф had a detection limit of respectively 78 pg/ml, 19.5 
pg/ml, 19.5 pg/ml and 12 pg/ml. 
Intracellular CXCL10 staining. PBMCs were stimulated with RSV in combination 
with HS for 18h at 37°C. Subsequently, PBMCs were incubated for another six hours 
in the presence of 1 μl/ml Golgiplug. PBMCs were permeabilized and CXCL10 was 
intracellularly stained using the BD Cytoﬁx/Cytoperm Fixation/Permeabilization 
Solution Kit (BD Biosciences). PBMCs were extracellularly stained with CD3, CD4, 
CD8, CD14, CD19 and CD56 (BD Biosciences) to determine speciﬁc cell populations. 
Flow cytometry was used to collect the data. Data was analyzed with FLOWJO, 
version 8.8.7. (TreeStar, Inc.). 
Statistical analysis. Inﬂammatory mediator data between groups were compared 
using a Mann–Whitney U-test. Inﬂammatory mediator data within groups were 
compared using a Wilcoxon-signed rank test. Signiﬁcance of ﬂow cytometry data 
were tested by a paired Student’s T-test. Data shown are representative of two or 
more independent experiments, performed in duplicate, with a minimum of n = 5. 
Graph-Pad Prism 5.03 was used for statistics (GraphPad Software). Values of p < 0.05 
were considered statistically signiﬁcant. Data are given as mean + SEM. 
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Results
RSV and RSV in combination with human serum induce strong expression of 
innate inﬂammatory mediators. The inﬂuence of RSV, human serum and antibodies 
on inﬂammation was studied in an unbiased manner using microarray transcriptional 
proﬁling of adult PBMCs. To reduce the effect of inactivation by RSV-speciﬁc anti- 
bodies in the serum, we ﬁrst screened for relevant genes with inactivated RSV. 
The top 25 genes that showed the highest differential gene expression are shown in 
Fig. 1. The strongest expression was found for DEFB1, IFI27, CXCL10, CXCL11 and 
IFNт. The latter three are all secreted innate inﬂammatory mediators (highlighted in 
Fig. 1), which are of interest for this study. 
Inactivated RSV by itself induced upregulation of CXCL10 and CXCL11 expression 
(Fig. 1A). The addition of human serum to RSV further increased the expression of 
CXCL11, whereas RSV-induced expression of CXCL10 was not affected (Fig. 1B). 
Expression of these genes after incubation with infectious RSV was comparable 
(data not shown). When looking at the speciﬁc effect of antibodies on innate gene 
expression, CXCL11 and multiple IFNт genes were upregulated (Fig. 1C), suggesting 
that both IFNт and CXCL11 expression were upregulated in the presence of antibodies 
(21-fold and 19-fold respectively), whereas CXCL10 was strongly upregulated by RSV 
(180-fold) and this was hardly inﬂuenced by the presence of serum (160-fold). 
In conclusion, these data indicate that antibodies in serum enhance the innate 
immune response on a transcriptional level. CXCL10, CXCL11 and IFNт were selected 
for further study. 
CXCL10, CXCL11, IFN͂ and IFN̈́ production is dependent on the presence of 
antibodies but unrelated to viral replication. To conﬁrm the transcriptional ﬁndings 
on a protein level, CXCL10, CXCL11 and IFNт ELISAs were performed on the same 
samples as used for the microarray. Both CXCL10 and CXCL11 are known as IFNф 
induced chemokines. Therefore, also IFNф ELISAs were performed, to determine whether 
CXCL10 and CXCL11 were produced independently or possibly as a secondary 
response to IFNф. 
Adult PBMCs were stimulated with RSV and inactivated RSV in combination with 
human serum (HS) or immunoglobulin depleted HS (Ig- HS). Although CXCL11 mRNA 
expression could be induced by RSV itself, CXCL11 and IFNт (Fig. 2B and C) protein 
expression appeared to be enhanced in the presence of antibodies, which was in 
accordance with the transcriptional results. This antibody mediated increase was 
not dependent on viral replication, as inactivated RSV showed the same phenotype 
for both secreted inﬂammatory mediators. Although transcription of CXCL10 was 
induced in an RSV-dependent manner, CXCL10 protein expression was enhanced in 
an antibody dependent manner (Fig. 2A). Intracellular staining showed that both RSV 
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alone as well as the addition of HS induced intracellular CXCL10 (Supplemental Fig. 2), 
suggesting that CXCL10 was produced but not secreted in the absence of antibodies. 
IFNф showed limited inﬂuence of antibodies on its production (Fig. 2D). 
In conclusion, although presence of antibodies reduced RSV infection rate (Supplemental 
Fig. 1), it enhanced the inﬂammatory response. These data strongly indicate that 
innate inﬂammatory mediators show an antibody-dependent increase after RSV 
stimulation independent of replication. 
CXCL10 production by infant immune cells increases in the presence of 
antibodies. To study the effect of antibodies on the innate immune response of infant 
immune cells, PBMCs from healthy infants (<3 months) were stimulated with RSV in 
combination with HS or Ig- HS. In contrast to adult PBMCs, CXCL11 (Fig. 3B), IFNт 
(Fig. 3C) and IFNф (Fig. 3D) were produced in very low amounts and no clear antibody 
Figure 2  CXCL10, CXCL11, IFN͂ and IFN̈́ production is dependent on the presence of 
antibodies but unrelated to viral replication. PBMCs from six healthy volunteers were stimulated 
with RSV (MOI = 0.2), inactivated RSV (MOI = 0.2, as determined prior to inactivation) in 
combination with 10% human serum (HS) or 10% immunoglobulin depleted (Ig-) HS for 24 h at 
37°C. CXCL10 (A), CXCL11 (B), IFNт (C) and IFNф (D) levels were measured by ELISA. Data are 
presented as mean + SEM of the pooled duplicates of all six samples and are representative 
of minimal two experiments performed. Inﬂammatory responses were compared and 
signiﬁcance was determined using a Wilcoxon- signed rank test (*p < 0.05).
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dependent effect was seen. However, consistent with adult PBMCs, antibodies 
clearly enhanced CXCL10 production (Fig. 3A) in infant immune cells. 
Monocytes produce CXCL10 depending on the amount of antibodies and RSV 
load.Intracellular CXCL10 staining was performed to determine which cell type 
produces CXCL10. Adult PBMCs were stimulated with RSV in combination with HS. 
Monocytes were the only cell subset that showed a strong intracellular CXCL10 
staining (Fig. 4A). 
To test if the CXCL10 production was dependent on both viral load and amount of 
antibodies, dose–response experiments were performed. Higher amounts of human 
serum resulted in more CXCL10 (Fig. 4B) suggesting that the CXCL10 production was 
dependent on the antibody titer. In contrast, palivizumab completely abrogated the 
CXCL10 production. Higher RSV concentrations also resulted in an increase in 
Figure 3  CXCL10 production by infant immune cells increases in the presence of antibodies. 
PBMCs from ﬁve healthy infants (<3 months of age) were stimulated with RSV (MOI = 1) in 
combination with 10% human serum (HS) or 10% immunoglobulin depleted (Ig-) HS for 24 h at 
37°C. CXCL10 (A), CXCL11 (B), IFNт (C) and IFNф (D) levels were measured by ELISA. Data are 
presented as mean + SEM of the pooled duplicates of all ﬁve samples and are representative 
of minimal two experiments performed. Inﬂammatory responses were compared and 
signiﬁcance was determined using a Wilcoxon-signed rank test (*p < 0.05).
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Figure 4  Monocytes produce CXCL10 depending on the amount of antibodies and RSV 
load. PBMCs from four healthy volunteers were stimulated with RSV (MOI = 1) in combination 
with 10% human serum (HS) for 24 h at 37°C. CXCL10 was detected using intracellular staining 
while the cells were immunophenotyped using the following markers: CD3, CD4, CD8, CD14, 
CD19 and CD56. Mean ﬂuorescence intensity (MFI) was determined for all cell subsets. Data 
are presented as mean + SEM of all four samples (A). PBMCs from six healthy volunteers were 
stimulated with different doses of HS (B) in combination with different doses of RSV (C). After 
24 h of incubation at 37°C, CXCL10 production was measured by ELISA. Data are presented as 
mean + SEM of the pooled duplicates of all six samples and are representative of minimal two 
experiments performed. Signiﬁcance of reduction in infection was tested by a paired Student’s 
T test (*p < 0.05, **p < 0.01). Inﬂammatory responses were compared to RSV stimulation 
alone and signiﬁcance was determined using a Wilcoxon-signed rank test (*p < 0.05).
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CXCL10 production (Fig. 4C), which showed that the CXCL10 production was also 
dependent on viral titer. 
In conclusion, these data indicate that monocytes are the main source of CXCL10 
and CXCL10 production is dependent on both viral titer as well as antibody titer. 
Discussion 
That speciﬁc antibodies reduce RSV infection rate is common knowledge. However, 
in this study, we demonstrate that antibodies also inﬂuence the inﬂammatory response 
after RSV infection. RSV induces upregulation of CXCL10 transcription, while the presence 
of antibodies determines the secretion of CXCL10 protein. Moreover, immune cells 
from very young infants are able to produce high levels of CXCL10 protein in response 
to the combination of RSV and antibodies. 
We have shown that infant immune cells, contrary to adult immune cells, do not produce 
signiﬁcant amounts of IFNф, IFNт or CXCL11. It is well established that infants have 
deﬁciencies in T cell activation, more naive T cells, less memory T cells and a bias 
toward a Th2 response, which includes a lower Th1 response and therefore less IFNф 
production22-25. So, our observation that these infant PBMCs hardly produce IFNф is 
in line with the literature. This also holds through for IFNт. Current literature on IFNт 
also shows that the responses are lower in infants26,27, possibly as a result of lower 
amounts of pDCs in the blood of infants28. Regarding CXCL11, it has been described 
that, contrary to CXCL10, CXCL11 protein was not found in serum samples of RSV 
infected infants29, suggesting CXCL10 and CXCL11 are induced independently of 
each other. It is very well possible that CXCL11 induction is completely IFNф 
dependent, which would explain our results. 
CXCL10 is an important chemokine, attracting inﬂammatory cells to the site of infection. 
Our results are in line with previous literature describing the strong upregulation of 
CXCL10 in response to RSV infections both on transcriptional as well as on protein 
level29,30. However, to our knowledge, a role of antibodies in this process has not 
been reported. 
The role of CXCL10 in RSV pathogenesis is unclear. CXCL10 is mostly regarded as a 
typical Th1 chemokine, whereas RSV pathogenesis is associated with a Th2 
response. However, a higher expression of CXCL10 has been found during Th2 im-
munopathology in a mouse model31 suggesting that CXCL10 is not necessarily 
associated with a Th1 response. As we have shown, CXCL10 can indeed be produced 
independent of IFNф, as PBMCs from infants do not produce IFNф in response to 
RSV, but they do produce CXCL10 in high levels. 
Recently, Ichikawa and co-workers show that high CXCL10 levels are also associated 
with severe H5N1 infections32. The authors argue that CXCL10 may not be a bystander 
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but may directly contribute to pathogenesis by mediating a neutrophil-dependent 
excessive pulmonary inﬂammation. Typically, severe RSV infections are also characterized 
by a strong neutrophil inﬂux into the lungs and by severe pulmonary inﬂammation. 
CXCL10 could therefore be a relevant chemokine to study in the context of RSV 
infections. 
As stated above, high CXCL10 levels are not uniquely associated with RSV infections 
but have also been found during other respiratory viral infections like rhinovirus and 
inﬂuenza virus infections29,33 and were found to correlate with viral load34,35. CXCL10 
may therefore be a more general but pivotal chemokine during severe pulmonary 
inﬂammation due to respiratory viral infections. 
In our study, we cannot differentiate between RSV-speciﬁc neutralizing antibodies, 
RSV-speciﬁc non-neutralizing antibodies and non-speciﬁc antibodies that are present 
in human serum. It is possible that RSV-speciﬁc neutralizing antibodies inﬂuence the 
immune response in a different manner than RSV-speciﬁc non-neutralizing antibodies 
and non-speciﬁc antibodies. Considering our data on palivizumab and the fact that 
most of the evidence in literature points toward a protective function of RSV-speciﬁc 
neutralizing antibodies, we speculate that the enhancement of chemokine production 
is due to one of the other two possibilities. So, either the RSV-speciﬁc antibodies that 
are not able to neutralize induce these enhanced responses or the non-speciﬁc 
antibodies are responsible. 
Previous studies have shown that RSV neutralizing antibodies induce an enhanced 
IFNф response by CD4+ T cells36,37. Another paper has shown that antibody- opsonised 
pathogens can be recognized by cytosolic receptor TRIM21, which induces an 
antiviral state, pro-inﬂammatory cytokines and chemokines38. However, they also 
showed that this was not the case for RSV as RSV uses membrane fusion and thereby 
it does not enable antibodies to reach the cytosol. Therefore, it is more likely that the 
phenomenon that we describe occurs on the membrane. A growing body of evidence 
shows that FccRII is able to cross-talk with multiple TLRs, IL-1R and IFNфR, thereby 
inducing enhanced cytokine proﬁles39-42. This is possibly also the mechanism behind 
our observations. 
In conclusion, antibodies not only inﬂuence the ability of RSV to infect cells, but also 
enhance CXCL10 secretion after RSV infection of infant immune cells. Antibody- 
dependent CXCL10 production might play an important role in the pathogenesis of 
RSV infections. The differential inﬂuence of RSV-speciﬁc antibodies, non-speciﬁc anti- 
 bodies and palivizumab on RSV pathogenesis requires more research, as does the 
possible involvement of CXCL10. Elucidating these antibody-mediated effects will 
result in a better understanding of RSV pathogenesis and may give possibilities for 
modulation, prevention and treatment of these severe infections.  
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Supplemental Figure 1  PBMCs from six healthy volunteers were infected with RSV (MOI 
=0.2) in the presence of different concentrations of human serum (HS), 10% immunoglobulin 
depleted (Ig-) HS or 5 μg/ml palivizumab. After 24h of incubation at 37°C the infection rate was 
determined by ﬂow cytometry.
Supplemental Figure 2  PBMCs from four healthy volunteers were stimulated with RSV 
(MOI =1) in combination with 10%HS for 24h at 37°C. CXCL10 was intracellularly stained. MFI 
ratio’s were calculated by dividing by the control condition. Data are presented as mean + SEM 
of all four samples. Signiﬁcance was determined using a paired T-test (*p < 0.05).
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Newborns express distinct immunity from adults, resulting in age-speciﬁc susceptibility 
to infection1. Deﬁning the ontogeny of host defense to pathogens provides insight 
into age-speciﬁc susceptibility and may inform translation of new biomarkers and 
therapeutic modalities. During viral respiratory tract infections, B cells play an important 
role in the antiviral immune response and contribute to the development of adaptive 
immunity2. Respiratory syncytial virus (RSV) infection induces local pulmonary B-cell 
activation and virus-speciﬁc antibodies, including IgM that may mitigate disease 
severity.3 Maternal IgG antibodies may provide protection against RSV infection in 
newborns and infants.4 In addition, innate IgM-based B-cell mechanisms may 
function in early life, though it is unclear whether they contribute to anti-RSV immunity. 
To assess whether human newborns might mount an innate humoral response 
against RSV, we used newborn cord blood mononuclear cells (CBMCs) and adult 
PBMCs. Furthermore, we investigated the presence of RSV-IgM in newborn plasma 
and its ability to inhibit RSV infection of epithelial cells. Methodologic details are 
found in the Methods section in this article’s Online Repository at www.jacionline.org. 
CD69 or CD86 were used as B-cell activation markers (see Fig E1, A and B, in this 
article’s Online Repository at www.jacionline.org). CBMCs and PBMCs demonstrated 
similar RSV-induced CD69 expression (Fig 1, A). Because RSV activates Toll-like 
receptor 4 (TLR4) signaling and production of type I IFNs that could contribute to 
B-cell activation, we compared RSV-induced activation of mononuclear cells (MCs) 
to that induced by LPS (TLR4 agonist), cytosine-phosphate-guanine dideoxynu-
cleotide (type I IFN-inducing TLR9 agonist), or live inﬂuenza virus (GFP-PR8/34; 
H1N1 strain, known to activate TLR7/8). Each of these stimuli induced newborn and 
adult B-cell activation (Fig 1, A). To investigate direct B-cell activation without potential 
interactions with other types of MCs, experiments were conducted on isolated 
newborn B cells. Neither RSV nor LPS induced B-cell activation as measured by the 
expression of CD69 and CD86. Cytosine-phosphate-guanine dideoxynucleotide 
and IFN-b directly activated newborn B cells, whereas IFN-a was less potent (Fig 1, 
B and C, and Fig E1, C). Similar results regarding IFN- and IFN- ß were obtained with 
adult B cells (see Fig E1, D). These data suggest that RSV-induced newborn B-cell 
activation may result from IFN-b production and is not dependent on direct interactions 
between RSV and TLR4 on B cells. The activation of B cells upon exposure to RSV 
and inﬂuenza virus indicates that a general antiviral immune response is present in 
newborns. Simultaneous exposure of B cells to LPS and IFN-ß did not result in 
increased B-cell activation compared with IFN-b alone (data not shown). However, 
the observed IFN-ß–mediated B-cell activation in newborns suggests that IFNb-ß 
may potentiate B-cell activation during infectious diseases. 
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Figure 1  A-H, RSV induces IFNAR-dependent activation of newborn B cells. CD691 B cells 
after 18-hour stimulation of (Fig 1, A) MCs or (Fig 1, B-C) newborn B cells (N 5 5-11).  induction 
of (Fig 1, D) IFN-a and (Fig 1, E) IFN-b in MCs. CD691 B cells after 18-hour stimulation of (Fig 1, 
F and G) newborn B cells or (Fig 1, H) adult B cells in the absence or presence of anti–
IFNAR-blocking antibodies or isotype controls (N 5 3-5) (mean 6 SEM). INFAR, Interferon-a/b 
receptor; NS, not signiﬁcant. *P < .05. **P < .01. ***P < .001.
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To further characterize RSV-induced B-cell activation, we measured induction of 
IFN-a and IFN-b. Supernatants from RSV-stimulated CBMCs and PBMCs contained 
IFN-a and IFN-b (Fig 1, D and E) and activated newborn and adult B cells that express 
interferon-a/b receptor 1 and interferon-a/b receptor 2 (Fig 1, F, and see Fig E2, 
A and B, in this article’s Online Repository at www.jacionline.org) Moreover, blocking 
interferon-a/b receptor on isolated newborn and adult B cells prevented the induction 
of CD691 B cells by IFN-b (see Fig E2, C and D) and by supernatants from 
RSV-stimulated MCs (Fig 1, G and H). We next assessed whether RSV functionally 
activates B cells by measuring total-IgM, RSV-IgM, and total-IgG antibody-secreting 
cells (ASCs) (see Fig E3, A, in this article’s Online Repository at www.jacionline.org). 
RSV-activated newborn and adult MCs demonstrated increased total-IgM and 
RSV-IgM ASCs (Fig 2, A and B). Beta-propiolactone–inactivated RSV also increased 
the number of total-IgM ASCs, suggesting that induction of IgM ASCs occurs 
independently of viral replication (Fig 2, A). RSV induced an increase in total-IgG 
ASCs in adult MCs. In contrast, RSV-stimulated newborn MCs demonstrated low 
numbers of total-IgG ASCs with no increase in total-IgG ASCs (see Fig E3, B). 
Consistent with RSV-IgM ASCs in the newborn MC fraction, detectable levels of 
RSV-IgM were present in newborn plasma with even higher concentrations in infant 
and adult plasma (Fig 2, C). Finally, we measured the neutralizing capacity of puriﬁed 
newborn IgM from pooled plasma (IgM purity conﬁrmed by ELISA; data not shown) 
on RSV infection of A549 cells, a bronchial epithelial cell line used to investigate RSV 
neutralization.5 IgG concentrations in puriﬁed IgM were undetectable (<4,000,000-
fold diluted standard). Newborn IgM reduced RSV infection of A549 cells (Fig 2, D 
and E). Newborn plasma, also containing maternal IgG, completely neutralized RSV 
infection (Fig 2, D and E). Puriﬁed IgM from 4 newborn samples each reduced RSV 
Figure 1  Continued.
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Figure 2  A-F, RSV-IgM ASCs in newborns and functional RSV-IgM in neonatal plasma that 
reduces RSV infection. (Fig 2, A) Total-IgM ASC or (Fig 2, B) RSV-IgM ASCs determined by 
Enzyme-linked Immunospot. N 5 5-8. Fig 2, C, RSV-IgM plasma concentrations. N 5 6-9. (Fig 2, D) 
Microscope images and (Fig 2, E) quantiﬁcation of ﬂuorescent A549 cells after exposure to 
RSV in medium, puriﬁed newborn IgM (RSV 1 IgM), or newborn plasma (RSV 1 plasma). N 5 3. 
(mean 6 SEM). Fig 2, F, Graphical summary of the IFNARdependent humoral response to RSV 
in newborns. INFAR, Interferon-a/b receptor; NS, not signiﬁcant. *P < .05. **P < .01. ***P < .001. 
fffNewborn vs adult: P < .001.
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infection of A549 cells (see Fig E3, C). Overall, we demonstrate for the ﬁrst time that 
(1) RSV and IFN-b induce surface upregulation of CD69 on newborn and adult B cells 
to a similar extent in a model of MCs, (2) RSV-induced IFN-b derived from mixed MCs 
directly activates newborn and adult B cells via interferon-a/b receptor signaling, and 
(3) RSV increases the amount of newborn and adult total-IgM and RSV-IgM ASCs. 
Finally, we demonstrate the neutralizing capacity of human newborn plasma IgM on 
RSV infection of human epithelial cells (Fig 2, F). Because IgM does not cross the 
placental barrier, RSV-IgM ASCs and plasma RSV-IgM titers may reﬂect newborn 
innate B cells and natural antibodies.6 Natural antibodies include polyreactive 
pathogen- binding IgM antibodies that are present without previous exposure and 
Figure 2  Continued.
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are part of the innate immune system, opsonize pathogens, and promote phago-
cytosis.7 RSV envelope proteins include fusion protein (F protein) and attachment 
protein (G protein), both glycosylated and potentially targeted by natural IgM 
antibodies. Our study is novel but also has limitations, including the uncertain 
applicability of our in vitro model to the clinical
setting. Future studies should investigate additional factors including immune cells 
and immunoglobulin transport, potentially by using a murine model of RSV infection. 
Clinically, RSV infections have a broad range of disease and only approximately 1% 
of those with RSV infections develop symptoms resulting in hospitalization.8 These 
epidemiologic observations indicate that the early life immune system does not 
prevent RSV infection but, in most cases, does protect against severe disease. Our data 
suggest that innate IgM-based B-cellmechanisms may contribute to early life protection 
against RSV. Of note, IgM-enriched fractions have demonstrated potential efﬁcacy 
to prevent or treat septic shock,9 suggesting potential IgM-based translational 
opportunities. In conclusion, human newborns mount robust RSV-induced and 
IFN-b–mediated B-cell activation and IgM production, indicating that this humoral 
mechanism is present at birth. Although detection of neutralizing RSV-IgM in human 
newborns suggests the presence of natural anti-RSV IgM antibody at birth, the higher 
levels of RSV-IgM in infants indicate that the RSV/IFN-induced pathways we have 
described may be relevant in vivo, providing a ﬁrst line of defense during RSV 
infections in early life. Future studies should examine whether the relative presence of 
RSV-IgM could predict the frequency and severity of RSV infection and assess the 
potential utility of anti-RSV IgM as a prophylactic or therapeutic agent. 
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Figure E1  A-D, Soluble mediators activate adult isolated B cells. Representative gating 
strategy to determine (Fig E1, A) CD691 B cells or (Fig E1, B) CD861 cells. Fig E1, C, Percentage 
of CD861 B cells after stimulation of newborn isolated B cells (N 5 5). Fig E1, D, Percentage of 
CD691 B cells after stimulation of adult isolated B cells with IFN-a or IFN-b (N 5 5) (mean 6 
SEM). 7-AAD, 7-Aminoactinomycin D; FSC, forward-scattered light; SSC, side-scattered light. 
*P < .05. ***P < .001.
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Figure E2  A-D, IFNAR-dependent activation of newborn and adult B cells after exposure to 
IFN-b. Fig E2, A, Percentage of CD691 B cells (N 5 6). Fig E2, B, Expression of IFNAR1 and 
IFNAR2 on newborn and adult B cells (N 5 5-6). Percentage of CD691 B cells after stimulation 
of (Fig E2, C) newborn or (Fig E2, D) adult MCs with IFN-b (500 IU/mL) in the absence or 
presence of anti–IFNAR-blocking antibodies or isotype controls (N 5 5) (mean 6 SEM). INFAR, 
Interferon-a/b receptor; NS, not signiﬁcant. *P < .05. **P < .01.
***P < .001.
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4Figure E3  A-C, Puriﬁed IgM reduces RSV infection of epithelial cells. Fig E3, A, representative 
ELISpot of total-IgM, RSV-IgM, and total-IgG ASCs. Fig E3, B, Total-IgG ASC (ASC/1 3 106 
plated cells) after stimulation of MCs with RSV (MOI, 0.5) (N 5 5-9). Fig E3, C, Percentage of 
RSV-infected GFP1 A549 cells after exposure to RSV (MOI, 2.5) in medium or to RSV in medium 
with puriﬁed newborn IgM from 4 different donors (mean 6 SEM). GFP, Green ﬂuorescent 
protein; MOI, multiplicity of infection; NS, not signiﬁcant.
*P < .05. **P < .01. ffNewborn vs adult: P < .01.
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Methods
Cell isolation and stimulation. Human newborn cord blood was collected from the 
umbilical cord after Cesarean section. Peripheral blood was collected from healthy 
adult volunteers. After centrifugation at 800g, plasma was collected from cord blood, 
healthy infants (between age 2 and 4 months), or healthy adults. MCs were collected 
using Ficoll-Hypaque gradient and B cells with CD19 microbeads (Miltenyi Biotec, 
Leiden, The Netherlands; purity >93%). When indicated, cells were incubated with 
anti-interferon-a/b receptor-blocking antibodies (MMHAR-2, PBL Interferon Source, 
5 mg/mL) or isotype controls. MCs (5 3 105/well) or isolated B cells (1 3 105/well) 
were stimulated for 18 hours for ﬂow cytometry or 5 days for the Enzyme-Linked 
Immunospot (ELISpot) assay. Recombinant green ﬂuorescent protein–expressing 
RSV A2 (Rhinella-green RSV30), kindly provided by Dr M. E. Peeples, was cultured 
and used at a multiplicity of infection of 0.5 unless otherwise indicated. When 
indicated, Rhinella-green RSV was inactivated using b-propriolactone. 
Cytokine induction. IFN-a concentrations were measured by ELISA (R&D Systems, 
Minneapolis, Minn) with a lower limit of detection of 39 pg/mL. Induction of IFN-b was 
determined by RT-qPCR using TaqMan Assays for beta-2-microglobulin (Hs00187842_
m1) and IFNB (Hs0621180_s1) (ThermoFisher Scientiﬁc, Waltham, Mass). IFNB gene 
expression was normalized to the housekeeping gene beta-2-microglobulin. DDCT 
was calculated by subtracting normalized gene expression in unstimulated cells from 
RSV-stimulated cells. 
Total IgM and RSV-IgM B-cell ELISpot. ASCs were determined using ELISpot 
assay (R&D Systems). Membrane plates (Millipore, Amsterdam, The Netherlands) 
were coated with goat anti-human IgM or b-propriolactone-RSV (4 3 105/well) in PBS 
overnight at 48C and blocked with PBS/1% BSA/5% sucrose. MCs were added in 
triplicate at 2 3 104 to 1 3 106 cells/well for 18 hours and ASCs were determined 
according to the manufacturer’s protocol (R&D Systems). Spots were calculated as 
the number of ASCs/1 3 106 plated cells. RSV-IgM ELISA RSV-speciﬁc IgM 
concentrations in plasma samples were determined by coating ELISA plates with 
Rhinella-green RSV (23104/well) in PBS. Plasma samples were added and 
subsequently incubated with AP-conjugated antihuman IgM in PBS/1% BSA for 2 
hours (1:500; Southern Biotech, Birmingham, Ala). Detection of AP activity used 
10mMdiethanolamine with 0.5mM MgCl2. The ODs of PBS-coated wells were 
subtracted from those of RSV-coated parallel samples. Serial dilutions of healthy 
adult pooled plasma ranging from 1:10 to 1:10,240 (vol/vol) were used as standard to 
calculate arbitrary units. The detection limit for RSV-IgM was 32 arbitrary units.
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Neutralization assay. Human bronchial epithelial A549 cells (ATCC CCL-185) were 
seeded in 96-well plates at 23104 cells/well and incubated in Dulbecco modiﬁed 
Eagle medium110% FCS for 24 hours at 378C and 5% CO2 to adhere. Anti-human 
IgM (m-chain speciﬁc)-Agarose beads (Sigma, St Louis, Mo) were used to purify IgM 
from newborn plasma. Cells were incubated with RSV (multiplicity of infection 5). 
When indicated, puriﬁed IgM or 5% newborn plasma was added. After 20 hours, cells 
were detached with trypsin and infection quantiﬁed by ﬂow cytometry as green 
ﬂuorescent protein1 cells. 
Statistics. Statistical analyses used the Wilcoxon matched-pairs signed rank test for 
paired analysis between 2 conditions and repeated-measures ANOVA or 1-way 
analysis of variance with Bonferroni multiple comparison test for, respectively, paired 
and unpaired analysis between more than 2 conditions. Comparative testing between 
newborns and adults was performed with Mann-Whitney U test. Statistical analysis 
was performed with GraphPad Prism version 6 software (La Jolla, Calif). 
Study approval. Guidelines of the US Department of Health and Human Services, 
the Brigham & Women Hospital, Beth Israel Hospital, Boston Children’s Hospital, and 
the Regional Committee on Research involving Human Subjects Arnhem-Nijmegen 
were observed, following protocols approved by the local institutional review boards.
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In this last chapter, we discuss the main results of this thesis, which are based upon 
observed similarities and differences between the immune response in newborns, 
infants and adults. For this purpose, we investigated monocytes, T cells, B cells and 
antibodies during viral infections (Figure 1). Our aim was to create a better under- 
standing of the immune system after birth. We speciﬁcally focus on the role of IFN-у 
as a key regulator with differential effects on the innate and adaptive immune system. 
Once upon an infection
The ﬁrst essential step in the pathogenicity of virus infection is cell entry. Kryzaniak et al. 
developed a model to explain how epithelial cells regulate uptake of RSV via cell- 
intrinsic actin-dependent properties and virus-speciﬁc mechanisms such as fusion 
of the F protein of RSV with endosomes1. Monocytic cells such as monocytes and 
macrophages are equally susceptible to RSV infection. Residential macrophages are 
present at the site of infection in the lungs and peripheral monocytes are recruited 
to the lungs at an early stage during RSV infection2. However, in contrast to 
the knowledge regarding epithelial cells, little is known about cell entry and viral 
replication of RSV in monocytes. 
Elucidation of the mechanism of RSV infection of monocytes will support the 
development of antiviral drugs that apply to the innate immune system. Eleven 
antiviral drugs are under investigation in clinical trials for RSV infections. These 
include compounds that target cell entry and viral replication3. Nucleolin is present 
on epithelial and immune cells and has been identiﬁed as the receptor for RSV fusion 
(F) protein4. Antibodies that bind nucleolin reduce cell entry of  RSV4. Another 
anti-viral drug, ALS-008176, is a cytidine nucleoside analogue that inhibits viral 
replication of RSV in epithelial cells resulting in viral clearance, as determined in a 
human RSV challenge model5. 
Monocytes are recruited to the lungs to limit viral replication and reduce disease 
severity in a mouse model2. Human monocytes and macrophages are highly 
susceptible to RSV infections as compared to other immune cells such as T and B 
cells6,7.  In Chapter 2.2, we show the results of studies about the role of actin 
dynamics for cell entry and viral replication of RSV in monocytes (Figure 1, part A). 
Antiviral therapy that blocks infectivity of monocytic cells could therefore be of interest 
in the context of pediatric RSV infections.  
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Ribavirin inhibits viral replication and has been approved to treat children with severe 
RSV infections. However, current guidelines from the American Academy of Pediatrics 
(AAP) no longer recommend this treatment for severe RSV infections due to negative 
results from randomized-controlled trials3,8. Nevertheless, delivery of antiviral drugs 
to the mononuclear system could possibly still serve as a therapeutic modality. 
Liposomes have effectively been used to encapsulate antifungal therapy and to 
deliver these drugs to the mononuclear system9. Comparable techniques could be 
applied to antiviral therapy to investigate whether recruited monocytes can be used 
to efﬁciently deliver antiviral drugs to the site of infection. The identiﬁcation of 
molecular mechanisms in Chapter 2.2 with respect to cell entry and viral replication 
of RSV in monocytes could be used to develop novel approaches to inhibit viral 
infection which in turn can be applied as part of a combination therapy with existing 
antiviral drug treatments. 
It takes two to tango 
Monocytes interact with the adaptive immune system through soluble mediators 
such as cytokines or by means of cell-cell interactions. Kollmann et al. investigated 
the ontogeny of cytokine production upon innate immune stimulation with Toll-like 
receptor (TLR) agonists10. It was found that monocytes derived from newborns 
produce larger amounts of interleukin 23 and interleukin 6 (IL-6) compared to adult 
monocytes, whereas production of interleukin 12p70 and tumor necrosis factor (TNF) is 
reduced. Components present in whole blood can further increase IL-6 production in 
newborns indicating cell-intrinsic and cell-extrinsic immune responses in newborns10,11. 
Kollmann et al. conclude from these experiments that the neonatal innate immune 
system supports Th17- rather than Th1-type responses10.  In addition to the secretion 
of cytokines, monocytes can interact with T cells via cell-cell interactions using 
membrane-bound receptors, such as MHC-I and MHC-II which are important for the 
antigen-presenting process 12. 
In Chapter 2.2, we show that the RSV-induced upregulation of MHC-II on adult 
monocytes is clathrin-dependent (Figure 1, part A). We did not study this process in 
monocytes of newborns but others have shown that neonatal monocytes are 
defective in antigen presentation as compared to adult cells. Interestingly, Canadat 
et al. did not observe a clear correlation between the level of antigen-presentation 
and the subsequent activation of T cells13. Additional factors, apart from antigen- 
presentation by MHC, may therefore inﬂuence the cross-talk between monocytes and 
T cells. The immunological synapse is formed at the interface of antigen-presenting 
cells (APCs) and T cells and is necessary for efﬁcient T cell activation. The combined 
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 215
215
Summarizing discussion and concluding remarks
5
Figure 1  Graphical abstract thesis. Depicted are the main conclusions from this thesis on 
the topic of newborn and adult immunity divided in three groups: the innate immune system, 
the cellular immune system and the humoral immune system. A: Monocytes: cell entry of 
RSV is actin-dependent and upregulation of MHC-II is clathrin-dependent in adult monocytes. 
B & C: T cells: (B) RSV induces Siglec-1 on newborn and adult monocytes. RSV induces T-cell 
dependent production of IFN-ф that is inhibited by Siglec-1 only in adults. The expression of 
CD43 is higher on adult T cells compared to newborns. (C) the inhibitory effect of IFN-у on the 
capacity of CD4 T cells to proliferate is reduced in newborns. IFN-у induces higher levels of the 
oncogene c-MYC in newborn CD4 T cells, whereas the anti-proliferative gene p21 is highly 
induces in adult CD4 T cells. D-E: B cells: (D) Newborn plasma contains RSV-IgG and RSV-IgM 
that reduce RSV infection of epithelial cells. (E) IFN-у activated newborn and adult T cells to a 
similar extent.
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action of co-stimulatory and co-inhibitory molecules determines the degree of T cell 
activation14. Siglec-1, a surface bound protein binding to sialic acid has been found 
to inhibit the T cell stimulatory capacity of DCs during human rhinovirus infection15. In 
Chapter 3.1, we compared transcriptome analyses from infants and adults to select 
Siglec-1 as our gene of interest. We realize that the comparison of these infant and 
adult gene signature is highly inﬂuenced by the presence of RSV-speciﬁc CD4+ and 
CD8+ memory T cells in adults. Therefore, we only used the array data as a selection 
strategy to identify a gene of interest and based our conclusions on the subsequent 
in vitro experiments. We show that the cell-intrinsic upregulation of Siglec-1 on 
monocytes is fully intact in newborns during in vitro RSV infection However, the 
inhibitory effect of Siglec-1 on the production of IFN-ф by T cells after exposure to RSV 
is only present in adults and not in newborns (Figure 1, part B). These data underline 
discrepancies that may exist between the presence of a receptor and its functionality 
(Figure 1, part B). We propose to investigate whether the expression of Siglec-1 on 
monocytes affects the regulatory role of monocytes at the site of infection in vivo. 
Intravital imaging using chemical and genetic labeling could be a very valuable tool 
to monitor this regulatory role of monocytes in vivo16. In addition, live imaging without 
tissue damage can be used to track monocytes17 to give detailed information of the 
kinetics in which monocytes are recruited and end up at the site of infection. 
Alternatively, ex vivo induction of Siglec-1 on monocytes or selection of Siglec-1+ 
monocytes using cell sorting followed by adoptive transfer would allow to determine 
whether the expression of Siglec-1 on monocytes alters its destination, maturation 
and regulatory role on T cells. 
What goes up, must come down?
The ontogeny of T cell immunity in newborns and adults has previously been studied18. 
Newborns are mainly dependent on their T cell repertoire to ﬁght intracellular infections 
by viruses. Quantitative differences in the percentage of naïve and memory T cells 
arise from the high percentage of naïve T cells in newborns. Qualitatively, newborn 
T cells are not completely immature and show a spectrum of responses ranging 
from no response at all to a fully functional response. Newborn CD4+ T cells are 
generally skewed towards a Th2-response but can exert strong Th1-responses as is 
the case after exposure to Mycobacterium bovis bacillus Calmette-Guerin (BCG)19. 
T cells need to be properly activated without causing inﬂammatory immunopathology. 
Both activating and inhibitory signals are important prerequisites to accomplish an 
adequate T cell response. The low production of cytokines such as interferon gamma 
(IFN-ф) in newborns indicates the presence of an impaired activation of T cells20. 
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However, the disease pattern caused by neonatal sepsis21,22 and severe viral infections, 
including those caused by RSV, herpes simplex and enterovirus infections23, in early 
life is characterized by a strong inﬂammatory response.  Many factors may inﬂuence 
the quality and quantity of the neonatal immune response. Seasonality, differences in 
pathogens and transfer of maternal antibodies may be considered as external factors. 
In addition, intrinsic differences in immunity may be due to genetic predisposition of 
the newborn and/or age-dependent differences in the ontogeny of the immune 
response. 
Type I interferon (IFNs) such as interferon bèta (IFN-у) are rapidly induced after viral 
respiratory tract infections and released in the micro-environment of the lung tissue. 
IFN-у has many immunomodulatory effects including activation, suppression and 
containment of the immune response24. The interferon alpha/bèta receptor (IFNAR) 
is expressed on T cells (Chapter 3.2) and IFN-у-mediated signaling regulates the 
activity of T cells after recruitment to the site of infection25. 
In Chapter 3.2, we show that IFN-у has a strong inhibitory effect on adult T cells 
whereas neonatal T cells maintain a large part of their capacity to proliferate and 
produce cytokines (Figure 1, part C). We did not investigate the in vivo consequences 
of these IFN-у-dependent differences between newborns and adults. Instead, we 
investigated how newborn T cells deviate from adult cells upon exposure to IFN-у 
and pinpointed a difference in gene expression upon IFNAR ligation. In Chapter 3.2, 
we show that the pro-proliferative gene c-MYC is highly induced in newborns after 
exposure to IFN-у, whereas the anti-proliferative gene p21 is not (Figure 1, part C). 
We conﬁrmed that pathways leading to the induction of c-MYC by IFN-у such as 
 IFNAR-expression, STAT1 phosphorylation and several transcription factors were 
comparable between newborn and adult T cells. Signals that follow c-MYC induction 
such as phosphorylation of Rb and induction of p21 to suppress T cell proliferation 
were different between newborns and adults. We thus showed differences between 
newborn and adult T cells at the level of gene expression.
Ivashkiv et al. extensively reviewed the regulation of gene expression by IFN-у, in 
particular IFN-у-mediated induction of STAT124. Our data suggest that the induction 
of STAT1 is comparable between newborns and adults but that the following steps 
such as expression of c-MYC and p21 are different in newborns. IFN-у-induced 
transcription is complex and can be modulated at different levels such as (a) post- 
translation modiﬁcation, (b) cooperation with other transcription factors than STAT1, 
(c) chromatin remodeling and (d) epigenetics. Factors that regulate transcription 
factors and chromatin remodeling are CREB-binding protein (CBP), BRG1 chromatin 
remodeling factor, the multi-subunit Mediator co-activator complex, the Pol II-associated 
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factor 1 homologue (PAF1) elongation factor and bromodomain-containing proteins 
(BRD) such as BRD424. The next step in our research would be to investigate these 
processes after exposure of newborn and adult T cells to IFN-у. 
With regards to epigenetics, hypermethylation of the promoter region of IFN-ф is 
proposed to result in the Th2 skewing of the newborn immune response20. Our data, 
in combination with the documented effects of IFN-у on gene regulation, indicate that 
future research should seek to understand processes that determine the differences 
in gene induction between newborns and adults. Factors such as epigenetic regulation 
would form an interesting candidate to investigate the effects of IFN-у on the alteration 
of cell cycle genes in newborns.  
For newborn B cells, it comes naturally
B cells are part of the adaptive immune system and are a second line of defense 
once the innate immune system has been alerted. In Chapter 4.4, the presence of 
RSV-IgM in newborn plasma that inhibits RSV infection suggests the existence of an 
innate B cell defense system that is already present at birth without previous exposure 
to RSV (Figure 1, part D). Such innate-like B cells may represent B1 cells that have 
mainly been studied in mice26,27. The human equivalent of these B1 cells has not yet 
decisively been determined. Nevertheless, innate B cells are found in germ-free mice 
and produce natural IgM antibodies without previous exposure to a pathogen. Their 
localization at mucosal surfaces such as the pleural and peritoneal cavities suggests 
a role in the mucosal immune defense. 
The spontaneous production of natural IgM with antimicrobial activity in newborn 
plasma indicates a mode of action independent of maturation at the germinal center 
in the lymph nodes. Natural IgM antibodies include polyreactive pathogen-binding 
IgM antibodies that are present without previous exposure and are part of the innate 
immune system, able to opsonize pathogens and to promote phagocytosis28. RSV 
envelope proteins include fusion protein (F protein) and attachment protein (G 
protein), which are glycosylated and potentially targeted by natural IgM antibodies31-
33. The rapid response of naïve B cells that produce natural IgM antibodies in the 
lungs may play an initial role during the infection until mature and class-switched 
plasma cells arrive from the lymph nodes. 
We performed all our studies with cord blood or peripheral blood. This material is 
easily accessible but does not accurately reﬂect the site of infection during viral 
respiratory tract infections. Residential B cells are more likely to be responsible for a 
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rapid humoral response. The acquisition of lung tissue to study these immune 
responses is challenging and even more so in newborns due to ethical considerations. 
Thus far, no study investigated humoral responses in newborn lungs. Opportunities 
to do so may be found by using material from fetal, neonatal and pediatric surgical 
specimens to conﬁrm or debunk basic mechanisms of innate B cells and natural 
antibodies that are observed in mice. Congenital abnormalities such as cystic 
malformations usually require surgery early in life and specimens obtained by surgery 
could be used to investigate the humoral response of newborn and/or infant lungs. 
The presence of innate B cells or natural antibodies that may be functional against 
respiratory pathogens, could be determined in lung biopsy material. We speculate 
that this might provide more insights into the early-life innate B cell immunity.
Boosting baby B cells
Neonatal vaccination is a rapidly emerging ﬁeld which aims to reduce early life 
mortality and limit the disease burden of infectious diseases in infants29. The immature 
immune system of neonates and interference with maternal antibodies make it 
difﬁcult to induce a proper B cell response upon newborn vaccination. In addition, the 
adaptive immunity in newborns is characterized by a Th2 skewed immunity and a 
defective T cell-dependent B cell response in newborns18. In Chapter 4.4, we show 
that neonatal and adult B cells are activated to a similar extent in the context of 
RSV-induced and IFN-у-mediated activation (Figure 1, part E). This suggests that 
IFN-у may potently activate B cells during neonatal immunity and RSV infections. In 
early life, however, analysis of whole gene expression proﬁles of infants with severe 
RSV infections indicates that the B cell response in these children is suppressed30. 
The discrepancy between the results of the study by Meijas et al. and ours may be 
due the differences in the study design. Epithelial cells produce large amounts of 
type I IFNs upon RSV infection31, whereas blood from RSV-infected infants contains 
low levels of IFN-у. Transcriptome analyses of whole blood from RSV-infected infants 
possibly reﬂect the state of B cells in the peripheral blood, whereas our model to 
study IFN-mediated B cell activation may be more representative of  the actual site of 
infection in the lung with IFN-producing cells2.
Vaccination with BCG induces protection that may depend on the induction of type I 
IFNs32. The induction of type I IFNs by TLR agonists such as CpG or direct inter feron-
adjuvanted vaccination may therefore be considered to increase the efﬁcacy of 
neonatal vaccination33,34. The majority of studies that aim to develop new vaccines 
use murine models to investigate protection and immunogenicity. Mice and humans 
can be used in parallel to investigate molecular mechanisms of disease. However, it 
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is important to consider that IFN-dependent pathways are different in human an 
mice. For instance, IFN-т induces STAT4 activation in humans and not in mice35. In 
addition, IFN-т enhances the production of antibodies induced by inﬂuenza vacccine 
in mice, which could not be conﬁrmed in a human trial36. IFN-у as a molecular 
adjuvant has only been proven effective in mice37. Reproduction of murine vaccine 
studies with in vitro human experiments that employ newborn and infant blood may 
identify immunological differences between humans and mice in an early stage of 
vaccine development.
Winter is coming…
Every year in late fall a new period of RSV infections occurs in the northern 
hemisphere38. Nearly all infants get infected with RSV and only a small percentage 
develops symptoms of lower respiratory tract infections that require hospitalization 
and/or mechanical ventilation. Elucidation of the immune response and other factors 
that enhance or reduce disease severity will enable us to develop new therapies and 
prepare infants for RSV infections. Children with co-morbidities such as cardio-
pulmonary disease and prematurity account for approximately 50% of the severe 
RSV infections. Children below 6 months of age have a higher risk to develop severe 
infections. This may be due to a rapid decline of maternal antibodies (matAbs) 
against RSV in the ﬁrst months after birth39. However, the protective effect of anti-RSV 
matAbs is currently under discussion40,41. It is becoming increasingly clear that 
in-depth analysis of anti-RSV matAbs will be necessary to explain the apparent 
contradictions of its effects published in literature. Palivizumab is a monoclonal 
antibody that is administered to high-risk infants to prevent severe RSV infections. 
Palivizumab mainly binds the prefusion F protein but also interacts with the post-fusion 
F protein. Naturally occurring antibodies against a speciﬁc pre-fusion epitope correlate 
with neutralization in vitro42. Neonatal and maternal vaccination trials indicate that 
antibodies against the pre-fusion F protein protect against severe RSV infections3. 
However, in Chapter 4.2, we show that the level of infection-induced matAbs against 
a prefusion epitope does not correlate with disease severity. This may indicate that 
the level of matAbs after vaccination needs to be higher than the level induced by 
infection to confer protection against severe disease. The neutralizing capacity of 
antibodies is used to predict clinical efﬁcacy of a vaccine. Antibodies have additional 
properties in addition to neutralization that may inﬂuence the efﬁcacy of a vaccine.  In 
Chapter 4.1, we review and investigate the immunomodulatory effects of antibodies 
during RSV infections. Analysis of the immunomodulatory effect of antibodies is 
clinically important because the inﬂammatory response during RSV infection is the 
major determinant of disease progression. The failure of vaccination with Lot 60, a 
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formalin-inactivated RSV vaccine, shows the importance of the inﬂammatory 
response and the effects of antibodies on inﬂammation43. Lot 60 induced low-afﬁnity 
antibodies that resulted in a detrimental inﬂammatory response and fatal cases 
following RSV infection in vaccinated infants43. We propose that a complete charac-
terization of matAbs should include the immunomodulatory properties of matAbs in 
addition to their neutralizing capacity. Future research should not only focus on the 
neutralizing capacity of antibodies but also on their activity to direct the immune 
response towards protective immunity and reduction in immunopathology. 
The small size of the airways of young infants partly explain the increased vulnerability 
for severe RSV disease early life. However, the majority of RSV-infected infants below 
3 months of age experience relatively mild symptoms after RSV infections thus 
indicating that additional factors may also contribute. Young infants mainly rely on 
their innate immune system for the protection against infectious diseases. The innate 
immune system is the ﬁrst line of defense after infection. The susceptibility for severe 
RSV infection may depend on differences in innate immune responses. In Chapter 2.3, 
we show that a reduction of HLA-DR expression on innate immune cells such as 
monocytes is correlated with severe RSV infection. A similar pattern of immuno-
suppression of monocytes has been observed during severe bacterial infections and 
sepsis44,45.  The observed suppression of monocytes during RSV infection may lead 
to an inadequate T cell response during primary infections.
In vivo studies may determine the relative contribution of different cell types such as 
monocytes or neutrophils to disease outcome. However, to deﬁne the molecular 
mechanisms of disease and interactions between immune cells it is inevitable to 
study speciﬁc and/or isolated cell types in vitro. 
Concluding remarks
The neonatal period represents an important time window during which viral infections 
occur and long-lasting modulation of the immune response takes place46. 
Immunological triggers in the ﬁrst months of life can have long-term implications 
(Figure 2). The impact of neonatal immunity on long term processes such as im-
mune-mediated diseases is a big current topic of interest. Immune triggers in early 
life may enhance or promote long term skewing of health and disease rather than 
being a decisive mediator of such processes. 
The ‘hygiene hypothesis’ or ‘microbial exposure hypothesis’ implies that the reduction 
of infections due to vaccination and antibiotics combined with the improvement of 
hygiene increases the occurrence of immune-mediated diseases such as asthma 
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Figure 2  The relationship between newborn immunology, adjacent areas of research 
and the consequences of immunomodulation during the neonatal window of opportunity. 
On the left, areas of research are depicted that are related to neonatal immunology. Metabolism: 
newborn immunology is inﬂuenced by metabolic processes. The generation of ATP and 
glucose consumption are essential to support activation of multiple immune responses. 
Microbiology: newborn immunology is thought to be directed by a complex interaction between 
host and microbe and the genetic predisposition of both the host and the pathogen are of 
inﬂuence. Immunology: newborn immunology should be positioned in the context of infectious 
diseases that are prevalent in the ﬁrst months of life such as RSV, herpes simplex, enterovirus 
and group B streptococcal disease. On the right, consequences of newborn immunology are 
divided into two groups: early effects and late effects. Early effects entail the direct effect due 
to the distinct immune response in newborns such as the development of effective vaccines 
and the prevalence of severe viral and bacterial infections in early life. Late effects of newborn 
immunology are comprised of the development of asthma or allergies due to distinct imprinting 
directly after birth.
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and allergies46. A reduction in bacterial diversity may increase the occurrence of im-
mune-mediated diseases47 As an example, exposure to stable dust extracts may 
have immunomodulatory effects. Stable dust reduces allergic responsiveness and 
inﬂammation of the airways in a murine model48. Interestingly, age is an important 
factor in the development of immune-mediated diseases. Early life events such as 
mode of delivery, diet and use of antibiotics shape the microbiota of newborns49. 
Therefore, it is not surprising that particularly newborns and young infants are more 
sensitive to changes in their microbiota with long-term effects50.
The early postnatal life is currently considered a major window of opportunity 
during which environmental factors can alter the immune homeostasis later in life46. 
The microbiome and the use of antibiotics in early life are associated with immuno-
modulation49,51 and the risk of immune-mediated diseases such as atopic dermatitis 
and asthma52. The focus of these studies has been on bacterial colonization, whilst 
the gut virome, including bacteriophages, could potentially also affect immune 
homeostasis53. The virome is highly variable between individuals and changes 
during the ﬁrst months of life. It is still unclear which environmental or genetic factors 
can contribute to the composition of the virome and whether the virome may 
contribute to postnatal immune homeostasis. In this thesis, we have shown the 
immuno regulatory role of a virus, such as RSV, or IFN-у on newborn T- and B-cells. 
Interestingly, IFN-у derived from gut commensal bacteria protects mice against 
colitis54. Future research may elucidate whether the neonatal period is a window of 
opportunity due to the immunomodulatory effect of IFN-у that is induced by either 
the bacterial or viral microbiome.  
We characterized different aspects of the immune response of newborns by physically 
separating a single blood sample into plasma, monocytes, T cells and B cells and 
used it for different studies (Figure 1). In all our stimulation assays, a laboratory strain 
of RSV A2 was used. Schijf et al showed that different cytokine responses in vitro are 
elicited depending on the RSV strain that is used6. A laboratory strain can, therefore, 
be used to investigate the antiviral response in general but caution should be made 
regarding conclusions about clinical applicability during in vivo RSV infections.
Acquisition of large volume is easily obtainable by using umbilical cord blood. 
However, in infants, ethical considerations ask for an optimal use of samples. Small 
volumes can be used to phenotype cell types and plasma components by ﬂow 
cytometry and mass spectrometry respectively. Performance of functional assays 
with a small number of cells is still a challenge and future research should identify the 
functionality of immune cells with a limited number of cells. This way, small amounts 
of biological material can be acquired throughout all age groups. The acquisition of 
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pediatric samples for research purposes should be standard rather than incidental 
due to the abundance of opportunities in an academic hospital to perform basic 
research.
In this thesis, we performed ex vivo studies to correlate disease severity with maternal 
antibodies and with the expression of innate receptors on monocytes, in respectively 
Chapter 4.2 and Chapter 2.3. We could correlate the results with the in vivo situation 
because we used clinical markers during RSV infections in infants to deﬁne different 
disease severity groups. A causal relationship, however, cannot be proven in a retro- 
spective study. To this purpose, a prospective study or, even more ideally, a randomized 
clinical trial or a valid mice model would be more informative. Nevertheless, our data 
may contribute to a better understanding on how the innate immune response in 
young infants during severe RSV infections works and can lead to the design of future 
clinical research questions.
 The remaining chapters of this thesis mainly studied the immune response in vitro of 
newborns compared to adults. In Chapter 3.1 and Chapter 3.2, we focus on the 
T cell responses in newborn and adults. We used a model to investigate newborn and 
adult CD4+ T cells, the production of IFN-ф by these cells and their responsiveness 
after exposure to IFN-у. It is important to note that different populations of CD4+ 
T cells are compared in these assays, speciﬁcally naïve and memory CD4+ T cells in 
respectively newborn and adult blood. We observed a delayed IFN-ф response by 
newborn immune cells and a reduced inhibitory effect of IFN-у on T cells. These 
results may be explained by functional differences between naïve and memory 
T cells. We therefore conclude that the entire population of CD4+ T cells in newborns 
has a delayed IFN-ф production and responds differently to IFN-у compared to entire 
population of adult CD4+ T cells. Future research should elucidate whether this is due 
to differences in subsets of CD4+ T cells or whether a direct comparison between 
newborn and adult naïve CD4+ T cell will lead to the same conclusions.  
We chose however to compare all subsets of newborn and adult T cells. We believe 
that our results may resemble in vivo T cell responsiveness to a greater extent than 
results obtained by comparison of isolated subsets of CD4+ T cells. Two approaches 
can be taken to translate the delayed newborn production of IFN-ф and the reduced 
inhibitory effect of IFN-у on newborn T cell proliferation into practice: First, (a) 
newborns are prone to develop severe infections and therefore our data could explain 
the increased susceptibility of newborns for bacterial and viral infections. Clinically 
this could mean that skewing of the T cells response in newborns, resulting in a low 
IFN-ф production and an increased proliferation, contributes to disease susceptibility 
early in life. On the other hand, (b) newborns are evolutionary evolved to efﬁciently 
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battle infections in 99% percent of the cases. Every day 353,000 babies are born and 
only a small fraction gets severely ill. Our model of cells derived from (healthy) 
newborns after cesarean sections therefore may reﬂect the cases for which an 
infection is efﬁciently cleared and our data may provide more insight in the question 
why so many babies do not get severely ill. In Chapter 3.2, the reduced inhibitory 
effect of IFN-у on newborn T cells may offer some preservation of the otherwise 
reduced functionality of newborn T cells. From an evolutionary perspective, a low 
level inhibition of T cells is needed in newborns to mount an adequate immune 
response, whereas, in adults, IFN-у should have profound inhibitory effects to prevent 
auto-immune diseases. 
In addition, the innate humoral IgM response in newborns described in Chapter 4.4 
may relate to the normal early immune response against RSV that occurs in newborns 
and explain the low incidence of severe RSV infection in the ﬁrst months of life54. 
Future research should therefore combine data from healthy newborns with data 
from newborns that develop severe disease to distinguish an effective from a non- 
effective response. 
The biggest struggle for many laboratory scientists is to translate their research to 
clinical applications. Is it scientiﬁcally plausible to suggest that there is a causal 
relation between immune markers and disease severity? Or what does cytokine 
production in an experiment mean? Do newborns beneﬁt from increased inﬂammation 
or should their immune response be dampened? Essential in the interpretation of 
data is to contemplate on its meaning.
This thesis combines aspects of immunology, microbiology and cell cycle processes 
in the context of neonatal immunity. The complexity of the newborn immune response 
impedes the comprehension of all aspects and clinical consequences in detail. 
Collaborations between different disciplines ranging from molecular biology to 
clinical immunology will contribute to a better understanding of the consequences of 
early encounters with microbes early in life.
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Nederlandse samenvatting
Hoe goed zijn pasgeborenen na de geboorte voorbereid op de infecties die ze tegen 
gaan komen? En in hoeverre is het afweersysteem van pasgeborenen vergelijkbaar 
met dat van volwassenen? Rond 350 voor Christus postuleerde Plato dat men geboren 
werd met kennis die geschonken was door een goddelijk wezen, een fenomeen dat 
ook wel ‘innatisme’ genoemd werd. Descartes steunde Plato’s ideeën enkele eeuwen 
later en suggereerde dat kinderen geboren worden met een voor geprogrammeerd 
niveau van kennis. Het tegenovergestelde werd gesteld door Aristoteles. Hij beweerde 
dat iedereen blanco geboren wordt en dat de mens zich ontwikkelt op basis van 
ervaring. Tegenwoordig zijn de meeste wetenschappers ervan overtuigd dat beide 
stromingen een deel van de waarheid vertegenwoordigen. We worden geboren met 
een van tevoren bepaald ontwikkelingsniveau en vergroten dit door de ervaring die 
we opdoen. Dit geldt ook voor het afweersysteem van de mens. Wetenschappelijk 
onderzoek naar de ontwikkeling van het afweersysteem dat reeds aanwezig is bij 
geboorte, draagt bij aan een beter begrip over infectieziekten op de kinderleeftijd. 
Respiratoir syncytieel virus (RSV) is de belangrijkste verwekker van infectieziekten 
bij jonge kinderen. Sinds de ontdekking van RSV wordt veel onderzoek gedaan naar 
de afweerreactie tegen dit virus. Dit betreft zowel onderzoek naar het aangeboren 
afweersysteem als naar het adaptieve afweersysteem.  Elk jaar ontwikkelt zich in de 
herfst een nieuwe cyclus van infecties door RSV. De meeste kinderen hebben slechts 
last van snotterigheid en hoesten. Echter, één derde van de kinderen heeft een infectie 
van de onderste luchtwegen hetgeen resulteert in benauwdheid en verminderde 
zuurstofuitwisseling in de longen. Eén procent van alle kinderen met een RSV infectie 
wordt ernstig ziek, moet opgenomen worden in het ziekenhuis en heeft extra zuurstof 
of kunstmatige beademing nodig. Leeftijd is de meest bepalende factor voor het 
ontwikkelen van een ernstige RSV infectie. Kinderen in de eerste paar maanden van 
het leven lopen het grootste risico op een ernstig beloop van infectie. Ernstige RSV 
infecties worden gekenmerkt door een overactieve afweerreactie met een overmaat 
aan ontsteking. 
Antistoffen van de moeder worden voor de geboorte aan het kind doorgegeven via 
de placenta. Dankzij deze antistoffen is het kind in de eerste maanden na de geboorte 
beschermd tegen veel infecties. Antistoffen kunnen RSV neutraliseren en voorkomen 
dat het virus de cel binnendringt. Toch worden nog veel kinderen in de eerste maanden 
na de geboorte ziek van RSV, hetgeen suggereert dat de antistoffen die via de moeder 
overgedragen worden onvoldoende bescherming bieden. In Hoofdstuk 4.2 worden 
de hoeveelheid antistoffen en de kwaliteit van deze antistoffen (de mate waarin ze het 
virus neutraliseren) tegen RSV bepaald in het bloed van kinderen met een RSV infectie. 
Kinderen met milde RSV infecties werden bij dit onderzoek vergeleken met kinderen 
met ernstige RSV infecties. Uit de resultaten van dit onderzoek blijkt dat de hoeveelheid 
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antistoffen en de mate waarin de antistoffen RSV neutraliseren niet verschillen tussen 
beide groepen. Mogelijk zijn er dus nog andere eigenschappen van antistoffen die 
een invloed hebben op het beloop van een RSV infectie. Een voorbeeld hiervan is 
de modulatie van het afweersysteem en van de ontstekings reactie door antistoffen. 
In Hoofdstuk 4.1 vatten we de studies samen die tot nu gepubliceerd zijn over het 
effect van antistoffen op het afweersysteem. Neutralisatie van RSV speelt hierin een 
belangrijke rol. Daarnaast beïnvloeden antistoffen ook de reactie van afweercellen 
van ons afweersysteem. Wanneer deze sturing van het afweersysteem door anti- 
stoffen niet goed verloopt, verandert de ontstekingsreactie en draagt deze mogelijk 
bij aan de ernst van de RSV infectie. In Hoofdstuk 4.3 tonen we aan dat antistoffen 
de ontstekingsreactie van het afweersysteem doen toenemen. Omdat deze experimenten 
in een laboratorium uitgevoerd zijn, is het vooralsnog niet goed aan te geven of 
deze toename van de ontstekingreactie gunstig of ongunstig is voor een kind met 
een RSV infectie.
Direct na de geboorte hebben pasgeborenen en jonge kinderen meestal nog geen 
infecties doorgemaakt. Daardoor is hun afweersysteem nog niet volledig uitgerijpt en 
zijn met name jonge kinderen afhankelijk van het aangeboren afweersysteem. 
Monocyten vormen een belangrijk onderdeel van dit aangeboren afweersysteem. 
Deze afweercellen kunnen RSV herkennen, opnemen en vervolgens een afweerreactie 
in gang zetten. Voor het in gang zetten van deze afweerreactie zijn onder andere 
antigeen-presenterende moleculen (MHC-II) essentieel. Deze moleculen komen op 
de buitenkant van de monocyt tot expressie en zijn nodig om het verworven (adaptieve) 
immuunsysteem te activeren om viraal geïnfecteerde cellen te verwijderen. In 
Hoofdstuk 2.1 beschrijven we een model waarbij we experimenten uitvoeren met 
monocyten uit het bloed van gezonde vrijwilligers. In dit onderzoek hebben we 
aangetoond dat celstructuren, zoals actine en clathrine, nodig zijn om RSV op te 
nemen en een afweerreactie in gang te zetten (Hoofdstuk 2.2). Dezelfde afweercellen, 
de monocyten, hebben we getypeerd in Hoofdstuk 2.3 in het bloed van kinderen 
met een RSV infectie. De resultaten van deze studie tonen aan dat antigeen- 
presenterende moleculen (MHC-II) op de buitenkant van monocyten in mindere mate 
aanwezig zijn bij kinderen met een ernstige RSV infectie vergeleken met kinderen met 
een milde RSV infectie. Hierdoor wordt de afweerreactie tijdens een ernstige RSV 
infectie mogelijk niet goed in gang gezet, met als gevolg dat deze kinderen ernstiger 
ziek worden. 
Zoals hierboven aangegeven, is naast het aangeboren afweersysteem, ook het 
verworven (adaptieve) afweersysteem belangrijk voor het beloop van infecties door 
RSV. Het verworven afweersysteem bestaat voornamelijk uit B- en T-cellen. Deze 
cellen zijn in pasgeborenen grotendeels naïef, hetgeen betekent dat ze nooit eerder 
betrokken zijn geweest bij het bestrijden van een RSV infectie. De B- en T-cellen in 
volwassenen zijn met name geheugencellen omdat ze al een keer contact met RSV 
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hebben gehad. Tussen de T-cellen van pasgeborenen en volwassenen zijn er ook 
functionele verschillen, met name in de productie van ontstekingsstoffen. In Hoofstuk 3.1 
hebben we aangetoond dat RSV de expressie van het eiwit ‘Siglec-1’ op het cel- 
membraan van monocyten induceert. Dit eiwit kan de afweerreactie van volwassenen 
T-cellen remmen door de productie van antivirale ontstekingsstoffen te blokkeren. 
T-cellen van pasgeborenen worden echter niet geremd door Siglec-1. Hieruit blijkt 
dat de interactie tussen monocyten en T-cellen bij pasgeborenen mogelijk anders 
verloopt dan bij volwassenen. 
Behalve de hierboven beschreven directe interactie tussen monocyten en T-cellen, 
kan het aangeboren afweersysteem ook via ontstekingsstoffen communiceren met 
het verworven afweersysteem. Interferon bèta (IFN-у) is een voorbeeld van een dergelijke 
ontstekingsstof, die geproduceerd wordt door het aangeboren afweersysteem tijdens 
virale infecties en daarbij de B- en T-cel kan beïnvloeden. In Hoofstuk 3.2 beschrijven 
we de remmende werking van IFN-у op T-cellen. De mate van remming is groter bij 
T-cellen van volwassenen dan bij T-cellen van pasgeborenen.  Dit kan veroorzaakt 
worden door een verschil in de verhouding van naïeve en geheugen (‘memory’) 
T-cellen. Het gebrek aan remming van T-cellen bij pasgeborenen zou mede een rol 
kunnen spelen bij het ontwikkelen van een schadelijke afweerreactie.
B-cellen worden in tegenstelling tot T-cellen juist geactiveerd door IFN-у (Hoofdstuk 4.4). 
Zowel de B-cellen van pasgeborenen als die van volwassenen worden geactiveerd 
na blootstelling aan RSV en IFN-у. Dit was een onverwachtse bevinding, omdat de 
B-cellen van jonge kinderen tijdens vaccinatie juist minder goed geactiveerd worden 
in vergelijking met de B-cellen van oudere kinderen of volwassenen. De rol van IFN-у 
tijdens vaccinaties is tot op heden nog onderbelicht. Vaccinaties kunnen in de 
toekomst mogelijk nog effectiever zijn als er een adequate productie van IFN-у plaats 
vindt en daarmee een activering van de B cellen
In Hoofstuk 4.4 hebben we via onderzoek aangetoond dat B-cellen van pasgeborenen 
antistoffen maken tegen RSV. Dit is een verrassende bevinding, omdat we tot op 
heden van uit waren gegaan dat antistof producerende B-cellen pas aanwezig zijn 
nadat het kind een RSV infectie heeft doorgemaakt. Vlak na de geboorte is dit echter 
niet mogelijk, omdat het kind daarvoor in een (semi-)steriele omgeving verkeerde. 
Ons onderzoek bevestigt dat kinderen mogelijk al geboren worden met B-cellen die 
bijdragen aan de afweer tegen RSV. In hoeverre deze experimenten in het laboratorium 
met bloed van pasgeborenen vergelijkbaar zijn met hetgeen daadwerkelijk in het 
lichaam van dezelfde pasgeborene plaats vindt, dient nader onderzocht te worden.
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Conclusies en toekomstig perspectief
De gebeurtenissen gedurende de eerste maanden na de geboorte hebben een grote 
impact op de rest van het leven. Tijdens deze periode vinden veel veranderingen plaats 
in het afweersysteem van de pasgeborene en de zuigeling. De baby wordt direct na 
de geboorte blootgesteld aan de buitenwereld, terwijl de darmen, de huid en de 
luchtwegen worden gekoloniseerd door bacteriën. Vaccinaties vinden plaats kort na 
de geboorte. Daarnaast is dit ook de periode waarin medisch ingrijpen vaak nood- 
zakelijk is en krijgen veel baby’s antibiotica vanwege een verdenking op (ernstige) 
infecties. 
Het onderzoek beschreven in dit proefschrift levert een bijdrage aan de kennis van 
het afweersysteem direct na de geboorte. Zowel het aangeboren als het verworven 
immuunsysteem zijn bestudeerd alsmede de interactie tussen deze beide systemen. 
Een betere kennis van de ontwikkeling van het afweersysteem is essentieel om te 
kunnen begrijpen hoe interventies, zoals het doormaken van een infectie, of medische 
ingrepen, zoals vaccinaties, het afweersysteem beïnvloeden. Deze interventies kunnen 
zowel directe effecten als effecten op de lange termijn hebben. Een interessant voorbeeld 
hiervan is het voorschrijven van antibiotica en het risico op allergie en astma op latere 
leeftijd. Een aantal studies op dit terrein tonen aan dat er een relatie bestaat tussen 
antibioticagebruik tijdens de zwangerschap of vlak na de geboorte en de ontwikkeling 
van allergieën. Het afweersysteem is buitengewoon complex. In één cel vinden tijdens 
een infectie honderden processen plaats, die elkaar ook onderling beïnvloeden. 
Daarnaast kunnen afweercellen andere cellen van het afweersysteem activeren, 
remmen of instrueren. Tegelijkertijd kunnen verschillende orgaansystemen, zoals de 
longen en de darmen, elkaar beïnvloeden door middel van ontstekingsmediatoren 
die vrijkomen tijdens infecties. Fundamenteel onderzoek in het laboratorium kan in 
de toekomst verder bijdragen aan een beter begrip van het afweersysteem na de 
geboorte en het effect van de buitenwereld op deze belangrijke periode.
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Jop Jans werd op 24 april 1987 geboren in Sint-Oedenrode, beter bekend als ‘Rooi’. 
Hij voltooide zijn middelbare school op het gymnasium Beekvliet te Sint-Michielsgestel 
in 2005. Hij studeerde Geneeskunde aan de Radboud Universiteit te Nijmegen van 
2005-2012 en verrichte zijn onderzoeksstage op het Laboratorium Kinderinfectieziekten 
met als onderwerp ‘Schimmelinfecties bij kinderen met chronisch granulomateuze 
ziekte’. Hierna werkte hij acht maanden als arts-assistent niet in opleiding in het 
Canisius Wilhelmina Ziekenhuis te Nijmegen. In april 2013 begon Jop met zijn 
promotie traject ‘Immunity against RSV infections’ onder begeleiding van dr. Gerben 
Ferwerda, dr. Marien de Jonge en professor Ronald de Groot in het Laboratorium 
Kinderinfectieziekten van het Radboudumc. Van september 2013 t/m april 2014 is 
Jop met behulp van het Ter Meulen Fonds werkzaam geweest als promovendus in 
het laboratorium van dr. Ofer Levy in Harvard Medical School te Boston, dat zich 
specialiseert in het neonatale afweersysteem. Bij terugkomst in Nederland heeft 
Jop samen met zijn begeleider dr. Gerben Ferwerda een vergelijkbaar model van 
onderzoek opgezet in het Radboudumc. Gedurende zijn promotietraject heeft Jop 
zich ingezet voor het maatschappelijke belang van wetenschappelijk onderzoek. 
Hij heeft voorlichting gegeven aan kinderen van de basisschool en de middelbare 
school. Daarnaast heeft hij een congres georganiseerd getiteld ‘Science and Society’. 
Momenteel volgt Jop zijn opleiding tot kinderarts in het Amphia Ziekenhuis te Breda 
met als opleider dr. H.M. van Wering en met prof. dr. M. de Hoog als academische 
opleider vanuit het Sophia kinderziekenhuis/Erasmus Medisch Centrum te Rotterdam.
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Dankwoord
Aan de Kortekade te Rotterdam schrijf ik mijn dankwoord. Een jaar nadat ik het 
laboratorium Kinderinfectieziekten fysiek ‘verlaten’ heb, is het tijd om mijn boekje af 
te ronden. Af te ronden met hulp van een grote groep mensen die ik wil bedanken.
Beste Gerben, van iedereen wil ik jou het meest bedanken. Dankzij jou heb ik een 
PhD kunnen volgen in het lab. Vanaf dag één voelde het als een team op ontdekkings-
tocht. Jouw oneindige enthousiasme en het denken buiten de gebaande (wetenschap-
pelijke) paden hebben ervoor gezorgd dat ik veel geleerd heb over het verrichten van 
onderzoek. Dankzij jou heb ik het maximale uit mijn tijd als promovendus kunnen halen, 
ook los van de wetenschappelijke inhoud. Flamenco danseressen, zelf gemaakte 
pizza’s, jazzclubs in Boston, skypen met basisscholen, RSV meetings, cocktails in 
Marbella en met de NS het land door. Het was een feest van begin tot eind. Je hebt 
me de vrijheid gegeven wetenschap te bedrijven. Dankzij jou heb ik me kunnen 
ontwikkelen als wetenschapper en als persoon. Bedankt. 
Beste Ronald, je bent een geweldige promotor. Je adviezen zijn eerlijk en recht door 
zee. Je zet je promovendi op nummer één. Mede dankzij jou zit ik nu op een prachtige 
opleidingsplek in Rotterdam. 
Beste Marien, het begon allemaal met een vraag over pH metingen en schimmels. 
Jij zat nog tussen de PhD studenten en de postdocs en ik was nog student Genees- 
kunde. Ontzettend bedankt dat ik mijn PhD bij jou in het lab heb mogen uitvoeren. 
Ik bewonder jou in je functie als hoofd Laboratorium Kinderinfectieziekten en je 
betrokkenheid bij alle leden van het lab. Dat er nog veel kofﬁe momenten mogen 
volgen. 
De leden van de manuscriptcommissie, prof. dr. A. Cambi, prof. dr. M.G. Netea en 
prof. dr. A.D.M.E. Osterhaus, ik wil jullie hartelijk bedanken voor het beoordelen van 
mijn proefschrift. Aan alle leden van de corona; hartelijk dank voor jullie komst en ik 
kijk uit naar onze discussies. Special thanks to prof. Kollmann for ﬂying over from 
Vancouver and for your presence at my defense.
Beste Stefanie en Adilia. Mijn wetenschappelijke carrière is bij jullie begonnen. Op een 
kamer met een boek vol plaatjes van schimmels. Het enthousiasme op jullie gezicht 
bij het openslaan van dat boek zal ik nooit vergeten. Ik ben blij dat ik met jullie 
heb mogen werken en dat jullie me hebben geïntroduceerd in de wereld van het 
fundamentele onderzoek. 
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Dear Ofer, I still remember the ﬁrst time we met. It was at your house with your wife 
and children during the Shabbat. During a wonderful meal, we talked about everything 
except for work. A great start of my Bostonian period. I would like to thank you for the 
opportunity to work at your lab, for your hospitality and your guidance throughout that 
part of my PhD. Annette, David, Ian, Ilana, Jana, Mariana, Matthew, Meredith, 
Simon and Willeke, thank you for the warm welcome and great time in the lab and 
in Boston. Sabrina, my time in Boston wouldn’t have been the same without you. 
Thank you for being a friend. Then, now and in the future. 
Ook wil ik iedereen bedanken die hebben meegeholpen met het schrijven van deze 
thesis. Ivy, Jacco, Lilid, Oliver, Teun, Willem en Xander. Renate en Dorien van het 
LMI. Wendy, ik kijk uit naar ons toekomstig onderzoek samen in het Sophia kinder-
ziekenhuis. 
Collega’s van het lab. Team LKI wil ik bedanken met Christa, Dimitri, Elles, Evi, 
Inge, Jeroen, Josh, Koen, Fred, Liz, Lucille, Marc, Michiel, Ria, Saskia, Sandra 
en oudgedienden Aldert, Amelieke, Daan, Erika, Fredrick, Hester, Inge, Lilly, 
Maaike, Marloes, Marrit, Stan en Stefan. Corné, hopelijk volgen er nog meer 
heerlijke gesprekken en net zo heerlijke drankjes aan de bar in de toekomst. Esther, 
altijd in voor een kopje kofﬁe of avondmaal in het restaurant, top!  Ada, je bent niet 
meer onder ons, maar bedankt voor je inzet en onmisbare ondersteuning. Ook LKO 
met Arthur, Dorette, Frank, Hanneke, Jeroen, Kirsten, Laurens, Liesbeth, Miriam 
en René wil ik bedanken. Bedankt voor jullie bijdrage, Arthur, Cas, Gracián en 
Lisanne. Het was ontzettend leuk om jullie te begeleiden.
De kinderafdeling van het Amphia; alle kinderartsen, arts-assistenten, verpleegkundig 
specialisten en verpleegkundigen. Ook dankzij jullie heb ik het afgelopen jaar mijn 
proefschrift kunnen afronden en tegelijkertijd ben ik enorm aan het genieten van mijn 
baan als arts-assistent in Breda. Collega’s vanuit het SKZ, zonder ontspanning geen 
inspanning. Inclusief de borrels en maandelijkse nascholing. Ivar, buddy, zonder jou 
zou ik regelmatig (ook letterlijk) de weg kwijt zijn in Rotterdam. 
Lieve Nelleke, bedankt dat ik altijd bij je terecht kan. Of het nou is voor een Brabants 
biertje of voor een goed gesprek.
Nijmeegse Mockols (en aanhang), Wendy, Anke en Loeki bedankt voor de prachtige 
studententijd en vriendschappen die we hebben opgebouwd. Steef, dat we nog vele 
dagen arty-farty, Dana, compleet gemarineerd en in alle heerlijkheid samen mogen 
doorbrengen. Lara en Christiaan, inmiddels zijn we alle drie verspreid geraakt over 
het land, maar jullie bezoek aan Boston was er één om nooit te vergeten. Jantien 
515892-L-sub01-bw-Jans
Processed on: 11-12-2017 PDF page: 239
239
Appendices | Dankwoord
6
(en Joost en Kato), ik ben blij dat er niets veranderd is, ondanks dat de afstand groter 
is geworden. 
Dear DK. I am honored to have you with me as one of my paranymphs. During my 
stay in Boston, you started with being my direct supervisor in the laboratory. Luckily, 
this quickly changed into a friendship. I had so much fun working and hanging out 
with you. At the lab, in the restaurant, in San Francisco, driving in the car or in the bar. 
#Britney.
Lieve Kirsten, vier jaar lang hebben we zij aan zij opgetrokken door dik en dun, zowel 
in het lab als buiten de werktijden. Evalueren van onze dagen (en weekenden), 
fantaseren over de toekomst. Een toekomst samen in de wetenschap. De kers op de 
taart was het congres in Hannover. Ja, want onze PhD was niet compleet zonder een 
congres samen. Super dat je één van mijn paranimfen bent en blijft!
Dorien, Fons, Loes en Wies…de Janskes. En inmiddels ook Martijn, Ruud en Guus. 
Jullie hebben mij de Hollandse nuchterheid bijgebracht en ik weet dat jullie altijd voor 
me klaar staan als het nodig is. Het wordt niet vaak genoeg uitgesproken, maar 
ontzettend bedankt daarvoor!
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